CURRICULUM VITAE

PERSONAL DATA

Name: Jonathan S. BrombergOffice: University of Maryland

Transplant Office29 S. Greene St., Ste. 200Baltimore, MD 21201Tel – 410-328-5408FAX – 410-328-6343<jbromberg@smail.umaryland.edu>

EDUCATION

1970-1973 Wyoming High School, Wyoming, OH1973-1974 Gresham’s School, Holt, Norfolk, England1974-1977 Harvard College, Cambridge, MA; A.B. (summa cum laude, phi

beta kappa, Biology)1978-1983 Harvard Medical School, Boston, MA; M.D.1979-1983 Harvard Graduate School of Arts and Sciences, Boston, MA; Ph.D.

(Immunology, Drs. Baruj Benacerraf and Mark Greene)

POSTGRADUATE AND POSTDOCTORAL TRAINING

1977-1978 Postgraduate researcher, ICRF Tumor Immunology Unit, University College, London (Drs. N. Avrion Mitchison and P. Lake)

1983-1988 Intern, resident, chief resident, Department of General Surgery, University of Washington Affiliated Hospitals, Seattle, WA

1986-1988 Coinvestigator, Human Antigen-Specific T Suppressor Cell Genetic Markers, University of Washington and Virginia Mason Research Center, Seattle, WA (Dr. Jerry Nepom)

1988-1990 Fellow, Division of Transplantation, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

ACADEMIC APPOINTMENTS

7/88 – 6/90 Clinical Instructor, Hospital of the University of Pennsylvania

7/90 – 6/93 Assistant Professor of Surgery and Microbiology and Immunology,Medical University of South Carolina

7/93 – 6/94 Associate Professor of Surgery and Microbiology and Immunology,

Medical University of South Carolina

7/94 – 6/98 Associate Professor of Surgery and Microbiology and Immunology, Division of Transplantation, Department of Surgery, University of Michigan Medical Center

7/98 – 6/99 Professor of Surgery and Microbiology and Immunology, Surgical Director, Liver Transplant Program, Division of Transplantation,

Department of Surgery, University of Michigan Medical Center

7/99 – 9/10 Professor of Surgery and Gene and Cell Medicine, Surgical Director, Kidney and Pancreas Transplantation; Surgical Director, Transplantation Research, Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine and Mount Sinai Hospital.

10/10 – present Professor of Surgery and Microbiology and Immunology, Chief, Division of Transplantation; Director of Research, Division of Transplantation; Director of Strategic Planning for Transplantation Services, University of Maryland School of Medicine

CONSULTING POSITIONS

1991-1996 Procept, Inc., Cambridge, MA1994-1997 Biotransplant, Inc., Cambridge, MA2000-2002 XOMA Corp., Berkeley, CA2003-2013 Scientific Advisory Board, Astellas, Chicago, IL2003-2005 Pfizer, Inc., Groton, CT2008-present External Scientific Council, Transplant Institute ITUN and Labex

IGO, Nantes, France

SCIENTIFIC ACTIVITIES

Editorial Boards

1993-1999 Journal of Immunology, Associate Editor1995-2014 Transplantation1996- 2003 Clinical Immunology and Immunopathology1997- 2001 Graft2003- Current Gene Therapy2004 Journal of Surgical Research2008- Surgery2000-2003 American Journal of Transplantation, Associate Editor2003-2014 American Journal of Transplantation, Deputy Editor2010-2014 American Journal of Transplantation, Section Editor for Literature

Watch2000-2005 Journal of Immunology, Section Editor2014- Transplantation, Clinical Sciences Executive Editor

2

Ad Hoc Reviewer for:American Journal of PathologyArchives of SurgeryArthritis Research and TherapyBioTechniquesCell ReportsEMBO ReportsEuropean Journal of ImmunologyGastroenterologyGene TherapyHuman Gene TherapyHuman ImmunologyImmunityinScightInternational ImmunologyJournal of the American Academy of DermatologyJournal of the American Society of NephrologyJournal of Biological ChemistryJournal of Clinical InvestigationJournal of Experimental MedicineJournal of Immunological MethodsJournal of ImmunologyJournal of ImmunotherapyJournal of Leukocyte BiologyJournal of VirologyMolecular TherapyNature CommunicationsNature ImmunologyNature BioTechnologyNature MedicineNew England Journal of MedicineProceedings of the National Academy of SciencesScienceStem CellsThe Lancet

Study Sections

1993 - 1998 NIH, Ad Hoc Member, Immunobiology1993 NIH, Special review committee for program projects on

Transplantation Immunology and Immunogenetics1995 NIAID expert panel on immunologic interventions for promoting

transplant tolerance1995 - 1999 NIH, Ad Hoc Member, Surgery, Anesthesia, Trauma1993 - present VA Merit Review, ad hoc reviewer1996 - 1998 NIH, Regular Member, Special Study Section for SBIR grants1996 NATO Advanced Study Institute, ad hoc reviewer

3

1997 NIAID, Special review committee for program projects on Transplantation Tolerance

1997 Juvenile Diabetes Foundation International, program project grantson immunology and transplantation

1997-2000 Juvenile Diabetes Foundation International, Medical ScienceReview Committee

1998 NIH, Ad Hoc Member, ET-11998 NIH, NIAID, Transplantation program project grant review1999-2003 NIH, Regular member, Immunobiology Study Section1998 United States-Israel Binational Science Foundation, ad hoc grant

reviewer2002 Wellcome Trust, ad hoc reviewer2003 NIH, special immunology RO1grant review2003 NIH, review for RFA AI-03-010: Innovative Grants on Immune

Tolerance2004 NIH, chair Transplantation Immunology special phone review,

ZRG1 IMM-C 03 S2004 NIH, ad hoc, Transplantation, Tolerance, and Tumor study section2005 NIH, ad hoc, Transplant Immunology study section, ZRG1 IMM-E

03 M, special emphasis panel2005 Science Foundation Ireland, ad hoc reviewer2005 NIH, ad hoc, Cellular and Molecular Immunology – B2005 NIH, ad hoc, Transplant Immunology study section, ZRG1 IMM-L

03 M, special emphasis panel2006 Two-year site review for REMEDI, National University Galway

Ireland, Science Foundation Ireland2006 JDRFI, special study section on Innate Immunity and Type 1

Diabetes2007 NCI, Study section for PPGs in cancer immunology and

angiogenesis2007 TTT NIH Study Section special grants ad hoc review.2007-8 Chair, Study section for PPG in costimulation, ZAI1-LR-I-J2.2008 NCI, Study section for PPGs in cancer immunology and

angiogenesis2009 State of Pennsylvania, review of PPGs in Diabetes2010 Two-year site review for REMEDI, National University Galway

Ireland, Science Foundation Ireland2010-14 National Institute of Dental and Craniofacial Research, NIH, Board

of Scientific Counselors2010 Israel Science Foundation, ad hoc reviewer2010 Medical Research Council (England), ad hoc reviewer2011 TTT NIH Study Section special review panel ZRG IMM-C 022011 Swiss National Science Foundation, ad hoc reviewer2012 Armed Forces Institute of Regenerative Medicine2013 Clinical and Rehabilitative Medicine Research Program (CRMRP),

U.S. Army, Restorative Transplantation Research Cooperative Agreement (RTRCA)

2013 British Heart Foundation, ad hoc reviewer

4

2013 Leukemia and Lymphoma Research, ad hoc reviewer2014 State of Pennsylvania, review of PPGs in Diabetes2014 NIAID Special Emphasis Panel 2015/01 ZAI1 QV-I (J3) 12014 PSI Foundation, Toronto, Ontario, Canada2015 NIH CMI-B Special Emphasis Panel ZRG1-IMM-C 02 M2015 NIH 2015/10 AICS, Atherosclerosis and Inflammation of the

Cardiovascular System Study Section2015 NCI ZCA1 SRB-D (O1) Omnibus R03 & R21 SEP-7 Review2015 Chair, ZAI1 PA-I (S1) 1 NIAID SBIR Phase II Clinical Trial

Implementation Cooperative Agreement and Clinical Trial Planning Grants Review

2015 Dutch Kidney Foundation (Nierstichting Nederland), DKF Kolff Program for individual kidney research grants

2015 Chair, 2016/01 ZAI1 AWA-M (J1) 1 Investigator-initiated Clinical Trials (IICT)- PAR-13-151 and PAR-13-250

2015 Swiss National Science Foundation2016 CDMRP Reconstructive Transplant Translational Research

[Vascularized Composite Allotransplantion] Panel2016 NIH ZRG1 DKUS-J(56)2016 NIAID Clinical Trial Planning Grant (R34) and Implementation

Cooperative Agreement (U01) Special Emphasis Panel ZAI1-BDP-I-S1, chair

2016 NIH 2016 10 ZRG1 IMM-C (02), co-chair2016 NIH 2016 ZAI1-LR-M-J1, chair.

GRANT SUPPORT

Current, Basic: Induction and Migration of Regulatory T Cells: Role of Lymphotoxin, NIH 1RO1AI062765, 8/1/15-1/31/20, $1,125,000. (PI)

Harnessing intra-lymph node controlled release to promote myelin-specific tolerance, National Multiple Sclerosis Society, 10/1/15-9/30/18, $150,000. (co-I)

The role of lymphotoxin in Treg migration and suppressor function, Living Legacy Foundation Transplantation Grant, 7/1/14-6/30/16, $114,300. (co-PI and mentor for C. Colin Brinkman, CVID)

Microbiota Structure and Transplant Outcomes: Preclinical Studies, Living Legacy Foundation Transplantation Grant, 7/1/14-6/30/16, $114,300. (co-PI with Emmanuel Mongodin, IGS)

Lymph Node Structure and Function in Tolerance: Role of Laminins. NIH 1R01AI114496-01, 5/1/15-4/30/20, $2,031,250. (PI)

5

Tunable Assembly of Regulatory Immune Signals to Promote Myelin-specific Tolerance. VA Maryland Health Care System, 12/1/16-11/30/20, $1,092,451. (co-I)

Engineering local lymph node function to promote systemic, antigen-specific tolerance in T1D. JDRF, 9/1/16-8/30/18, $192,792. (co-I)

Current, Clinical: Immunosuppression with Antithymocyte Globulin, Rituximab, Tacrolimus, and Sirolimus, Followed by Withdrawal of Tacrolimus and Sirolimus, in Living-donor Renal Transplant Recipients (ITN039ST), Immune Tolerance Network-NIAID, 6/12 - , $383,480. (site PI).

The International Collaborative Microarray Study Alberta Transplant Applied Genomics Centre, 10/11 - , $52,345. (site PI).

A 12 month, single-center, non-randomized, open-label study of outcomes of intermediate risk Maryland Aggregate Pathology Index (MAPI) scores in de novo renal transplant recipients, Bristol-Myers Squib, 5/12 – 6/17, $211, 538. (co-investigator)

A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients, Astellas, 5/13 – 4/17, $165,150. (site PI).

Circulating Donor-Derived Cell-free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients, CareDx, Inc., 5/3/15-ongoing, $329,787. (site PI)

A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney, Angion Biomedica Corp, 10/5/15-12/31/18, $143,040. (site PI)

A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant (ReGIFT), QUARK Pharmaceuticals, Inc., 1/7/16-1/20/20, $366,601. (site PI)

A 12-month randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combination with mycophenolate mofetil (MMF) and corticosteroids (CS), with and without tacrolimus (Tac), in de novo

6

renal transplant recipients (part 1), Novartis Institutes for BioMedical Research & Clinical Development, 11/6/2014- 7/31/16, $406,195. (co-I)

A 12-month randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combination with mycophenolate mofetil (MMF) and corticosteroids (CS), with and without tacrolimus (Tac), in de novo renal transplant recipients (part 2), Novartis Institutes for BioMedical Research & Clinical Development, 5/17/16-11/30/2018,$271,813.40. (co-I)

A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM), Novartis Clinical Development,IRB approved 12/11/2014- 2018, $239,431. (co-I)

Evaluating Nulojix Long Term Safety in Transplant ENLiST Registry, Bristol-Myers Squibb, 1/10/12-ongoing. $63,481. (co-I)

Past, Basic: In Vivo Role of the CD2 Molecule in Cellular Immunity, MUSC Biomedical Research Support Grant, 7/90 - 7/91, $40,000

Mechanisms of Anti-CD2 Induced Immunosuppression, Procept, Inc., Cambridge, MA., 6/91 - 6/93, $45,000

Sandoz unrestricted basic research grant, 1991, $2,000.

Development of a Model for Human Esophageal Cancer, Co-Investigator with Dr. Paul Baron, ACS Institutional Funds for MUSC, 2/91 - 2/92, $15,000, #1RG-175B.

Production and Characterization of Soluble CD2, MUSC Institutional Research Funds, faculty sponsor for Adam Kaplan, 7/91-6/92, $2,000.

Production and Characterization of Soluble CD2, Clinical Research Fellowship Program, faculty sponsor for Adam Kaplan, 7/91 - 6/93, $20,000.

Modulation of CD2 Function in Transplantation, R29 AI32655, 12/92 - 11/97, $493,230.

7

UpJohn unrestricted basic research grant, 1992, $2,000.

Evaluation of the Utility of Soluble Murine CD2 Receptor, Summer Health Professional Research Program, faculty sponsor for Steve Lookadoo, 5/92 - 8/92, $2,850.

Alteration of Transplantation Immunity through the CD2 Molecule, American Surgical Association, 7/92 - 7/94, $65,000.

Production and Characterization of CD2, MUSC Institutional Research Funds, faculty sponsor for Adam Kaplan, 3/93 - 2/94, $2,000.

Evaluation of Soluble LFA-3 in Human CD2 Transgenic Mice, Biogen, Cambridge, MA, 1/94 - 12/94, $5,000.

Evaluation of Small Immunosuppressive Molecules, Procept, Inc., Cambridge, MA, 1/94 - 12/94, $6,593.

Development of a Human CD2 Transgenic Mouse Model for in vivo Investigation of the Human CD2-CD58 Interactions, Procept, Inc., Cambridge, MA, 1/94 - 6/95, $9,680.

Gene Transfer and Gene Therapy in Allografting, Baxter Healthcare Extramural Grant Program, McGaw Park, IL, 2/94 - 2/97, $120,000.

Evaluation of Small Immunosuppressive Molecules, Procept, Inc., Cambridge, MA, 8/95-7/96, $6,155.

The Effect of BTI-322 in Cardiac Allografting, Biotransplant, Inc., 9/95-8/96, $16,431.

Gene Therapy in Transplantation: Prolongation of Graft Survival with IL-10, Edward Mallinckrodt, Jr. Foundation, St. Louis, MO, 9/95-8/98, $165,000.

Role of CD4+ T cells in Cardiac Allograft Tolerance, RO1 AI/HL 31946, 7/95 - 6/99, $802,541 (D.K. Bishop, P.I.).

Evaluation of Integrin Ligand Analogues, Tanabe Research, 10/1/96-4/30/97, $6,500.

Gene Transfer of ALLOTRAP peptides, SangStat, Inc., 7/1/96 -06/30/98, $12,000.

Tucker Schumaker Transplantation Research and Education Foundation, 6/1/96 - 5/30/99, $64,000. Gene Transfer and Gene

8

Therapy in Allografting, Baxter Healthcare Extramural Grant Program, McGaw Park, IL, 7/97 - 6/00, $60,000.

Genetic Modifications of Striated Muscles during Aging, NIH PO1 AG15434, 04/98 - 03/03, $506,292 (J. Chamberlain, P.I.).

Transplantation Tolerance: Role of Receptor Ligation and TH2 Induction, NIH RO1 AI41428, 02/98 - 01/02, $1,191,410.

Interleukin-10 Immunosuppression: Molecular Aspects, University of Michigan Medical Center, Technology Transfer Committee 01/01/99-06/30/99, $25,000.

Chemokine Antagonists to Block Alloimmune Responses, ROTRF, 11/99-10/02, $200,000.

Cytokine Regulation of Gene Therapy Vectors, NIH RO1 AI42840, 04/98 - 02/03, $809,332. (Minority Supplement to NIH R01 AI42840, 01/99 - 01/00, $30,720.)

Interleukin-10 Immunosuppression: Cellular and Molecular Aspects, NIH RO1 AI44929, 02/01/00-01/31/05, $1,970,793. (PI)

Tolerance Induction to Alloantigen – the Role of T Cell Trafficking, Howard Hughes Medical Institute, 07/01-06/02, $30,000 (faculty mentor for medical student Shaun Honig)

Transplantation Tolerance: T Cell Trafficking, NIH R21 AI42840, 09/01 – 09/02, $295, 000.

Generation of murine pancreatic endocrine stem cells from embryonic stem cells, JDFI, 10/01-09/02, $55,000.

Isolation and characterization of murine adult pancreatic endocrine stem cells, JDFI, 10/01-09/02, $55,000.

Effect of innate immune responses on vector and islet function, JDFI, 09/01-12/03, $255,393. (PI)

Generation of murine pancreatic endocrine stem cells from embryonic stem cells, JDFI, 01/01/03-12/31/03, $60,000. (PI)

In vitro generation of pancreatic endocrine stem cells, JDRFI, 03/01/04-02/28/07, $495,000. (Co-PI)Lymphatic Migration, Howard Hughes Medical Institute, 07/05-06/06, $30,000 (faculty mentor for medical student Levi Ledgerwood)

9

Committing human ES cells to pancreatic insulin expressing cells, NIH/JDRFI, 06/01/05-05/31/07, $165,000. (Co-PI)

Endoderm induction and pancreatic specification from ES cells, NIH UO1 DK072513, 08/01/05-12/31/06, $518,450. (co-PI Project 2)

Endocrine pancreas from Sox17+ endoderm progenitors, NIH R21 DK69997, 04/01/06-06/39/07, $339,000. (co-PI)

T cell regulation of islet innate immunity, JDRFI 1-2005-16, 03/01/05-02/28/08, $495,000. (PI)

Treg-pDC Interactions, Howard Hughes Medical Institute, 07/07-06/08, $30,000 (faculty mentor for medical student Eric Gehrie)

Role of chemokines in diabetes and islet transplantation, NIH RO1 DK067381, 12/01/04 – 11/30/08, $205,000. (Coinvestigator)

Induction and function of regulatory T cells, NIH RO1 AI62765, 12/01/04 – 11/30/09, $2,118,000. (PI)

Regulation of migration of lymphocytes from peripheral tissues through afferent lymphatics to lymph nodes, Emerald Foundation, 01/01/07-12/31/09, $50,000. (PI)

Islet and LN Lymphatics: Role in Inflammation and Immunity, JDRFI 5-2008-236, 03/01/08-02/28/09, $110,000. (PI)

Lymph Node Structure and Islet Allograft Tolerance, JDRFI, 03/01/08-02/28/11, $495,000. (PI)

Lymphangiogenesis in pancreatic islet autoimmunity and alloimmunity, Emerald Foundation, 07/01/10 – 06/30/12, $250,000. (PI)

Lymphoid Structure in Tolerance, NIH R01 AI072039, 05/01/07-04/30/12, $250,000. (PI)

Migration and Trafficking in Tolerance, NIH RO1 AI41428, 06/15/08 – 05/31/13, $1,695,000. (PI)

Lymphoid Structure in Tolerance, NIH R56 AI072039, 08/01/12-07/31/13, $250,000. (PI)

Pancreatic islet-homing peptides for disease monitoring and treatment of T1D, Diabetes Research And Training Center Pilot and Feasibility Award Program (DRTC-P&F Program), JHU-UMD

10

Diabetes Research Center, 7/1//13 – 6/30/14, $50,000. (co-investigator)

Induction and Migration of Regulatory T Cells, NIH RO1 AI62765, 05/01/10 – 04/30/15, $2,119,000. (PI)

Migration and Trafficking in Tolerance, NIH R56 AI41428, 04/15/14 – 03/31/15, $268,625. (PI)

Exploiting intra-lymph node controlled release to combat autoimmunity without broad immunosuppression, University of Maryland Innovation Initiative, 5/1/15-4/30/16, $150,000 (co-inv.)

Past, Clinical: Investigation of the pharmacokinetics and safety of mycophenolate mofetil given by intravenous infusion followed by oral dosing to liver allograft recipients (MYCS2378) (amendment) Syntex (USA), Inc., 11/1/94 - 7/14/96, $130,908 (R. Merion, P.I.).

A One-Year Randomized, Open-Label, Comparative Trial of Mycophenolate Mofetil or Azathioprine for the Prevention of Acute Renal Allograft Rejection in Uremic Patients with Type I Diabetes Mellitus Receiving Simultaneous Kidney-Pancreas Transplantation (MYCS 2401), Roche Bioscience, 12/22/94-3/28/97, $153,045 (R. Merion, P.I.).

A multicenter, randomized, double blind, placebo controlled trial of SDZ CHI 621 for the prevention of acute rejection after renal transplantation, Sandoz Pharmaceutical Corporation, 3/15/95 - 3/14/96, $99,196 (A. Leichtman, MD; P.I.).

Multicenter, open label study of the safety and tolerability of Neoral in stable renal transplant patients, Sandoz Pharmaceutical Corporation, 4/1/95 - 9/30/96, $113,516 (A. Leichtman, MD; P.I.).

Investigation of the pharmacokinetics and safety of mycophenolate mofetil given by intravenous infusion followed by oral dosing to liver allograft recipients (MYCS2378) (amendment) Roche Bioscience, 8/20/95 -2/15/97, $8,412, (R. Merion, P.I.).

Phase III study of the treatment of acute renal graft rejection with BMY-42215-1, Bristol-Myers Squibb, 11/10/95-05/31/98,

$144,923 (A. Leichtman, P.I.).

An open-label, randomized study of mycophenolate mofetil for treatment of refractory acute cellular rejection Roche Laboratories, 4/30/95 -4/30/99, $52,425, (J. R. Baker, Jr., P. I.).

11

A Randomized, Double-Blind Comparative Study of the Efficacy and Safety of Intravenous and Oral Mycophenolate Mofetil and Azathioprine, each in Combination with Cyclosporine (Neoral) and Corticosteroids in Liver Transplant Recipients (MYCS 2646), Roche Bioscience, 10/31/96-10/31/97, $768,940 (R. Merion, P.I.).

A Single Dose Open-Label Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerance of Cytotab Administered to Renal Transplant Patients During Rejection Episodes, Therapeutic Antibodies, 09/19/96-09/19/97 (A. Leichtman, P.I.).

A Double-Blind, Comparative Study of the Effect of Two Dose Levels of Sirolimus Versus Azathioprine, Administered Concomitantly with Standard Immunosuppressive therapy in Renal Allograft Recipients (0486E1-301-US), Wyeth-Ayerst

Laboratories, 9/1/96-9/1/99, $206,051 (A. Leichtman, P.I.).

A Randomized Comparative Trial of the Effect of OKT3Induction on Tacrolimus plus Mycophenolate Mofetil MaintenanceImmunosuppression after Simultaneous Kidney Pancreas Transplantation, Fujisawa, USA, Inc. (R. Merion, P.I.)

Open label study of neoral as primary immunosuppressent therapy intransplant patients who are unable to maintain satisfactory immunosuppression on prograf (Tacrolimus, FK506), Novartis, 10/01/97-09/30/98, $16,421 (R. Merion, P.I.).

The pharmacokinetics and safety of HBIG5%. NABI-Rockville, 08/01/97-12/31/98, $63,901 (R. Merion, P.I.).

A pharmacokinetic and safety, open-label, conversation study of Abbott Cyclosporine and Neoral in stable six month post-renal allograft recipients, Abbott Laboratories 4/15/98-12/15/98, $120,657 (R. Merion, P. I.)

Cytokine inhibition of adenovirus mediated gene transfer, Central Surgical Association Foundation, 2/1/98-2/1/99, $11,900 (faculty mentor for Randy Sung).

A comparative study of the effect and equivalence of sirolimus oral liquid versus sirolimus tablets, administered concomitantly with cyclosporine and corticosteroids in renal allograft recipients (Sirolimus 309), Wyeth-Ayerst Laboratories (A. Leichtman, P.I.).

A multicenter, open-label, pharmacokinetic, pharmacodynamic, safety and tolerability study of SDZ CHI 621 in pediatric de novo

12

liver transplant recipients, Novartis, 01/15/98-02/28/00, $49,940 (R. Merion, P.I.)

A phase III, randomized, double-blind, placebo controlled multicenter study of the efficacy of odulimomab (ANTILFA ) In preventing delayed graft function (DGF) of cadaveric renal allografts in patients not receiving biological induction immunosuppressive therapy, IMTIX-Pasteur Merieux Connaught Transplantation, 01/01/98-06/30/00, $79,560 (R. Merion, P.I.)

A Three-Year, Randomized, Multi-center, Double-Blind, Double Dummy, Parallel Group Study of the Efficacy and Safety of SDZ RAD Tablets versus Mycophenolate Mofetil as Part of Triple Immunosuppressive Therapy in De Novo Renal Transplant Recipients, Novartis Pharmaceuticals, 8/31/98-8/31/05, $150,000 (J.S. Bromberg, P.I.)

An Open-Label Extension Study of the Safety of Long-term Administration of Sirolimus (RapamuneTM) in Solid Organ Transplant Recipients, Wyeth-Ayerst, 06/01/99-5/31/02, $36,000 (J.S. Bromberg, P.I.)

A Multicenter, Randomized, Open-Label, Exploratory Dose Finding Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of FTY720 versus Mycophenolate Mofetil (MMF, CellCept®) in Combination with Neoral® and Corticosteroids in de novo Renal Transplant Recipients. Novartis, 3/1/00-2/28/01, $98,255 (J.S. Bromberg, P.I.)

A 1-Year, Multicenter, Single Arm, Open Label, Pilot Study of the Efficacy and Safety of RAD in de novo Renal Transplant Recipients At Immunological High Risk of Rejection, Novarits, 5/1/00-4/30/01, $53,760 (PI)

A 1-Year Multicenter, Randomized, Open-Label, Parallel Group Pilot Study of the Efficacy and Safety of RAD with Early Versus Possibly Delayed Initiation of Neoral® in de novo Renal Transplant Recipients at Increased Risk of Delayed Graft Function, Novartis, 5/1/00-4/30/01, $88,000 (J.S. Bromberg, P.I.)

A Comparative, open-label study to evaluate Graft Function in de novo Renal Allograft Recipients treated with either a “reduced dose” or a “standard dose” of Cyclosporine in combination with Rapamune® (Sirolimus) + Corticosteroids, Wyeth-Ayerst, 6/1/00-5/31/01, $60,000 (J.S. Bromberg, P.I.)

A Randomized, Double-Blind, Double-Dummy, Active-Comparator Controlled Multi-Center Study of the Efficacy and

13

Safety of Valganciclovir (Ro107-9070) Vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Heart, Liver and Kidney Allograft Patients, Roche, 2/1/00-10/31/02, $150,000 (J.S. Bromberg and T. Fishbein, P.I.)

Open-Labeled, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients, Bristol Myers Squibb, 12/01/00-12/31/04, $485,000 (J.S. Bromberg, P.I.)

An Open-Label, Concentration-Controlled, Randomized, 12 Month Study Of Prograf® + Rapamune® + Corticosteroids Compared To Cyclosporine, Usp (Modified) + Rapamune® + Corticosteroids In High Risk Renal Allograft Recipients, Wyeth-Ayerst, 7/15/02-7/14/03, $156,375.00 (J.S. Bromberg, P.I.).

Prospective Randomized Study of Cyclosporine/MMF vs. Tacrolimus/Sirolimus in a Steroid-Avoidance Protocol, University of Minnesota, 6/30/02-6/30-04, $22,000.00 (J.S. Bromberg, P.I.)

A Randomized, Open-Label, Comparative Evaluation Of Conversion From Calcineurin Inhibitor Treatment To Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment In Liver Allograft Recipients Undergoing Maintenance Therapy, Wyeth Pharmeceuticals, 9/15/02-6/30/04, $310.000 (G. Gondolesi, P.I.)

A Pilot Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study Of The Safety And Efficacy Of A Human Hcv-Antibody (Hcv-Abxtl68) For Prevention Of Hepatitis C Disease Recurrence In Patients Who Received Hepatic Allografts For Treatment Of End-Stage Liver Disease Due To Hepatitis C Virus Infection, Xtl Biopharmaceuticals. Ltd., 11/1/02-10/31/04, $105,680 (T. Schiano, P.I.).

An Open-Label, Concentration-Controlled, Randomized, 12 Month Study Of Prograf® + Rapamune® + Corticosteroids Compared To Cyclosporine Capsules, Usp (Modified) + Rapamune® + Corticosteroids In High Risk Renal Allograft Recipients, Wyeth Pharmaceuticals, 7/15/02-7/14/04, $101,644 (J.S. Bromberg, P.I.)

Randomized, Prospective, Phase II* Study Comparing Thymoglobulin In A Rapid Discontinuation Of Corticosteroids Protocol With Standard Corticosteroid Therapy In Living Donor Renal Transplantation Using Mycophenolate Mofetil And Tacrolimus Maintenance Therapy. Sangstat Medical Corporation, 8/15/03-8/14/04, $32,825 (E. Akalin, P.I.).

14

A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study To Assess The Safety And Efficacy Of Prograf (Tacrolimus)/Mmf, Modified Release (Mr) Tacrolimus/Mmf And Neoral (Cyclosporine)/Mmf In De Novo Kidney Transplant Recipients. Fujisawa Healthcare, Inc. 8/15/03 -8/14/04, $23,183 (S. Ames, P.I.).Thymoglobulin And IVIg Therapy In Kidney Transplant Patients With Positive Complement Dependent Cytotoxicity B Cell And/Or Flow Cytometry T And/Or B Cell Cross-Match, Sangstat Medical Corp., 5/1/03-5/8/04, $10,500 (E. Akalin, P.I.).

Phase II, Safety, Tolerability, And Efficacy Study Of A Capase Inhibitor, Idn 6556, In Patients Undergoing Liver Transplant, Idun Pharmaceuticals, 10/5/03-10/6/04, $83,083 (G. Gondolesi, P.I.).

An Open-Label, Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Early Calcineurin Inhibitors Withdrawal In Recipients Of Primary Renal Allografts Maintained Long Term On MMF And Sirolimus, Roche Laboratories, 8/18/03-8/18/04, $78,000 (B. Murphy, P.I.).

Phase II, Safety, Tolerability, And Efficacy Study Of A Capase Inhibitor, Idn 6556, In Patients Undergoing Liver Transplant, Idun Pharmaceuticals, 10/5/03-10/6/04, $83,083 (G. Gondolesi, P.I.).

A multicenter, phase 2, open-label, controlled, extension study for Stage 1 subjects of study A3921009 to evaluate the long-term safety and efficacy of CP-690,550 versus tacrolimus, when co-administered with mycophenolate mofetil in renal allograft recipients (A3921021), Pfizer, 1/31/05-11/28/06, $45,000 (J.S. Bromberg, P.I.)

Phase II, Randomized, Open Label Parallel Group Multi Center Study To Assess The Safety And Efficacy Of Prograf/FK778 And Prograf/MMF In De Novo Kidney Transplant Recipients, Fujisawa Health Care Inc., 10/1/03-10/20/07, $196,930 (S. Ames, P.I.).

A Ph III, rand., open-label, comparative, multi-ctr study to assess the safety & efficacy of Prograf/MMF, MRTac/MMF & Neoral/MMF in de novo Kid tx recipients, Astellas Pharmaceuticals 8/1/03-8/1/07, $90,000.00 (S. Ames, PI)

Rapid Steroid Withdrawal in African American Kidney Transplant Recipients, Astellas Pharmaceuticals 3/15/04-3/14/08, $60,000. (E. Akalin, PI).

15

A Randomized, Open-Label Study To Compare The Safety And Efficacy Of Two Different Sirolimus Regimens With A Tacrolimus + Mycophenolate Mofetil Regimen In De Novo Renal Allograft Recipients, Wyeth Research 3/15/04-3/14/08, $230,163.00 (E. Akalin, PI.)

A 3-month, open-label, 2 cohort study to investigate the safety & tolerability of Myfortic in combination with Neoral or Tac. In renal tx recipients with GI intolerance, Novartis Pharmaceuticals 1/15/04-1/14/08, $40,000 (G. deBoccardo, PI)

A six-month, prospective, multictr, open label, parallel, rand study of the safety, tolerability & efficacy of Myfortic with simulect, steroids, & 2 diff levels of tacrolimus in de novo renal tx recipient, Novartis Pharmaceuticals, 1/9/05-1/9/08, $40,000.00 (G. deBoccardo, PI).

A Randomized, open-label, comparative eval of the safety and efficacy of Sirolimus vs CsA when combined in a regimen containing Basilximab, MMF, & corticosteroids in primary de novo renal tx recipients, Wyeth Research, 9/1/04-9/1/07 $230,163.00 (E. Akalin, PI).

A Prospective, Randomized, Multi-Center Double-Blind Study of Early Corticosteroid Cessation vs Long Term Maintenance in Renal Transplant Recipients, Fujisawa, 10/1/99-7/3/08, $220,000 (PI)

An open label; prospective, randomized, controlled, multi-center study assessing fixed dose vs. concentration controlled CellCept regimens for patients following a single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors, Roche Pharmaceuticals, 7/19/05-7/30/08, $258,590.00 (E. Akalin, PI).

A 6-Month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study Of 2 Dose Levels Of Cp-690,550 Administered Concomitantly With Il-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil And Corticosteroids Versus A Tacrolimus-Based Immunosuppressive Regimen For The Prevention Of Allograft Rejection In De Novo Renal Allograft Recipients, Pfizer 1/31/04-11/28/06, $60,000 (J.S. Bromberg, P.I.)

Rapamycin treatment in chronic allograft nephropathy, Wyeth Research, 6/5/06-6/5/08, $90,000. (E. Akalin, PI)

A 12 month open-label, randomized, sequential cohort, dose finding study to evaluate the efficacy, safety & tolerabilitiy of oral AEB071 vs tacrolimus in combination with myfortic, simulect and

16

steroids in de novo adult renal tx recipients, 1/7/07-7/30/08, $179,130 (E. Akalin, PI)

Ph IV, rand., open-label, comparative, multictr study to assess safety & efficacy of induction agents Campath 1H, Simulect or Thymoglobulin in combination with tacrolimus, MMF, & a rapid steroid withdrawal in renal tx recipients, Astellas Pharmaceuticals 5/15/05-5/16/09, $150,000 (PI).

Noninvasive Monitoring to Predict Outcome in De Novo Kidney Transplant Recipients, 8/31/06-8/31/09, CTOT-01 $88,000. (E. Akalin, P.I.)

Prospective Randomized study of Cyclosporine/MMF vs. Tacrolimus/sirolimus in a steroid-avoidance protocol, University of Minnesota/Astellas, 3/1/02-6/30/09 (PI)

A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf/MMF, MRTac /MMF and Neoral/MMF in de novo kidney transplant recipients, Astellas, 8/12/03-8/4/09 (co-I)

An open-label, randomized, multicenter study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on mycophenolate mofetil and sirolimus, Roche Laboratories Spare the Nephron Trial, 8/25/03-8/18/09 (B. Murphy, PI)

Rapid steroid withdrawal in African-American kidney transplant recipients, Astellas, 3/23/04-3/15/09 (E. Akalin, PI)

A multicenter randomized, double blind, double dummy controlled study to assess the tolerability of an increased dose of myfortic after conversion from CellCept in renal transplant recipients who required CellCept dose reductions due to GI symptoms, Novartis, 11/6/08-11/5/09 (G. deBoccardo, PI)

Coronary screening in transplantation (COST) feasibility study, subcontract to Hennepin County Medical Center (Kassiske, P.I.), NIH, 10/20/08-01/31/10 (Bromberg, P.I.)

Clinical, Immunologic and Pharmacologic Consequences of Solid Organ Transplantation in People with HIV Infection, NIH, 6/30/01-06/30/10, $17,500 (B. Murphy, P.I.)

Open-label, randomized, controlled multi-dose study of efficacy & safety of BMS 224818 as part of a Quadruple drug regimen in renal transplant recipients--Long-Term Extension Study (Amend #3), BMS, 11/1/05-6/14/10, $186,144 (J.S. Bromberg, PI)

17

Multicenter, phase 2, open-label, controlled extension study for stage 1 subjects of study A3921009 to evaluate long-term safety and efficacy of CP690,550 vs tacrolimus when co-administered with MMF in renal transplant, 01/19/06-01/31/11, $101,755.00 (J. S. Bromberg, PI)

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors, Bristol Myers Squibb, 12/19/05-6/6/10, $210,000.00 (J.S. Bromberg, P.I.)

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial – Standard Donors, Bristol Myers Squibb, 01/18/06-11/17/10, $210,000.00 (J.S. Bromberg, P.I.)

Noninvasive monitoring to predict outcome in de novo kidney transplant recipients, CTOT-01, NIH, 01/22/07-08/31/10 (Heeger, P.I.)

Genomics of chronic renal allograft rejection, GoCAR, NIH, 03/07/08-07/31/10 (Murphy, P.I.)

A 12 month, multi-center, randomized, open-label non-inferiority study comparing the safety and efficacy of concentration-controlled Everolimus with low dose tacrolimus to CellCept (mycophenolate mofetil) with standard dose tacrolimus in de novo renal transplant recipients (CRAD001AUS92), Novartis, 7/10 – 6/14, $137,800. (PI).

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation (QRK.006), Quark, 6/11 – 5/14, $157,776. (PI).

Changes in the human microbiota induced by post-transplant medication, American Society of Transplant Surgeons, 07/01/11 – 06/30/13, $100,000. (coPI).

Multicenter Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation and at Risk for Dialysis (001-09), Angion, 3/11-9/15, $248,013. (site PI)

Allosensitization and red blood cell transfusions in end stage renal disease patients on the kidney transplant list, Amgen, 4/13 – 10/15, $258,603. (PI).

18

CERTIFICATION AND LICENSURE

1984 Washington1988 Pennsylvania1989, 1997, 2010 Certified, American Board of General Surgery1990 South Carolina1993 Fellow, American College of Surgeons1994 Certified, American Board of Surgery, Surgical Critical Care1994 Michigan1999 New York2010 Maryland

MILITARY SERVICE

None

HONORS AND AWARDS

1975 Edwards-Whitaker Award (Harvard College)1975,76,77 John Harvard Award (Harvard College)1976 Phi Beta Kappa (Harvard College)1977 Detur Book Prize (Harvard College)1977 Summa Cum Laude, Biology (Harvard College)1979-83 Medical Scientist Training Program Fellowship (Harvard Medical

School)1983 James Tolbert Shipley Prize (Harvard Medical School)1988-90 Sandoz Award, American Society of Transplant Surgeons1992-94 American Surgical Association Foundation Fellowship Award1992 Thomas A. and Shirley W. Roe Foundation Award1997 Excellence in reviewing, Journal of Surgical Research1998 ASTS Roche Presidential Travel Award2000 Mary Jane Kugel Award, Juvenile Diabetes Foundation,

International2001 Joel J. Roslyn Commemorative Lecture, New Considerations in

Tolerization, Society of University Surgeons2002 Andrew Lazarovits Lecture, Canadian Society of Transplantation2005 Alfred and Florence Gross Professor of Surgery2005-11 New York magazine’s Best Doctors2012 Washington magazine’s Best Doctors2013 Baltimore magazine’s Best Doctors2013 AST Basic Science Established Investigator Award2014 Physician - Attending Award, Nursing Excellence Awards2014 National Kidney Foundation of Maryland, Kidney Champion Award

MEMBERSHIPS/PROFESSIONAL SOCIETIES

19

American Association for the Advancement of ScienceAmerican Association of ImmunologistsAmerican College of SurgeonsAmerican Society of TransplantationAmerican Society of Transplant SurgeonsAmerican Surgical AssociationAssociation of Academic SurgeryClinical Immunology SocietyFederation of Associated Societies of Experimental BiologyHenry Harkins Surgical SocietyRavdin-Rhodes SocietySociety of University SurgeonsSurgical Biology Club IIThe Harvey SocietyTransplantation SocietyTransplantation Society of MichiganUnited Network for Organ SharingWestern Surgical Association

TEACHING ACTIVITIES

National

1993 Molecular Biology Section in Fundamentals of Surgical Research Course, Association of Academic Surgery

1994 Immunology Section in Fundamentals of Surgical Research Course, Association of Academic Surgery

1998 Transplantation Mock Study Section, Young Surgical Investigator’s Meeting, American College of Surgeons

1999 Transplantation Tolerance, Mini-Med School, Mt. Sinai School of Medicine

2000 Transplantation Mock Study Section, Young Surgical Investigator’s Meeting, American College of Surgeons

2009 Histocompatibility and Immune Function & Suppression, 3rd

Annual Surgical Fellows Symposium, Phoenix, AZ, November 12-14, 2009.

2010 "What Transplant Surgeons Need to Know About Histocompatibility" and “Clinical Immunosuppression and Drug Monitoring”, 4th Annual Surgical Fellows Symposium, Scottsdale, AZ, November 11-13, 2010.

20

2011 Clinical Immunosuppression and Drug Monitoring, 5th Annual Surgical Fellows Symposium, Tuscon, AZ, November 19-21, 2011.

2012 Grant Writing Lunch and Learn, ASTS 12th Annual State of the Art Winter Symposium, Miami, FL, January 14, 2012.

2013 Histocompatability and Immunosuppression, 7th Annual Surgical Fellows Symposium, Snowbird, UT, October 4-6, 2013.

2014 Clinical Immunosuppression and Antibody Mediated Rejection: Applications & Perils, ASTS 8th Annual Surgical Fellows Symposium , San Diego, CA, October17-19, 2014.

2014 Transplant Histocompatibility & Immunosuppression, ASTS 8th Annual Surgical Fellows Symposium, San Diego, CA, October17-19, 2014.

University

1990- Clinical transplant service rounds

1991-1993 Immunology Journal Club

1995- 1999 Experimental Immunopathology Training Program Faculty

1995-1999 Introductory Immunology (M&I 310) for PharmD students

1996- 1999 Cellular and Molecular Biology Program Faculty

1996- 1999 Immunology/Immunopathology Journal Club Director

1998-1999 Molecular Mechanisms in Microbial Pathogenesis Training Program Faculty

1999-2010 Gene Therapy and Molecular Medicine Faculty

1999- Immunology Faculty

1990- Graduate Research Preceptor

MUSC:Ken Chavin, 1990-1994, Ph.D.Robert Yon, 1991-1993, MSAdam Kaplan, 1991-1993, MSLiHui Qin, 1991-1994, Ph.D.Jixun Lin, 1992-1995, Ph.D.Jennifer Woodward, 1993-1996, Ph.D.

21

UMMC:Yaozhong Ding, 1993-2000, PhDQing Yang, 1994-1997, MSPeter Virsik, 1995-1996, MS

MSSM:William Van Der Touw, 2008-2010

1994- Graduate Research Committee MemberMary Stofega, 1994-1999Lisa Finkelstein, 1995-1997Traci Zell, 1995-1996Michael Eisenbraun, 1997-1999Emma Lo Kuan, 2007-2010Marvin Lin, 2008-2010Jessica Shiu, 2010-2013Gloria Serena, 2013-James Andorko, 2015-

1994- Graduate Research Preliminary ExaminerAmrita Joshi 1996Hae-Sun Park 1996Christiana Dellorusso 1998Meera Nathan 1998Chen Zhu 1999Silviu Tamashdan 2000

1990- Research Preceptor, Non-degreeTrey Moore, medical student, 1991Steve Lookadoo, medical student, 1992Robert Sawyer, MD, transplant fellow, 1994-1996Dominique Pahud, undergraduate, 1994-1996Katie Ezis, undergraduate, 1994-1995Lisa Debruyne, PhD, postdoc, 1995-1998Takeshi Tono, MD, postdoc, 1995-1998John Magee, MD, transplant fellow, 1996-1998Randy Sung, MD, transplant fellow, 1997-1999Yalai Bai, MD, PhD, postdoc, 1998-2000YiNong Wang, MD, PhD, postdoc, 1999-2000Hui Zhang, PhD, postdoc, 2000Annette Busch, PhD, postdoc, 2000Shuang Fu, PhD, postdoc, 2000-2004Shaun Honig, medical student, 2000-2002Tom Schmidt, high school student, 2000Chris Price, graduate student, 2000-2001Xia Mao, MD, PhD, postdoc, 2001-2003Dongmei Chen, MD, PhD, postdoc, 2001-2005

22

Dmitriy Zamarin, MSTP student, 2001Ruthie Su, medical student, 2001-2003Daniel Klein, undergraduate, 2002Laura Brown, undergraduate, 2002Adam Yopp, surgery resident, 2002-2004Veerawat Phongtankuel, undergraduate, 2003Wangyu Liu, undergraduate, 2003Nan Zhang, MD, PhD, postdoc, 2002-2008Tony Qian, undergraduate, 2003Jordi Ochando, PhD, postdoc, 2003-2007Eduardo Galeano, BS, medical student, 2004Jason Light, undergraduate, 2004Brad Kligman, undergraduate, 2004-2005Marina Frimer, undergraduate, 2004Levi Ledgerwood, BS, medical student, 2004-2008Chiho Homma, MD, postdoc, 2004-2005David Chen, undergraduate, 2005-2006Sarah Freeman, undergraduate, 2005Irene Epelboym, BS, medical student, 2005Herman Nikolayevski, high school student, 2004-2006Helene Peche, postdoc, 2005-2006Girdhari Lal, postdoc, 2006-presentChandni Saxena, undergraduate, 2006Josephine Giles, undergraduate, 2006Steven Esses, medical student, 2006Jonathan Yao, medical student, 2006Jefferson Lin, undergraduate, 2006Ann Monahan, medical student, 2007Eric Gehrie, medical student, 2007Na Yin, postdoc, 2008-2011Yumi Nakayama, postdoc, 2008-2013Bryna Burrell, postdoc, 2009-2013Jeremy Tietjens, medical student, 2009Colin Brinkman, postdoc, 2011-presentJiangnan Xu, postdoc, 2011-2012Daiki Iwami, postdoc, 2012-2014Kristi Warren, postdoc, 2012-2013Yanbao Xiong, postdoc, 2013-presentSarwat Ahmad, postdoc, 2013-present

1996-1999 Resident Mentor: David Axelrod

EXTRAMURAL INVITED PRESENTATIONS

CD2 and immune suppression, Procept, Boston, MA, September 27, 1990.

23

Anti-CD2 monoclonal antibodies inhibit cell mediated immunity in vivo, Virginia Mason Research Center, Seattle, WA, October 10, 1990.

CD2 and transplantation, Procept, Boston, MA, June 28, 1991.

CD2: Manipulation in immunity and homotypic adhesion, Dept. of Surgery, Stanford University, Palo Alto, CA, January 31, 1992.

Manipulation of immunity: Studies of CD2 receptor function, Virginia Mason Research Center, Seattle, WA, February 3, 1992.

Pancreas transplantation, Department of Surgery, Aachen, Germany, August 24, 1992.

Use of anti-CD2 antibodies in transplantation, Immunology Institute, Heidelberg, Germany, August 26, 1992.

A cytokine approach to transplantation tolerance, Transplant Department, California Pacific Medical Center, San Francisco, CA, October 14, 1993.

Gene therapy in transplantation, Department of Surgery, Willford Hall Medical Center, San Antonio, TX, April 9, 1994.

Adrenal suppression and steroid supplementation in transplant patients, Surgery Grand Rounds, Emory University Medical Center, Atlanta, GA, December 7, 1994.

CD2 and Transplantation Tolerance, University of Minnesota, Minneapolis, MN, April 6, 1995.

CD2 and Transplantation Tolerance, Biotransplant, Inc. Boston, MA, April 26, 1995.

Peripheral Tolerance Induction with Monoclonal Antibodies, ASHI, Dallas, TX, October 11, 1995.

Gene Therapy in Transplantation, Wayne State University, Detroit, MI, October 31, 1995.

CD2 Related Changes in T Cell Signaling and Immunosuppression, University of Pennsylvania, Philadelphia, PA, November 7, 1995.

Gene Therapy and Surgical Diseases, Academy of Surgery of Detroit, Detroit, MI, April 10, 1996.

CD2 Ligation and Transplant Tolerance, BioTransplant, Inc., Boston, MA, June 7, 1996.

24

Gene Therapy for Transplantation, University of Maryland, Baltimore, MD, September 10, 1996.

Current Status Immunosuppression for Liver Transplantation and Problems Related to Organ Availability, ACS, Postgraduate Course: Diseases of the Liver, Biliary Tract, and Pancreas, San Francisco, CA, October 8, 1996.

Liver Transplantation, Macomb Hospital Center, Warren, MI, November 12, 1996.

CD2 and Transplantation Tolerance, University of Cincinnati, OH, January 7, 1997.

Gene Therapy and Tolerance, Fourth International Conference on Tolerance Induction, Breckenridge, CO, January 22, 1997.

Focus Group Meeting on Tolerance Research, NIAID, Breckenridge, CO, January 20, 1997.

Gene Therapy and Tolerance, Transplantation Grand Rounds, University of Washington, Seattle, WA, February 11, 1997.

The CD2 Pathway, ASTP and ASTS Postgraduate Course, Chicago, IL, May 14, 1997.

Gene Transfer and Gene Therapy in Allografting, 8 th Annual Scientific Meeting Baxter Extramural Grant Program, Chicago, IL, June 11, 1997.

Gene Transfer for Prolongation of Allograft Survival, Mt. Sinai School of Medicine, New York, NY, July 31, 1997.

Gene Therapy for Cardiac Allografting, Genzyme, Framingham, MA, August 28, 1997.

Gene Transfer and Allografting, Oxford University, Oxford, England, December 1, 1997.

Interaction of the Immune System with Gene Therapy Vectors, 5th Annual Congress of the British Society of Immunology, Brighton, England, December 4, 1997.

Gene Therapy and Transplantation, University of Wisconsin, Madison, WI, March 17, 1998.

Gene Therapy in Transplantation, ASTP Basic Science for Clinicians Minicourse, Chicago, IL, May 9, 1998.

Transfer of Cytokine Genes in Transplantation, Fifth Nantes/Actualities/ Transplantation, Nantes, France, June 12, 1998.

25

Use of Antibodies in Transplantation, SUNY Rochester, Rochester, NY, May 4, 1998.

Use of Gene Therapy for Tolerogenic Signals, Immunobiology IV Symposium, Progress in Tolerance Induction, XVII World Congress of the Transplantation Society, Montreal, Canada, July 17, 1998.

Anti-CD2 Monoclonal Antibodies and Transplantation, Renal Transplant and Internal Medicine Grand Rounds, St. Barnabus Medical Center, Livingston, NJ, July 29, 1998.

IL-10 Immunosuppression, Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ, July 29, 1998.

IL-10 Immunosuppression, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, August 6, 1998.

IL-10 Immunosuppression and Immunostimulation, Department of Pathology, Washington University, St. Louis, MO, September 15, 1998.

Regulation of Gene Expression from Transfer Vectors, Division of Transplantation, Northwestern University, Chicago, IL, October 15, 1998.

Identification of Structural Elements Responsible for Immunostimulation by Cellular IL-10, Department of Immunology, Scripps Research Institute, La Jolla, CA, November 6, 1998.

Structural Definition of Immunomodulatory Epitopes of IL-10, Transplantation Research, Novartis Pharmaceuticals Corporation, Summit, NJ, January 19, 1999.

Structural Determinants of IL-10 Immunostimulatory and Immunosuppressive Domains, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, March 12, 1999.

Immunosuppressive Structure of IL-10, University of Maryland, Baltimore, MD, March 19, 1999.

Cytokine Gene Transfer, Immune Tolerance and Gene Therapy in Transplantation, Humboldt Universitat-Charite, Berlin, Germany, April 29, 1999.

Prospects for Tolerance, Update in Transplantation, Recanati/Miller Transplantation Institute, Mt. Sinai School of Medicine, New York, NY June 3, 1999.

Immunostimulatory structure of IL-10, Transplant Biology Initiative, University of Pennsylvania, Philadelphia, PA November 12, 1999.

Prospects for Transplantation Tolerance, Surgery grand rounds, University of British Columbia, Vancouver, British Columbia, December 8, 1999.

26

Molecular Determinants of Immunomodulatory Activity of IL-10, Transplantation research Day, British Columbia Transplant Society, Vancouver, British Columbia, December 9, 1999.

Immunosuppressive and Immunostimulatory Domains of IL-10, Virginia Mason Research Center, Seattle, WA, December 10, 1999.

Pancreas Transplantation and Tolerance, Nephrology Grand Rounds, Beth Israel Medical Center, New York, NY, February 11, 2000.

Pancreas Transplantation and Tolerance, Nephrology Grand Rounds, Winthrop-University Hospital, Mineola, NY, March 3, 2000.

Immunologic Domains of IL-10, Pathology Institute, Case Western Reserve University, Cleveland, OH, April 11, 2000.

Immunologic Tolerance in Transplantation: The ITN Network, Nephrology Division, Case Western Reserve University, Cleveland, OH, April 11, 2000.

Immunologic Structure of IL-10, Transplantation Grand Rounds, University of Cincinnati College of Medicine, Cincinnati, OH, April 18, 2000.

Pancreas Transplantation and Tolerance, Medicine Grand Rounds, Elmhurst Hospital, Queens, NY, April 27, 2000.

Immunologic Structure of IL-10, Transplantation Immunobiology Seminar, Columbia University, New York, NY, May 2, 2000.

Immunologic Effects on Gene Expression, International Society of Nephrology Forefronts in Nephrology Symposium on Gene Therapy, Beaver Creek, CO, June 6, 2000.

Pancreas Transplantation and Tolerance, Medicine Grand Rounds, Kingsbrook Medical Center, Brooklyn, NY, June 28, 2000.

Lymphocyte Trafficking in Tolerance, Symposium on Principles of Transplantation and Autoimmunity, University of Pennsylvania, Philadelphia, PA, October 17, 2000.

Gene Therapy in the Field of Transplantation, Transplant 2000, 2nd International Congress of the Transplantation Centers Coordination Association of Turkey, Istanbul, Turkey, October 26, 2000.

Gene Therapy and Tolerance, AST 5th Annual Winter Symposium, The Road to Clinical Tolerance, Island of Hawaii, February 18, 2001.

Pancreas Transplantation and Tolerance, Medicine Grand Rounds, The Brookdale University Hospital and Medical Center, Brooklyn, NY February 21, 2001.

27

Gene Therapy in Transplantation, Nephrology Research Seminar, The Brookdale University Hospital and Medical Center, Brooklyn, NY February 21, 2001.

Gene Therapy, Department of Veterinary and Biomedical Sciences, University of Nebraska, Lincoln, NE, April 26, 2001.

Gene Therapy in Solid Organ Transplantation, 5th annual Update in Pediatric Liver Transplantation, Mount Sinai School of Medicine, New York, NY, May 1, 2001.

Gene Therapy in Transplantation, North American Society for Dialysis and Transplantation Annual Meeting, Maui, Hawaii, July 17, 2001.

Tolerance, North American Society for Dialysis and Transplantation Annual Meeting, Maui, Hawaii, July 19, 2001.

Gene Therapy in Transplantation, The 7th Basic Sciences Symposium of the Transplantation Society, Thun, Switzerland, August 25, 2001.

Gene Therapy in Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN, September 5, 2001.

T Cell Trafficking in Tolerance, Transplant Conference, University of Maryland, Baltimore, MD, October 26, 2001.

Pancreas Transplantation, Department of Endocrinology, Metabolism, and Nutrition, St. Luke’s Hospital, New York, NY, November 7, 2001.

T Cell Trafficking in Tolerance, University of Edmonton, Alberta, Canada, February 6, 2002.

T Cell Trafficking in Tolerance, Pfizer, Groton, CT, April 4, 2002.

Update in Kidney Transplantation, Medical Grand Rounds, Staten Island University Hospital, Staten Island, NY, April 17, 2002.

Update in Kidney Transplantation, Urology Grand Rounds, Beth Israel Hospital, New York, NY, May 23, 2002.

Update in Kidney Transplantation, Medicine Grand Rounds, Englewood Hospital, Englewood, NJ, May 30, 2002.

T Cell Trafficking in Tolerance, Children’s Hospital Medical Center, Harvard Medical School, Boston, MA, June 6, 2002.

Lymphoid Homing in Tolerance, 2nd Annual FOCIS Meeting, San Francisco, CA, June 28, 2002.

Gene Therapy: Manipulating the Allograft, XIX International Congress of the Transplantation Society, Miami, FL, August 30, 2002.

28

New Considerations in Tolerance, UCLA, Los Angeles, CA, September 10, 2002.

Trafficking of T Cells: New Thoughts on Tolerance and New Mechanisms, University of Pennsylvania, Philadelphia, PA, September 21, 2002.

T Cell Trafficking in Tolerance, Ohio State University, December 4, 2002.

Lymphoid Trafficking and Tolerance, AST Symposium of the American Association of Immunology annual meeting, Denver, CO, May 8, 2003.

Secondary Lymphoid Organs and Induction of Tolerance, ATC 2003, Washington, DC. June 2, 2003.

Lymphoid Homing and Tolerance, Basic Science Symposium 2003 of the Transplantation Society, Keystone, CO, September 16, 2003.

Kidney Transplantation, Medical Grand Rounds, St. Barnabas Hospital, Bronx, NY, November 6, 2003.

Regulation of Lymphocyte Homing to Secondary Lymphoid Organs, American Society of Nephrology Annual Meeting, San Diego, CA, November 14, 2003.

Kidney Transplantation, Medical Grand Rounds, Cabrini Hospital, New York, NY, February 9, 2004.

Kidney Transplantation, Surgical Grand Rounds, New York Methodist Hospital, Brooklyn, NY, February 24, 2004.

New Considerations in Renal Transplantation, Emerging Threats in Health and Medicine Course, New York, NY, March 27, 2004.

Organ and Cell Transplantation: Challenges and Opportunities, American Society of Gene Therapy, 7th Annual Meeting, Minneapolis, MN, June 3, 2004.

Innate Immune Responses to Viral Vectors: Modulation by Regulatory T Cells, American Society of Gene Therapy, 7th Annual Meeting, Minneapolis, MN, June 5, 2004.

Sphingolipid Signaling and Leukocyte Trafficking, FASEB Summer Research Conference in Transplantation Immunology, Snowmass, CO, June 23, 2004.

Gene Therapy and Transplantation, Plenary Session V: Future in Transplantation, XX International Congress of the Transplantation Society, Vienna, Austria, September 10, 2004.

T Cell Trafficking in Transplantation: Role of S1P, Cleveland Clinic, October 20, 2004.

29

Work-up and Listing of Patients for Kidney Transplantation, NS-LIJ Renal Grand Rounds, November 16, 2004.

The Pathways Less Traveled, 5th Annual ASTS Winter Symposium, The Science and Art of Immunosuppression, Miami Beach, FL, January 23, 2005.

Migration and Trafficking in Transplantation and Tolerance, Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA, May 20, 2005.

Chemokine Function and Cell Trafficking in Transplantation, Basic Immunology Course, American Transplant Congress, Seattle, WA, May 21, 2005.

Sphingosine 1-Phosphate Receptor Signaling in Trafficking and Homing, Sunrise Symposium: T-Cell Signaling in Activation, Trafficking, and Tolerance, American Transplant Congress, Seattle, WA, May 24, 2005.

Gene Transfer in Transplantation, 9th Basic Science Symposium of the International Transplantation Society, La Baule, France, June 21, 2005.

Trafficking and Migration in Tolerance, Nephrology Seminar Series, New York University School of Medicine, New York, NY, November 7, 2005.

Migration and Trafficking in Tolerance and Rejection, Alberta Transplant Institute Rounds, Edmonton, Alberta, Canada, December 14, 2005.

T Cell Migration in Tolerance, Immunobiology and Transplantation Biology Research Conference, University of Maryland Institute of Transplantation, Baltimore, MD, January 6, 2006.

Appropriate Preparation for Basic Research: Acquiring the Necessary Tools, 2006 ASTS Winter Basic Science Course, The Fundamentals of Basic Science Research, Scottsdale, AZ, January 19, 2006.

Lymphocyte Trafficking in Rejection and Tolerance: The Right Place at the Right Time, 2006 AST Winter Transplant Forum, Cancun, Mexico, February 16, 2006.

Migration and Trafficking in Transplantation Tolerance, Department of Microbiology and Immunology, London Health Sciences Center, University of Western Ontario, London, Ontario, Canada, March 9, 2006.

Treatment of Immunologically High Risk Kidney Transplant Patients, The Transplantation Society of Taiwan, Taipei, Taiwan, May 27, 2006.

The New You – How You Can Replace Everything, 2nd Annual Challenges in Internal Medicine, Mount Sinai School of Medicine, New York, NY, June 22, 2006.

Chemokines and Chemokine Receptors, Basic Science Update for Clinicians Postgraduate Course, World Transplantation Congress, Boston, MA, July 22, 2006.

30

Therapeutic Implications of Trafficking, State of the Art Symposium on Migration and Trafficking, World Transplant Congress, Boston, MA, July 24, 2006.

T Cell and Dendritic Cell Migration in Transplantation, Gordon Research Conference, Chemotactic Cytokines, Centre Paul Langevin, Aussois, France, September 20, 2006.

How Trafficking of Dendritic Cells and Regulatory Suppressive T Cells Contributes to Tolerance, 30th Congresso Nazionale Societa Italiana Trapianti d’Organo, Padova, Italy, November 30, 2006.

Management of Immunologically High Risk Patients in Kidney Transplantation, 30th

Congresso Nazionale Societa Italiana Trapianti d’Organo, Padova, Italy, December 1, 2006.

The Role of Plasmacytoid Dendritic Cells in Allograft Tolerance, Congres Annuel du Club Francophone des Cellules Dendritiques, Institut Gustave Roussy, Villejuif, France, December 13, 2006.

T Cell and Dendritic Cell Trafficking and Migration in Transplantation Tolerance, Transplantation Research Seminar, University of California at San Diego, San Diego, CA, January 18, 2007.

Management of Immunologically High Risk Patients in Kidney Transplantation, Surgery Grand Rounds, New York Methodist Hospital, Brooklyn, NY March 27, 2007.

T Cell – APC Interactions and the Generation of Treg, Basic: Tolerance, Sunrise Symposium, American Transplant Congress, San Francisco, CA, May 8, 2007.

Trafficking of T Cells and Antigen Presenting Cells for Transplantation Tolerance, RCAI-JSI International Symposium on Immunology, Development and Maintenance of Immune System, Yokohama, Japan, July 26-27, 2007.

Trafficking of T Cells and Antigen Presenting Cells for Transplantation Tolerance, ImClone Systems Incorporated, New York, NY, October 3, 2007.

T Cell Migration in Afferent Lymphatics: New Targets and New Models, Department of Microbiology, Columbia University, New York, NY, December 5, 2007.

S1P1 Stimulation Inhibits Afferent Lymphatic Migration, Keystone Symposium on Leukocyte Trafficking, Keystone, CO, January 14, 2008.

Interruption of Lymphocyte Trafficking and Development of Tregs, 27th Annual Congresss of the The Egyptian Society of Nephrology, Cairo, Egypt, February 13, 2008.

31

Lymphocyte Migration and Tolerance, Medical University of South Carolina, May 15, 2008.

Chemokines and Cell Trafficking, Pre-Meeting Symposium #1 – Transplant Immunology for the Clinician: Transplant Immunology II: Antigen Independent Mechanisms, American Transplant Congress, Toronto, Canada, May 31, 2008.

Plasmacytoid DC in Transplantation, FASEB Summer Research Conference on Transplantation Immunology, New Haven, CT, July 14, 2008.

Migration and Function of Treg, Transplant Immunology Institute, Harvard Medical School, Boston, MA, December 11, 2008.

Migration and Function of Treg, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, January 16, 2009.

Migration and Function of Treg, Department of Surgery, University of Minnesota School of Medicine, Minneapolis, MN, January 21, 2009.

Migration and Function of Treg, Division of Transplantation Surgery, Johns Hopkins Hospital, Baltimore, MD, February 20, 2009.

Solid Organ Transplantation, an Overview, Department of Pediatrics, Brooklyn Hospital Center, Brooklyn, NY, February 25, 2009.

Regulatory T Cells Sequentially Migrate from the Site of Tissue Inflammation to the Draining LN to Suppress Allograft Rejection, Transplantation and its Immunology, Annual General Meeting of the Clinical Immunology and Allergy Section, Royal Society of Medicine, London, England, May 11, 2009.

Overview of solid organ transplantation, Surgery Grand Rounds, Methodist Hospital, Brooklyn, NY, May 19, 2009.

B cell alloimmunity – can we overcome it?, World Congress of Nephrology, Milan, Italy, May 24, 2009.

Migration, differentiation and function of regulatory suppressive T cells, Tolerance and Immunoregulation Satellite Symposium of the European Congress of Immunology, Berlin, Germany, September 12, 2009.

Migration, Trafficking and Tolerance: Anatomy of Immune Regulation, Distinguished Visiting Professors Lecture, USUHS, Bethesda, MD, January 28, 2010.

Induction, Migration and Function of Regulatory T Cells, University of Connecticut, Farmington, CT, February 11, 2010.

Induction, Migration and Function of Regulatory T Cells, University of Maryland, Baltimore, MD, February 16, 2010.

32

Induction, Migration and Function of Regulatory T Cells, University of Pittsburgh, Pittsburgh, PA, February 19, 2010.

Induction, Migration and Function of Regulatory T Cells, University of Chicago, Chicago, IL, March 1, 2010.

Debate: Where are we with islet transplantation? CON position, Rachmiel Levine Diabetes and Obesity Symposium, Las Vegas, NV, March 17, 2010.

Update on Kidnay and Pancreas Transplantation, Internal Medicine Grand Rounds, Brooklyn Hospital, Brooklyn, NY, March 23, 2010.

Regulating the immune response: does this really happen in people?, Pre-meeting: Essential Immunology for the Clinician, American Transplant Congress, San Diego, CA, May 1, 2010.

Lymph Nodes and Lymphatic Structures in Tolerance, in Transplantation in Depth: Toward Tolerance in Transplantation: Who Are the New Players?: Innate Mechanisms, American Transplant Congress, San Diego, CA, May 2, 2010.

Induction and Migration of Regulatory T Cells, 8th Annual Meeting of Cancer Immunotherapy (CIMT), Mainz, Germany, May 28, 2010.

Induction, Migration and Function of Regulatory T Cells, 36 th Annual ASHI Meeting, Fort Lauderdale, FL, September 27, 2010.

Do New Clinical Protocols Account for Treg and Is This Important? Lessons from Basic Studies, AST Annual Scientific Exchange, Orlando, FL, October 22, 2010.

Induction, Migration, and Function of Treg, AST Annual Scientific Exchange, Orlando, FL, October 24, 2010.

Induction, Migration, and Function of Treg, Immunology: Looking Forward, 25 th

Anniversary Symposium, Benaroya Research Institute, Seattle, WA, October 27, 2010.

Induction, Migration, and Function of Treg, Alberta Transplant Applied Genomics Center, University of Alberta, Edmonton, Canada, January 12, 2011.

Induction, Migration, and Function of Treg, Keystone Symposium on Immunoregulatory Netoworks, Breckenridge, CO, April 2, 2011.

Pancreas Transplantation, Laurel Regional Hospital, Laurel, MD, April, 21, 2011.

Regulating the immune response: does this really happen in people, ATC 2011 pre-conference meeting, Essential immunology for the clinician, Philadelphia, PA, April 30, 2011.

33

Cellular and physical requirements for tolerance induction in transplantation: role of MDSCs and lymph nodes, ATC 2011 Transplantation in depth: tolerance is an active immunological process: mechanisms of tolerance in transplantation and autoimmunity, Philadelphia, PA, May 2, 2011.

Migration and trafficking tolerance, National Kidney Foundation of Maryland, Baltimore, MD, May 19, 2011.

Treg as therapeutic tools for transplantation tolerance and control of autoimmunity, 13th World Congress of the International Pancreas and Islet Transplant Association, Prague, Czech Republic, June 4, 2011.

Homing of regulatory T cells, XII TTS Basic Science Symposium, II ESOT Basic Science Meeting, Brewster, MA, June 11, 2011.

B cells are required for transplantation tolerance, AST-ASHI Symposium Tolerogenic B Cells and B Cell Signatures in Transplant Rejection and Tolerance, FOCIS, Washington, DC, June 23, 2011.

Surgical Challenges, Solutions in the Lab, ASTS 12th Annual State of the Art Winter Symposium, Miami, FL, January 13, 2012.

Anatomy of tolerance, Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, January 23, 2012.

Transplantation Immunology, Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, January 23, 2012.

Anatomy of Tolerance (or Why Surgeons are so Important for Research), Honor lecturer, 32nd F.L. Raffucci Forum, 62nd meeting of the Puerto Rico Chapter of the American College of Surgeons, San Juan, Puerto Rico, February 24, 2012.

Innate and Adaptive Immunity: The Role of Myeloid Cells, Canadian Society for Transplantation Annual Scientific Meeting, Quebec City, Quebec, Canada, February 25, 2012.

Anatomy of Tolerance, PharmacoNeuroImmunology Program, University of Minnesota, Minneapolis, MN, April 5, 2012.

Regulating the Immune Response: does this really happen in people? Pre-Meeting Symposium: Applying Immunology to the Transplant Setting: Joint Program for Basic Scientists and Transplant Clinicians, American Transplant Congress, Boston,MA, June 2, 2012.

Anatomy of Tolerance: Lymph Node Migration and Induction of Treg, Transplantation in Depth – Basic Science, The Wild World of Regulatory Cells – From Bench to Bedside, American Transplant Congress, Boston, MA, June 4, 2012.

34

Anatomy of Tolerance: Lymph Node Migration and Induction of Treg, 12th International Conference on the Immunology of Diabetes, Victoria, British Columbia, Canada, June 18, 2012

Immune Regulation in Humans, TSANZ Postgraduate Training Course, ANU Campus, Canberra, Australia, June 26, 2012.

Treg: Induction, Migration, and Function, Novartis Pharmaceuticals Lecturer, Transplantation Society of Australia and New Zealand, 30th Annual Meeting, ANU Campus, Canberra, Australia, June 27, 2012.

B Cells and Tolerance, President’s Lecture, Transplantation Society of Australia and New Zealand, 30th Annual Meeting, ANU Campus, Canberra, Australia, June 29, 2012.

Treg: Induction, Migration, and Function, Royal Prince Alfred Hospital and the Centenary Institute, Sydney, Australia, July 2, 2012.

Anatomy of Tolerance: Lymph Node Migration and Induction of Treg, Transplant Grand Rounds, University of Wisconsin, Madison, WI, September 18, 2012.

Anatomy of Immunity (or Why Surgeons are so Important for Research), Surgery Grand Rounds, University of Wisconsin, Madison, WI, September 19, 2012.

American Transplant Congress 2013, PreMeeting Symposium, Basic Immunology and Transplant Immunology for the Clinician. Cell Mediated Rejection; Effector Mechanisms, Injury and Consequence. Seattle, WA, May 18, 2013.

American Transplant Congress 2013, Fundamental Concepts of Transplantation. Basic Science Research: Lessons from the Laboratory. Breakout Panels: Why I Love It *Basic Science. Seattle, WA, May 19, 2013.

American Transplant Congress 2013, Controversies in Transplantation. Basic: Establishing Chimerism for Transplant Tolerance: Necessary, Practical? Seattle, WA, May 21, 2013.

Anatomy of Tolerance, 12th Annual Department of Surgery Research Symposium, Distinguished Visiting Professor of Surgical Sciences, Emory University School of Medicine, Atlanta, GA, June 13, 2013.

Treg Trafficking, Leukocyte Trafficking to Inflammatory Sites, Basic and Clinical Science Symposium, ASN Week, Atlanta, GA, November 8, 2013.

Future Directions in Immunosuppression, 14th Canadian Transplant Forum, Montreal, Canada, November 23, 2013.

Career Development: Finding Your Niche, ASTS 14th Annual Winter Symposium, Miami Beach, FL, January 24, 2014.

35

TED Format: Science, ASTS 14th Annual Winter Symposium, Miami Beach, FL, January 25, 2014.

Regulatory T Cell Trafficking, Immunology Colloquim, University of Pennsylvania, Philadelphia, PA, March 4, 2014.

What’s Hot, What’s New – Basic Science, World Transplant Congress, San Francisco, CA, July 31, 2014.

Cell Mediated Rejection: Effector Mechanisms in Graft Injury, Pre-Meeting Course: Basic Immunology and Transplant Immunology for the Clinician, American Transplant Congress, Philadelphia, PA, May 2, 2015.

The Microbiotome Following Clinical Renal Transplantation, Microbiota (colon) A New Bug in Transplantation, Sunrise Symposium, American Transplant Congress, Philadelphia, PA, May 5, 2015.

The Influence of the Microbiota in Immunity and Transplantation, Plenary Session, 36th ISHLT Annual Meeting, Washington, D.C., April 30, 2016.

Regulatory T Cell Trafficking, University of Virginia, Charlottesville, VA, May 19, 2016.

Top 10 Immunology Papers of the Year, Advanced Immunology Updates for Basic and Clinical Scientists, ATC Postgraduate Course, Boston, MA, June 11, 2016.

Analyzing Treg in Vivo, Immune Cell Trafficking In Vivo New Insights, ATC Miday Symposium, Boston, MA, June 13, 2016.

How to Publish my Paper, Post-Graduate Course on Focussed Session 2 on Presentation and Writing Skills, 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

How the Microbiota Shape the Alloresponse, Post-Graduate Course on The Adaptive Immune System: T cells, 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

Migration and Trafficking of Regulatory T Cells, Lung Research Conference, Pulmonary Division, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, September 15, 2016.

Regulatory T Cell Migration, Transplant Grand Rounds, Mayo Clinic, Rochester, MN, October 17, 2016.

COMMITTEE AND ADMINISTRATIVE SERVICE

National

36

1991- 94 Diagnostic and Therapeutic Technical Assessment Panel, American

Medical Association

1992-94 Program Committee, Association for Academic Surgery

1992-94 Charleston County Medical Society, Medico-Legal Committee

1992 Chairman, Transplantation Section, Association of Academic Surgery, Montreal, Canada, November, 1992

1992 Co-chairman, Anti-Activation Factor Receptor Monoclonal Antibodies, XIV International Congress of the

Transplantation Society, Paris, France, August 17-21, 1992

1993 Chairman, Transplantation and Immunology Sections, Association for Academic Surgery, Hershey, PA, November 10-13, 1993

1994 Co-Chairman, Graft Tolerance and Rejection Minisymposium, Experimental Biology 94, Anaheim, CA, April 24-28, 1994.

1994-97 Program and Publications Committee, American Society of Transplant Surgeons.

1994 Moderator, Transplantation I, ACS Surgical Forum, Chicago, IL, October 10, 1994.

1995 Chairman, Strategies for Improvement of Graft Survival Minisymposium, Experimental Biology 95, Atlanta, GA, April 10-14, 1995.

1995 Co-chairman, Experimental Immunosuppression, American Society of Transplant Physicians, Chicago, IL, May 14-17, 1995.

1995 Chairman, Immunobiology, American Society of Transplant Surgeons, Chicago, IL, May 17-19, 1995.

1996-99 Chairman, Scientific Studies Committee, American Society of Transplants Surgeons.

1996 Chairman, Immunobiology, American Society of Transplant Surgeons, Dallas, TX, May 29-31, 1996

1997-00 SUS Representative to the National Association of Biomedical Research.

1997 Chairman, Immunobiology, American Society of Transplant Surgeons, Chicago, IL, May 14-16, 1997.

37

1997 Co-chairman, Program Committee, Basic Science-3 Subcommittee, American Society of Transplant Physicians.

1997 ASTP/ASTS Task Force on Transplantation Tolerance, Chicago, IL, Oct. 23-24, 1997.

1998 Co-chairman, Tolerance II, American Society of Transplant Physicians, Chicago, IL, May 9-13, 1998.

1998 Co-chairman, Immunobiology II, American Society of Transplant Surgeons, Chicago, IL, May 13-15, 1998.

1998-01 Awards Committee, American Society of Transplant Physicians.

1998 Co-chairman, Gene Therapy in Vascular Biology, XVII World Congress of the Transplantation Society, Montreal, Canada, July 12-17, 1998.

1998 Co-chairman, ASTS/ASTP Interdisciplinary Conference on Steroid Withdrawal, St. Louis, MO, September 16-17, 1998.

1999 UNOS Scientific Advisory Committee.

1999 UNOS Tumor Registry Scientific Advisory Committee.

1999 Co-chair, Immunopathogenesis of Allograft Rejection, AAI Annual Meeting/Experimental Biology ’99April 21, 1999, Washington, D.C.

1999 Transplant 2000 joint planning committee

2000 AST awards committee

2000 Transplant 2001 joint planning committee

2000-03 Program, Publications, and Postgraduate Course Committee, American Society of Transplant Surgeons

2000 Education Committee, American Society for Gene Therapy and moderator for Cellular Immunology and Humoral Immunology Education Programs

2001 ATC/Transplant 2002, executive planning committee

2001 Transplant 2001, co-chair Postgraduate Course

2001 Transplant 2001, co-chair Selected Posters on

38

Allorecognition/Tissue Injury

2001 Transplant 2001, What’s Hot, What’s New, Basic Science

2001 The 7th Basic Sciences Symposium of the Transplantation Society, co-chair Workshops on Gene Therapy and Gene Arrays

2001 The 7th Basic Sciences Symposium of the Transplantation Society, co-chair Tissue Engineering and Cell/Tissue Bioprocessing

2001 The 2nd International Congress on Immunosuppression, co-chair Basic Science

2002 American Transplant Congress, executive planning committee

2002 International Congress of the Transplantation Society, chair Gene Therapy and Protein Transduction Strategies

2003 American Transplant Congress, chairman executive planning committee

2003 American Transplant Congress, chair Basic Science Symposium, CD8 T Cell Biology

2004 American Transplant Congress, chair Chemokines and Adhesion Molecules session

2004 American Society of Transplantation, ad hoc Cellular Transplantation Committee

2004 XX International Congress of the Transplantation Society, co-chair Experimental Gene Therapy session

2004 American Society of Nephrology Transplantation Research Retreat, October 4-5, 2004, Arlington, VA.

2005-08 ASTS and AST planning committee for the 2006 and 2008 FASEB Conferences on Transplantation Immunology

2005 American Transplant Congress, chair The Nexus of Cell Transplantation, Tissue Engineering and Gene Therapy: Integrating Basic Science and Medicine: Gene Therapy

2005-6 World Transplant Congress, International Advisory Group, Basic Science 3

2005-7 Basic Sciences Abstract Review Committee, American Transplant Congress

39

2006-10 Flance/Karl Awards Committee, American Surgical Association

2006-7 New York State Department of Health Task Force on Living Kidney Donation

2008 Session Chair, new Developments in the Regulation of Tregs, American Transplant Congress, Toronto, Canada, June1, 2008.

2008-2016 Awards Committee, Co-chair (2008-2013), Chair (2013-2016) American Society of Transplant Surgeons

2008-11 Basic Science Advisory Council, American Society of Transplantation

2008-9 Advisory Committee on Issues, American Society of Transplant Surgeons

2008-10 Curriculum Committee Editorial Board, American Society of Transplant Surgeons

2010-13 Awards and Grants Committee, American Society of Transplantation

2010 Session Chair, Transplantation in Depth: Toward Tolerance in Transplantation: Who Are the New Players? American Transplant Congress, San Diego, CA, May 2, 2010.

2010-11 Chairman, Flance/Karl Awards Committee, American Surgical Association

2010 Session Organizer and Co-Chair for AST-ASTS and AST-TTS Joint Symposia for the AST 2nd Annual Scientfic Exchange

2011 Co-chair mid-day symposium, Lymphodepletion and reconstitution of the T cell repertoire, ATC 2011, Philadelphia, PA, May 2, 2011.

Co-chair early morning workshop, Grant Writing Workshop, ATC 2011, Philadelphia, PA, May 3, 2011.

Co-chair Plenary Session, ATC 2011, Philadelphia, PA, May 3, 2011.

Co-chair early morning workshop, Evolving role of NK cells in solid organ transplantation ATC 2011, Philadelphia, PA, May 4, 2011.

40

2012 Co-chair Pre-Meeting: Basic Science Morning Program: Molecular Sensors of Injury/Innate Reactivity to Cell Death and Injury: Molecular Sensors of Injury, American Transplant Congress,Boston, MA, June 2, 2012.

Basic Science Panel Topic: “Why I Love It”, Student Program: The Science, The Art, and The Allure of Transplantation, American Transplant Congress, Boston, MA, June 3, 2012.

Co-chair Early Morning Workshop: Grant Writing - Clinical Science, American Transplant Congress, Boston, MA, June 4, 2012.

2013 Co-chair Morning Workshop 1: Pre-clinical Models of Islet Transplantation, IPITA, Monterey, CA, September 25, 2013.

Co-chair Rapid-Fire 2: Clinical Allogeneic Islet Transplantation, Immunology and Tolerance, IPITA, Monterey, CA, September 25, 2013.

Co-chair Plenary Session IV: Immune Strategies in Beta Cell Therapy/The Paul Lacy Memorial Lecture, IPITA, Monterey, CA, September 27, 2013.

Chair, Grants Committee, ASTS (2013-2016)

2014 Chair, Immune Tolerance, IPITA Opinion Leaders Consensus Meeting on Beta Cell Replacement, Oxford, UK, May 7-9, 2014.

Co-chair, Plenary Session, World Transplant Congress, San Francisco, CA, July 28, 2014.

Co-chair, Kidney Complications: Sensitization, World Transplant Congress, San Francisco, CA, July 30, 2014.

2015 Co-chair, Controversies in Transplantation, Do We Have the Immunosuppressive Tool Box We Need or Should Tolerance Be the Goal? American Transplant Congress, Philadelphia, PA, May 5, 2015.

Co-chair, Transplant Tolerance, Animal Models II, American Transplant Congress, Philadelphia, PA, May 5, 2015.

2016 Co-chair, Allograft Tolerance 1: Animal Models, ATC, Boston, MA, June 12, 2016.

Co-chair, Immune Cell Trafficking In Vivo New Insights, ATC, Boston, MA, June 13, 2016.

41

Co-chair, Transplantomics in Motion, 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

Co-chair, Publishing in Transplantation, 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

University

1990 University Research Committee, Resident Subcommittee1990 Flow Cytometry Use Review Committee1992 Medical Records Committee1991 Anatomy Chairman Search Committee1993 Organizing Committee, 1993 South Carolina Research Conference1992-93 Associate Chief of Staff for Research at the VA Search Committee1993-94 Psychiatry Department, Dean’s Review Committee1994-95 Graduate and Advanced Studies Committee, Microbiology and

Immunology1994-99 Liver and Pancreas Committee, Transplantation Society of

Michigan1995-98 Medical School Biomedical Research Council1995- 99 University of Michigan Multipurpose Arthritis and

Musculoskeletal Disease Center

1995-99 Experimental Immunopathology Training Program Faculty Member

1996-99 Bylaws Committee, Transplantation Society of Michigan1996-99 Cellular and Molecular Biology Program Faculty Member1996-99 Tumor Immunology Program Faculty Member1996-99 Transplant Center Operating Committee1998 Immunology Task Force1999 Translational Facility Workgroup2000-02 Medical Board, New York Organ Donor Network2000-02 General Clinical Research Center Advisory Committee2000-05 Appointments and Promotions Committee1999- MSTP Steering Committee2000 Special Awards and Grants Committee2002-09 Board of Directors, New York Organ Donor Network2002-09 Executive Medical Board2002-09 IPA Board of Directors2002-2009 Surgeon-in-Chief and Clinical Director, Recanati/Miller

Transplantation Institute2003 Task Force on Human Subject Protection2003 Urology Chairman Search Committee2004-05 Endocrine Chairman Search Committee2004-05 ENT Chairman Search Committee2005 Faculty Committee for Honorary Degrees

42

2007-10 Performance Improvement Committee, New York Organ Donor Network

2007-09 Gastroenterology Chairman Search Committee2008 EMR Inpatient Systems Review Committee2008-09 Transplant Executive Committee, chairman2010- Flow Cytometry Shared Research Facility, oversight committee2010- Center for Stem Cell Biology & Regenerative Medicine2012- Oversight committee of the Greenebaum Cancer Center Shared

Flow Cytometry Facility2013- Living Legacy Foundation of MD, Board of Directors2013- Member, Marlene and Stewart Greenebaum Cancer Center2013- Dean’s Research Resource Advisory Group2013- School of Medicine Faculty Council

Department

1990 Surgical Research Committee1991-92 Microbiology and Immunology Graduate Committee1991-93 Microbiology and Immunology Journal Club, Director1994- 97 Microbiology and Immunology, Graduate and Academic

Studies Committee

1996-99 Immunology Journal Club, Director1996 Category IIb Committee1997- 99 Microbiology and Immunology, Medical Curriculum

Committee1998- 99 Surgical Director, Liver Transplantation1999-2010 Surgical Director of Transplantation Research1999-2000 Chairman, immunology faculty search committee for Gene Therapy

and Molecular Medicine2004-10 Surgery Department, Appointment and Promotion Committee2006 Chairman, immunology faculty search committee for Gene and Cell

Medicine2010- Director of Research, Division of Transplantation2010- Director of Strategic Planning for Transplantation Services2011- Chief, Division of Transplant Surgery2011- Chairman, Department of Surgery APT Committee2012- General Clinical Research Center Advisory Committee2015- Physician Compliance Liaison

BIBLIOGRAPHY

Completed Publications in Scientific Journals

Peer Reviewed Publications

43

1. Bromberg, JS, and Schachner, M. Localization of nervous system antigens in retina by immunohistology. Invest Opthalmol Visual Sci 1978; 17:920-924.

2. Pierres, A, Bromberg, JS, Sy, M-S, Benacerraf, B, and Greene, MI. Mechanisms of regulation of cell-mediated immunity. VI. Antigen density dependence of the induction of genetically restricted suppressor cells. J Immunol 1980; 124:343-348.

3. Bromberg, JS, Benacerraf, B, and Greene, MI. Mechanisms of regulation of cell-mediated immunity. VII. Suppressor T cells induced by suboptimal doses of antigen plus an I-J specific allogenic effect. J Exp Med 1981; 153:437-449.

4. Greene, MI, Perry, LI, Sy, M-S, and Bromberg, JS. The I-J subregion and surveillance. Immunol Today 1981; 2:23-25.

5. Bromberg, JS, Flynn, T, Sy, M-S, Benacerraf, B, and Greene, MI. Antigen and receptor driven regulatory mechanisms. IX. T cell - T cell interaction in the generation of first order idiotype bearing suppressor T cells. Clin Immunol Immunopath 1982; 22:180-193.

6. Bromberg, JS, Carpenter, CB, and Greene, MI. Genetics and mode of presentation of antigenic determinants: Influence on immunologic responsiveness in transplantation. Human Immunol 1982; 4:157-166.

7. Bromberg, JS, Nepom, JT, Benacerraf, B, and Greene, MI. Hapten-coupled monoclonal anti-I-A antibodies act as a first signal for the induction of suppression. J Immunol 1982; 128:834-837.

8. Bromberg, JS, Lake, P, and Brunswick, M. Viral antigens act as helper determinants for antibody responses to cell surface antigens. J Immunol 1982; 129:683-688.

9. Brunswick, M, Sainis, KB, Bromberg, JS, and Lake, P. I-J restriction of T cells that suppress in vivo antibody responses to Thy-1. J Immunol 1982; 129:688-698.

10. Bromberg, JS, Delovitch, TL, Kaufman, K, and Greene, MI. In vivo analysis of allogeneic lymphocyte interactions: Activation of suppressor T cells by an I-J restricted allogeneic effect factor (AEF). J Immunol 1983; 130:2250-2255.

11. Bromberg, JS, Eddy, AC, and Herman, CM. Thrombocytopenic purpura associated with the acquired immunodeficiency syndrome. Contemp Surg 1989; 34:89-92.

12. Lau, HT, Bromberg, JS, Chavin, KD, Naji, A, O’Neill, J, Barker, CF, Altevogt, P, Kyewski, B, and Guckel, B. Prolongation of rat to mouse islet xenografts with UV irradiation and antibodies to murine CD2 or CD4. Surgical Forum 1990; XLI:378-379.

44

13. Bromberg, JS, Chavin, KD, Lau, HT, Altevogt, P, Kyewski, BA, Guckel, B, Naji, A, and Barker, CF. Murine CD2 mediates cellular immune responses in vivo. Transpl Proc 1991; 23:856-858.

14. Chavin, KD, Bromberg, JS, Kunkel, SL, Naji, A, and Barker, CF. Effects of a polyclonal anti-TNF antibody on cell mediated immunity in vivo. Transpl Proc 1991; 23:847-848.

15. Bromberg, JS, Chavin, KD, Altevogt, P, Kyewski, BA, Guckel, B, Naji, A, and Barker, CF. Anti-CD2 monoclonal antibodies alter cell mediated immunity in vivo. Transplantation 1991; 51:219-225.

16. Bromberg, JS, Alfrey, EJ, Barker, CF, Chavin, KD, DaFoe, DC, Holland, T, Naji, A, Perloff, LJ, Zellers, LA, and Grossman, RA. Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation 1991; 51:385-390.

17. DaFoe, DC, Bromberg, JS, Grossman, RA, Tomaszewski, JE, Zmijewski, CM, Perloff, LJ, Naji, A, Asplund, MW, Alfrey, EJ, Sack, M, Zellers, L, Kearns, J, and Barker, CF. Renal transplantation despite a positive anti-globulin crossmatch with and without prophylactic OKT3. Transplantation 1991; 51:762-768.

18. Alfrey, EJ, Perloff, LJ, Asplund, MW, DaFoe, DC, Grossman, RA, Bromberg, JS, Naji, A, and Barker, CF. Normocalcemia twelve years after successful parathyroid allografting in a renal transplant recipient. Surgery 1992; 111:234-236.

19. Crumbley, AJ, Bromberg, JS, Cofer, JB, Rajagopalan, PR, and Fitts, CT. Medical aspects of transplantation. J.S.C. Med Assoc 1991; 87:313-328.

20. Redmond, HP, Chavin, KD, Bromberg, JS, and Daly, JM. Inhibition of macrophage activating cytokines is beneficial in the acute septic response. Ann Surg 1991; 214:502-508.

21. Chavin, KD, Lau, HT, and Bromberg, JS. Anti-CD2 monoclonal antibodies prolong allograft and xenograft survival in mice. Transplantation 1992; 54:286-291.

22. Bromberg, JS, Chavin, KD, and Kunkel, SL. Anti-tumor necrosis factor antibodies suppress cell mediated immunity in vivo. J Immunol 1992; 148:3412-3417.

23. Roark, JH, Posselt, AM, Campos, L, Kim, J, Chavin, KD, Bromberg, JS, Barker, CF, and Naji, A. Prolongation of rat pancreatic islet allograft survival by anti-CD2 monoclonal antibody treatment. Transplantation 1992; 54:1098-1099.

24. Bromberg, JS. The biology of CD2: Adhesion, transmembrane signal, and regulatory receptor of immunity. J Surg Res 1992; 54:258-267.

25. Chavin, KD, and Bromberg, JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival and decrease the associated cytokine syndrome. Surgical Forum 1992; XLIII:391-392.

45

26. Bromberg, JS, and Chavin, KD. Multiple mechanisms of anti-CD2 immunosuppression: Receptor blockade, generation of suppressors, and alteration of cytokine production. Surgical Forum 1992; XLIII:393-395.

27. Chavin, KD, Qin, L, Lin, J, Kaplan, AJ, and Bromberg, JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993; 55:901-908.

28. Cofer, J, Galbraith, B, Bailey, M, Bromberg, J, Rajagopalan, PR, Fitts, CT, Conroy, J, Wilson, F, and Crawford, F. Liver transplantation in South Carolina. JSC Med Assoc 1993; 89:111-118.

29. Chavin, KD, Qin, L, Lin, J, Kaplan, AJ, and Bromberg, JS. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease associated cytokine production. Transplant Proc 1993; XXV:823-824.

30. Chavin, KD, Qin, L, Lin, J, Woodward, JE, Baliga, P, and Bromberg, JS. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering IL-2, IL-4, TNF and TGF production. Ann Surg 1993; 218:492-503.

31. Bromberg, JS, and Grossman, RA. Care of the organ transplant recipient. J Am Board of Fam Prac 1993; 6:563-576.

32. Chavin, KD, Qin, L, Tahara, H, Robbins, PD, Lotze, MT, and Bromberg, JS. Gene transfer of TGF and viral IL-10 prolong cardiac allograft survival. Surgical Forum 1993; XLIV:407-409.

33. Chavin, KD, Qin, L, Lin, J, Yagita, H, and Bromberg, JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor specific tolerance in a cardiac transplant model. J Immunol 1993; 151:7249-7259.

34. Kaplan, AJ, Chavin, KD, Yagita, H, Sandrin, MS, Qin, L, Lin, J, Lindemayer, G, and Bromberg, JS. Production and characterization of soluble and transmembrane murine CD2: Demonstration that CD48 is a ligand for CD2 and that CD48 adhesion is regulated by CD2. J Immunol 1993;151:4022-4032.

35. Qin, L, Chavin, KD, Lin, J, Yagita, H, and Bromberg, JS. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med 1994; 179:341-346.

36. Roberts, CS, LaFond, J, Fitts, CT, Rajagopalan, PR, Baliga, P, Cofer, JB, and Bromberg, JS. New patterns of transplant nephrectomy in the cyclosporine era. J Am Coll Surg 1994; 178:59-64.

37. Rajagopalan RP, Hanevold, CD, Orak, JD, Cofer, JB, Bromberg, JS, Baliga, P, and Fitts, CT. Valve bladder does not affect the outcome of renal transplants in children

46

with renal failure due to posterior urethral valves. Transplant Proc 1994; 26:115-116.

38. Borowicz, MR, Hanevold, CD, Cofer, JB, Bromberg, JS, Orak, JK, and Rajagopalan, PR. Extrinsic compression in the iliac fossa can cause renal vein occlusion in pediatric kidney recipients but graft loss can be prevented. Transplant Proc 1994; 26:119-120.

39. Chavin, KD, Qin, L, Woodward, J, Lin, J, and Bromberg, JS. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine A or rapamycin to induce tolerance. Transplantation 1994; 57:736-740.

40. Chavin, KD, Qin, L, Yon, R, Lin, J, Yagita, H, and Bromberg, JS. Anti-CD2 monoclonal antibodies suppress cytotoxic lymphocyte activity by the generation of TH2 suppressor cells and receptor blockade. J Immunol 1994; 152:3729-3739.

41. Chernow, B, Salem, M, Tainsh, RE, Bromberg, JS, and Loriaux, DL. Perioperative glucocorticoid coverage - A reassessment 39 years after emergence of a problem. Ann Surg 1994; 219:416-425.

42. Chavin, KD, Qin, L, Lin, J, Woodward, J, Baliga, P, Kato, K, Yagita, H, and Bromberg, JS. Anti-CD48 (murine CD2 ligand) monoclonal antibodies suppress cell mediated immunity in vivo. Int Immunol 1994; 6:701-709.

43. Gates, CE, Reed, CE, Bromberg, JS, Everett, ET, and Baron, PL. p43 mutations found with high incidence in patients with squamous cell carcinoma of the esophagus. J Thoracic Cardiovasc Surgery 1994; 108:148-152.

44. Bromberg, JS, Self, S, Zellers, L, Baliga, P, Cofer, JB, and Rajagopalan, PR. OKT4 epitope correlates with renal allograft survival in African Americans. Cytometry 1994; 18:93-94.

45. Adams, DB, and Bromberg, JS. Laparoscopic cholecystectomy in pancreas transplant recipients. Surg Endoscopy 1994; 8: 890-892.

46. Qin, L, Chavin, KD, Ding, Y, Woodward, JE, Favaro, JP, Lin, J, and Bromberg, JS. Gene therapy for transplantation: Prolongation of allograft survival with TGF1. Ann Surg 1994; 220:508-519.

47. Chavin, KD, Qin, L, Ding, Y, Tahara, H, Robbins, PD, Lotze, MT, Bromberg, JS. Viral IL-10 gene transfer prolongs cardiac allograft survival by promoting TH2 mediated suppression. Surgical Forum 1994; XLV:407-408.

48. Baliga, P, Woodward, J, Qin, L, Chavin, K, Linsley, P, Bromberg, JS. Induction of tolerance by simultaneous blockade of multiple coreceptors. Surg Forum 1994; XLV: 436-438.

47

49. Baliga, P, Chavin, KD, Qin, L, Woodward, J, Lin, J, Linsley, PS, and Bromberg, JS. CTLA4Ig prolongs allograft survival while suppressing cell mediated immunity. Transplantation 1994; 58: 1082-1090.

50. Kaplan AJ, Chavin KD, Qin, L, Yagita, H, Bromberg, JS. Production of multiple murine CD2 receptor constructs using the baculovirus expression vector and a rapid dot-blot assay. Immunologic Res 1994; 13: 42-48.

51. Kaplan, AJ, Rames, R, Bromberg, JS, Multiple giant urethral diverticula: an unusual complication of confirmed kidney/pancreas transplantation. Transplantation 1995; 59: 910-912.

52. Qin, L, Chavin, KD, Ding, Y, Favarro, JP, Woodward, JE, Lin, J, Tahara, H, Robbins, P, Shaked, A, Ho, DY, Sapolsky, RM, Lotze, MT, Bromberg, JS. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model: Immunosuppression with TGF-1 or vIL-10. Transplantation 1995; 59: 809-816.

53. Lin, J, Yon, RW, Chavin, KD, Qin, L, Woodward, J, Ding, Y, Yagita, H, Bromberg, JS. Anti-CD2 monoclonal antibody induced receptor changes I. Down modulation of cell surface CD2. Transplantation 1995; 59: 1162-1171.

54. Bromberg, JS, Baliga, P, Cofer, JB, Rajagopalan, PR, and Friedman, RJ. Stress steroids not required for renal allograft patients undergoing operation. J American Coll Surg 1995; 180:532-536.

55. Punch, JD, Shieck, VL, Campbell, DA, Bromberg, JS, Turcotte, JG, Merion, RM. Corticosteroid withdrawal after liver transplantation. Surgery 1995; 118: 783-788.

56. Lin, J, Qin, L, Chavin, KD, Ding, Y, Punch, JD, Yang, Q, Burkly, LC, Bromberg, JS. CD3 and CD2 ligation alter CD49d epitope expression. Pathobiol. 1995; 63:119-132.

57. Lin, J, Chavin, KD, Qin, L, Ding, Y, and Bromberg, JS. Anti-CD2 monoclonal antibody induced receptor changes II: Interaction of CD2 and CD3. Cell. Immunol. 1996; 167:249-258.

58. Friedman, RJ, Schiff, CF, Bromberg, JS. Use of supplemental stress steroids in orthopedic surgery. J Bone Joint Surg 1995; 77-A:1801-1806.

59. Chavin, KD, Woodward, JE, Bayer, AL, Nabavi, N, Bromberg, JS, and Baliga, P. In vivo blockade of multiple receptor-ligand pairs of the T cell costimulatory pathway CD28/CTLA4 prolongs allograft survival indefinitely. Surg. Forum 1995; XLVI:431-432.

60. Lin, J, Qin, L, Chavin, KD, Yang, Q, Ding, Y, Punch, JD, and Bromberg, JS. Increased cAMP and PKA activity mediate anti-CD2 induced suppression of anti-CD3 driven IL-2 production and IL-2R expression. Pathobiol. 1995; 63:175-187.

48

61. Qin, L, Chavin, KD, Tahara, H, Ding, Y, Favarro, J, Woodward, J, Lin, J, Robbins, PD, Lotze, MT, Bromberg, JS. Retrovirus-mediated transfer of viral interleukin-10 gene prolongs murine cardiac allograft survival. J. Immunol. 1996; 156:2316-2323.

62. Ding, Y, Qin, L, Yang, Q, Punch, JD, Fox, DA, Hochman, PS, and Bromberg, JS. A novel murine model for the assessment of human CD2 related reagents in vivo. J. Immunol. 1996; 157:1863-1869.

63. Woodward, JE, Qin, L, Chavin, KD, Lin, J, Tono, T, Ding, Y, Linsley, PS, Bromberg, JS, Baliga, P. Blockade of multiple costimulatory receptors induces tolerance: Inhibition of CD2 and CD28 pathways. Transplantation 1996; 62:1011-1018.

64. Qin, L, Ding, Y, and Bromberg, JS. Gene transfer of transforming growth factor-1 prolongs murine cardiac allograft survival by inhibiting cell mediated immunity. Human Gene Therapy 1996; 7:1981-1988.

65. Krieger, NR, Most, D, Bromberg, JS, Holm, B, Huie, P, Sibley, RK, DaFoe, DC, Alfrey, EJ. Coexistence of TH1 and TH2 type cytokine profiles in anti-CD2 monoclonal antibody induced tolerance. Transplantation 1996; 62:1285-1292.

66. Qin, L, Ding, Y, Pahud, DR, Robson, ND, Shaked, A, and Bromberg, JS. Adenovirus-mediated gene transfer of viral interleukin 10 inhibits the immune response to both alloantigen and adenoviral antigen in a murine cardiac transplantation model. Human Gene Therapy 1997; 8:1365-1374.

67. Baron, PL, Gates, CE, Reed, CE, Dikeman, R.L.D., Drosieko, JT, Passmore, R, Bromberg, JS, Willingham, MC. p53 overexpression in squamous cell carcinoma of the esophagus. Ann. Surg. Oncol. 1997; 4:37-45.

68. Qin, L, Ding, Y, Virsik, PA, Pahud, DR, Chang, E, Imperiale, MJ, and Bromberg, JS. Promoter attenuation in gene therapy: IFN and TNF inhibit transgene expression. Human Gene Therapy 1997; 8:2019-2029.

69. Qin, L, Pahud, DR, Ding, Y, Bielinska, AU, Kukowska-Latallo, JF, Baker, JR, and Bromberg, JS. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Human Gene Therapy 1998; 9:553-560.

70. Bromberg, JS, DeBruyne, LA, Qin, L. Interactions between the immune system and gene therapy vectors. Bidirectional regulation of response and expression. Adv. Immunol. 1997; 69:353-409.

71. Merion, RM, Howell, T, and Bromberg, JS. Partial T cell activation, anergy, and Th1/Th2 switching induced by polyclonal antithymocyte globulin. Transplantation 1998; 65:1481-1489.

49

72. Punch, JD, Tono, T, Qin, LH, Bishop, K, and Bromberg, JS. Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: evidence for an IL-4 requirement. J. Immunol. 1998; 161:1156-1162.

73. Debruyne, LA, Li, K, Chan, SY, Qin, L, Bishop, KD, and Bromberg, JS. Lipid-mediated gene transfer of viral IL-10 prolongs vascularized allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Therapy, 1998; 5:1079-1087.

74. Punch, JD, Bluestone, J, Lin, J, and Bromberg, JS. CD2 and CD3 receptor mediated tolerance: constraints on T cell activation. Transplantation, 1999; 67:741-748.

75. Boasquevisque, CHR, Mora, BN, Boglione, M, Ritter, JK, Schule, RK, Yew, N, Debruyne, L, Qin, L, Bromberg, JS, and Patterson, GA. Liposome-mediated gene transfer in rat lung transplantation: A comparison between the in vivo and ex vivo approaches. J. Thorac Cardiovasc Surg, 1999; 117:8-15.

76. Campbell, DA, Magee, JC, Punch, JD, Merion, RM, Turcotte, JG, and Bromberg, JS. One center’s experience with liver transplantation: alcohol use relapse over the long term. Liver Transplantation and Surgery 1998; 4:S58-64.

77. Blazar, BR, Taylor, PA, Panoskaltsis-Mortari, A, Yagita, H, Bromberg, JS, and Vallera, DA. A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantation. Blood, 1998; 92:4453-4467.

78. Qin, L, Ding, Y, and Bromberg, JS. Use of gene therapy for tolerogenic signals. Transplantation Proc., 1999; 31:882-883.

79. Magee, JC, DeBruyne, LA, Buelow, R, Bromberg, JS. Gene transfer of immunosuppressive peptides B2702 and RDP1257 prolongs allograft survival: Evidence suggesting a role for heme oxygenase-I. Transplantation Proc., 1999; 31:1194.

80. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wienser RH, Swinnen LJ, Woodle SE, and Bromberg JS. EVB-induced post-transplant lymphoproliferative disorders (PTLD). Transplantation, 1999, 68:1517-1525.

81. Ding, Y, Qin, L, Kotenko, SV, Pestka, S, Bromberg, JS. A single amino acid determines the immunostimulatory activity of IL-10. J. Exp. Med., 2000, 191:213-224.

82. DeBruyne LA, Magee JC, Buelow R, and Bromberg JS. Gene transfer of immunomodulatory peptides correlates with heme oxygenase-1 induction and enhanced allograft survival. Transplantation, 2000, 69:120-128.

50

83. Henke PK, DeBruyne LA, Strieter RM, Bromberg JS, Prince M, Kadell AM, Sarkar M, Londy F, Wakefield TW. Viral interleukin-10 gene transfer decreases inflammation and cell adhesion molecule expression in a rat model of venous thrombosis. J. Immunol., 1999, 164:2131-2141.

84. DeBruyne LA, Li K, Bishop DK, Bromberg JS. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor specific immunity. Gene Therapy, 2000, 7: 575-582.

85. Wang Y, Boros P, Liu J, Qin L, Bai Y, Bielinska AU, Kukowska-Latallo JF, Baker JR, Bromberg JS. DNA/dendrimer complexes mediate gene transfer into murine cardiac transplants ex vivo. Molecular Therapy 2000, 2:602-608.

86. Qin L, Ding Y, Tahara H, Bromberg JS. Viral IL-10 induced immunosuppression requires TH2 cytokines and impairs APC function within the allograft. J.Immunol. 2001, 166:2385-2393.

87. Sung RS, Qin L, Bromberg JS. TNF and IFN induced by innate anti-adenoviralimmune responses inhibit adenovirus mediated transgene expression. Molecular Therapy 2001, 3:757-767.

88. Bai Y, Ding Y, Spencer S, Lasky LA, Bromberg JS. Regulation of the association between PSTPIP and CD2 in murine T cells. Exp. Molec. Pathol., 2001, 71:115-124.

89. Zhang, H, Fu, S, Busch, A, Chen, F, Qin, L, Bromberg, JS. Identification of TNF- sensitive sites in HCMVie1 promoter. Exp. Molec. Pathol., 2001, 71:106-114.

90. Ding, Y, Qin, L, Tarcsafalvi, A, Kotenko, SV, Pestka, S, Moore, KW, Bromberg, JS. Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. J. Immunol., 2001, 167:6884-6892.

91. Wang, Y, Bai, Y, Price, C, Boros, P, Qin, L, Bielinska, AU, Kukowska-Latallo, JF, Baker, JF, Bromberg, JS. Combination of electroporation and DNA/dendrimer complexes enhances gene transfer into murine cardiac transplants. Am. J. Transplant., 2001, 1:334-338.

92. Bai, Y, Liu, J, Wang, Y, Honig, S, Qin, L, Boros, P, Bromberg, JS. L-selectin dependent lymphoid occupancy is required to induce alloantigen specific tolerance. J. Immunol, 2002, 168:1579-1589.

93. Genden, EM, Boros, P, Liu, J, Bromberg, JS, Mayer, L. Orthotopic tracheal transplantation in the murine model. Transplantation, 2002, 73:1420-1425.

94. Yang, Z, Chen, M, Wu, R, Fialkow, LB, Bromberg, JS, McDuffie, M, Naji, A, and Nadler, JL. Suppression of autoimmune diabetes by viral interleukin 10 gene transfer. J. Immunol., 2002, 168:6479-6485.

51

95. Singer, NG, Fox, DA, Haqqi, TM, Beretta, L, Endres, JS, Prohaska, S, Parnes, JR, Bromberg, JS, and Sramkoski, RM. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int. Immunol., 2002, 14:585-597.

96. Bai YB, Fu S, Honig S, Wang Y, Qin L, Chen D, Bromberg JS. CD2 is a dominant target for allogeneic responses. Am. J. Transplant., 2002, 2:618-626.

97. Florman S, Benchimol C, Lieberman K, Burrows L, Bromberg JS. Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen. Pediatric Transplantation., 2002, 6:352-355.

98. Ding Y, Chen, D, Tarcsafalvi, A, Su R, Qin L, Bromberg JS. Suppressor of cytokine signaling 1 inhibits IL-10 mediated immune responses. J. Immunol., 2003, 170:1383-1391.

99. Honig SM, Fu S, Mao X, Yopp A, Gunn MD, Randolph GJ, Bromberg JS. FTY720 stimulates multidrug transporter and cysteinyl leukotriene dependent T cell chemotaxis to lymph nodes. J. Clin. Invest., 2003, 11:627-637.

100. Genden EM, Iskander AJ, Bromberg JS, Mayer L. Orthotopic tracheal allografts undergo reepithelialization with recipient-derived epithelium. Arch Otolaryngol Head Neck Surg, 2003, 129:118-23.

101. Genden EM, Iskander AJ, Bromberg JS, Mayer L. The kinetics and pattern of tracheal allograft re-epithelialization. Am J Respir Cell Mol Biol., 2003, 28:673-81.

102. Fu S, Chen, D, Mao, X, Ding, Y, Bromberg JS. Feline immunodeficiency virus mediated viral interleukin-10 gene transfer prolongs cardiac allograft survival. Am. J. Transplant., 2003, 3:552-561.

103. Yopp AC, Randolph GJ. Bromberg JS. Leukotrienes, sphingolipids, and leukocyte trafficking. J. Immunol., 2003, 171:5-10.

104. Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Murphy B, Bromberg JS. Cytomegalovirus disease in thymoglobulin treated transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am. J. Transplant., 2003, 3:731-735.

105. Akalin E, Dikman S, Murphy B, Bromberg JS, Hancock WW. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy. Am.J.Transplant., 2003, 3:1116-1120.

106. Chen D, Ding Y, Schroppel B, Zhang N, Fu S, Chen D, Zhang H, Bromberg JS. Differential chemokine and chemokine receptor gene induction by ischemia, alloantigen, and gene transfer in cardiac grafts. Am. J. Transplant., 2003, 3:1216-1229.

107. Zhang N, Schroppel B, Chen D, Fu S, Hudgkin KL, Zhang H, Murphy BM, Sung RS, Bromberg JS. Adenovirus transduction induces expression of multiple

52

chemokines and chemokine receptors in murine cells and pancreatic islets. Am. J. Transplant., 2003, 3:1230-1241.

108. Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, Bromberg JS. Intravenous immunoglobulin (IVIG) and Thymoglobulin facilitate kidney transplantation in complement dependent cytotoxicity (CDC) B cell and flow cytometry (FC) T and/or B cell cross-match positive patients. Transplantation, 2003, 76:1444-1447.

109. Chen D, Ding Y, Zhang N, Schroppel B, Fu S, Zhang H, Hancock WW, Bromberg JS. Viral IL-10 gene transfer inhibits the expression of multiple chemokine and chemokine receptor genes induces by inflammatory or adaptive immune stimuli. Am. J. Transplant., 2003, 3:1538-1549.

110. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Chen D, Mao M, Ding Y, Bromberg JS. CD4+CD25+CD62L+ T regulatory cell subset has optimal suppressive and proliferative potential. Am. J. Transplant., 2004, 4:65-78.

111. Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, Zhang H, Meseck M, Bromberg J, Dong, H. Elevated VEGF production in islets improves islet graft vascularization. Diabetes, 2004, 53:963-970

112. Paramesh AS, Roayaie R, Doan Y, Schwartz ME, Emre S, Fishbein T, Florman S, Gondolesi GE, Krieger N, Ames S, Bromberg J, Akalin E. Post liver transplant acute renal failure: factors predicting development of end stage renal disease. Clinical Transplantation, 2004, 18:94-99.

113. Bromberg JS. Commentary on Claman et al. The beginnings of T-B collaboration. J. Immunol., 2004, 173:7-8.

114. Yopp AC, Fu S, Honig SM, Randolph GJ, Bromberg JS. FTY720 enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J. Immunol., 2004, 173:855-865.

115. Akalin E, Murphy B, Sehgal V, Ames, S, Daly L, Bromberg JS. Rapid steroid withdrawal in hepatitis C virus (HCV) positive kidney transplant recipients. Clin Transplant., 2004, 18:384-389.

116. Schroppel B, Zhang N, Chen D, Hudkins KL, Kuziel WA, Sung R, Bromberg JS, Murphy B. Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. J. Am. Soc. Nephrol., 2004, 15:1853-1861.

117. Fu S, Zhang, N, Yopp AC, Chen D, Mao, M, Zhang, H, Chen D,Ding, Y, Bromberg JS. TGF- induces Foxp3+ T regulatory cells from CD4+CD25- precursors. Am.J.Transplant., 2004, 4:1614-1627.

53

118. Qu C, Edwards EW, Tacke F, Angeli V, Llodra J, Sanchez-Schmitz G, Garin A, Haque NS, Peters W, van Rooijen N, Sanchez-Torres C, Bromberg J, Charo IF, Jung S, Lira SA, Randolph GJ. Analysis of chemokine pathways that affect migration of monocyte-derived dendritic cells to lymph nodes: identification of a novel function for CCR8. J.Exp.Med., 2004, 200:1231-1241.

119. Ku HT, Zhang N, Kubo A, O’Connor R, Mao M, Keller G, Bromberg JS. Committing embryonic stem cells to early endocrine pancreas in vitro. Stem Cells, 2004, 22:1205-1217.

120. Yang Y, Ochando J, Yopp A, Bromberg JS, Ding Y. IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J. Immunol., 2005, 174:2720-2729.

121. Schroppel B, Zhang N, Chen P, Chen D, Bromberg JS, Murphy B. The role of donor-derived CCL2/MCP-1 in murine islet transplantation. J. Am. Soc. Nephrol., 2005, 16:444-451.

122. Bromberg JS, Silverstein J, Kirk AD. The American Journal of Transplantation policy for review of ethical standards of clinical research involving live human subjects. Am. J. Transplant., 2005, 5:648-650.

123. Liu J, Fishbein TM, Bromberg JS, Boros P. Orthotopic small bowel transplantation in mice. Transplantation, 2005, 79:973-976.

124. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match positive kidney transplant recipients. Human Immunology, 2005, 66:359-363.

125. Ochando, JC, Yopp, AC, Yang, Y, Li, Y, Boros P, Llodra, J, Ding, Y, Krieger, N, Bromberg, JS. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J. Immunol., 2005, 174:6993-7005.

126. Ames S, Krol M, Nettar K, Goldman J, Quinn T, Herron DM, Pomp A, Bromberg JS. Pre-donation assessment of kidneys by magnetic resonance angiography and venography: accuracy and impact on outcomes. Am. J. Transplant., 2005, 5:1518-1528.

127. Yopp AC, Ochando JC, Mao M, Ledgerwood L, Ding Y, Bromberg JS. Sphingosine 1-phosphate receptors regulate chemokine driven transendothelial migration of lymph node but not splenic T cells. J. Immunol., 2005, 175:2913-2924.

128. Safadi R, Alvarez CE, Ohta M, Brimnes J, Kraus T, Mehal W, Bromberg J, Mayer L, Friedman SL. Enhanced oral tolerance in transgenic mice with hepatocyte secretion of interleukin-10. J. Immunol., 2005, 175:3577-3583.

54

129. Zhang N, Clement N, Chen D, Fu S, Zhang H, Rebollo P, Linden RM, Bromberg JS. Transduction of pancreatic islets with pseudotyped adeno-associated virus: effect of viral capsid and genome conversion. Transplantation, 2005, 80:683-690.

130. Genden EM, Govindaraj S, Chaboki H, Cleven H, Fedorove E, Bromberg JS, Mayer L. Reepithelialization of orthotopic tracheal allografts prevents rejection after withdrawal of immunosuppression. Ann Otol Rhinol Laryngol., 2005, 114:279-88.

131. Boros P, Gondolesi, G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transplant., 2005, 11:1469-1480.

132. Zhang N, Qu S, Xu J, Bromberg JS, Dong HH. Inhibition of angiogenesis is associated with reduced islet engraftment in diabetic recipient mice. Transplant. Proceedings, 2005, 37:4452-4457.

133. Akalin E, Ames S, Seghal V, Murphy B, Bromberg JS. Safety of using hepatitis B virus core antibody or surface antigen positive donors in kidney or pancreas transplantation. Clinical Transplant., 2005, 19:364-366.

134. Wyatt CM, Dikman S, Sehgal V, Murphy BT, Bromberg JS, Ames S, Akalin E. Chronic organizing microangiopathy in a renal transplant recipient. Nephrology, Dialysis, and Transplantation, 2005, 20:1734-1737.

135. Huang B., Pan P.-Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.-H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res., 2006, 66:1123-1131.

136. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion. Am. J. Transplant., 2006, 6:652-658.

137. Chen D, Zhang N, Fu S, Schroppel B, Guo Q, Xu J, Garin A, Lira SA, Bromberg JS. CD4+CD25+ T regulatory cells inhibit the islet innate immune response and promote islet engraftment. Diabetes, 2006, 55:1011-1021.

138. Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F, Angeli V, Li Y, Boros P, Ding Y, Jessberger R, Lira SA, Randolph GJ, and Bromberg JS. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nature Immunology, 2006, 7:652-662.

139. Gondolesi G., Blondeau B., Maurette R., Hoppenhauer L, Rodriguez-Laiz G., Schiano T., Boros P., Bromberg J., Akalin E., Sauter B. Pre-transplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. Transplantation, 2006, 81:1743-1746.

140. Chen D, Bromberg JS. T regulatory cells and migration. Am. J. Transplantation, 2006, 6:1518-1523.

55

141. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Strain L, Goodship THJ. Favorable long-term outcome after liver-kidney transplant for recurrent atypical hemolytic uremic syndrome (HUS) associated with a factor H mutation. Am. J. Transplantation, 2006, 6:1948-1952.

142. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, Xu J, Bromberg JS, Dong HH. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes, 2006, 55:2429-2436.

143. Ochando JC, Krieger NR, Bromberg JS. Direct versus indirect allorecognition: visualization of dendritic cell distribution and interactions during rejection and tolerization. Am. J. Transplantation, 2006, 6:2488-2496.

144. Yopp AC, Ledgerwood LG, Ochando JC, Bromberg, JS. Sphingosine 1-phosphate receptor modulators: A new class of immunosuppressants. Clinical Transplants, 2006, 20:788-795.

145. Martin AP, Alexander-Brett JM, Canasto-Chibuque C, Garin A, Bromberg J, Fremont DH, Lira SA. The chemokine binding protein M3 prevents diabetes induced by multiple low-doses of streptozotocin. J. Immunol. 2007, 178:4623-4631.

146. Ku HT, Chai J, Kim Y-J, White P, Kaestner KH, Bromberg JS. Insulin-expressing colonies developed from murine embryonic stem cell-derived pancreatic -cell progenitors. Diabetes 2007, 56:921-929.

147. Huang JH, Cardenas-Navia LI, Caldwell CC, Plumb TJ, Radu CG, Rocha PN, Wilder T, Bromberg JS, Cronstein BN, Sitkovsky M, Dewhirst MW, Dustin M. Requirements for T lymphocyte migration in explanted lymph nodes. J. Immunol. 2007, 178:7747-7755.

148. Su D, Zhang N, He J, Qu S, Slusher S, Bottino R, Bertera S, Bromberg J and Dong HH. Angiopoietin-1 production in islets improves islet engraftment and protects islets from cytokine-induced apoptosis. Diabetes 2007, 56:2274-2283.

149. Merad M, Collin M, Bromberg J. Dendritic cell homeostasis and trafficking in transplantation. Trends in Immunology 2007, 28:353-359.

150. Yang Y, Ochando JC, Bromberg JS, Ding Y. Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFN/Stat1 signals. Blood 2007, 110:2494-2500.

151. Bromberg, JS, Kaplan, B, Halloran, PF, Robertson, RP. The islet transplant experiment: time for a reassessment. Am. J. Transplant. 2007, 7:2217-2218.

152. Akalin E, Dinavahi R, Dikman S, de Boccardo G, Friedlander R, Schroppel B, Sehgal V, Bromberg JS, Heeger P, Murphy B. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. J. Am. Soc. Nephrol. 2007, 2:1261-1267.

56

153. Chin EH, Hazzan D, Edye M, Herron DM, Gaetano JN, Ames SA, Bromberg JS. Laparoscopic donor nephrectomy. Surg. Endoscopy, 2007; 21:521-526.

154. Boros P, Liu J, Li Y, Bromberg JS. Organ transplantation in rodents: Novel applications of long-established methods. Transpl. Immunol., 2007; 18:44-52.

155. Ledgerwood, LG, Lal, G, Zhang, N, Garin, A, Esses, SJ, Ginhoux, F, Peche, H, Lira, SA, Ding, Y, Yang, Y, He, X, Schuchman, EH, Allende, ML, Ochando, JC, Bromberg, JS. Sphingosine 1-phosphate receptor S1P1 causes tissue retention by inhibiting peripheral tissue T lymphocyte entry into afferent lymphatics. Nature Immunol. 2008, 9:42-53.

156. Martin AP, Grisotto MG, Kunkel SL, Bromberg JS, Furtado GC, Lira SA. Islet expression of M3 uncovers a key role for chemokines in the development and recruitment of diabetogenic cells in NOD mice. Diabetes, 2008; 57:387-394.

157. Gu Y, Yang J, Liu W, Li H, Bromberg J, Chen S-H, Mayer L, Unkeless J, Xiong H. Interleukin-10 (IL-10) suppresses Th17 cytokines in macrophages and T cells. Eur. J. Immunol., 2008; 38:1807-1813.

158. Halloran PF, Bromberg J, Kaplan B, Vincenti F. Tolerance versus immunosuppression: A perspective. Am. J. Transplant., 2008; 8:1365-1366.

159. Boros P, Bromberg JS. De novo autoimmunity following organ transplantation: Targets and possible pathways. Human Immunol., 2008; 69:383-388.

160. Akalin A, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Sehgal V, Schroppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg JS. Addition of plasmapheresis decreases the incidence of acute rejection in kidney trnaplant recipients with strong donor-specific antibodies. Clinical JASN, 2008; 3:1160-1167.

161. Yang, Y, Niu, Y, Bromberg, JS, Ding, Y. T-bet and Eomes play critical roles in directing T cell differentiation to Th1 versus Th17. J. Immunol., 2008; 181:8700-8710.

162. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger E, Reid SP, Levy DE, Bromberg JS. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol., 2009; 182:259-273.

163. Bromberg, JS, Halloran PF. Nine things you might not say or hear in transplantation. Am. J. Transplant., 2009; 9:11-13.

164. Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid M, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G. Successful split liver-kidney transplant for atypical hemolytical uremic syndrome associated with a factor H mutation. CJASN, 2009; 4:201-206.

57

165. Krüger, B, Krick, S, Dhillon, N, Lerner, S, Ames, S, Bromberg, J, Lin, M, Walsh, L, Vella, J, Fischereder, M, Krämer, BK, Colvin, RB, Heeger, P, Murphy, B, Schröppel B. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc.Natl.Acad.Sci.(USA), 2009; 106:3390-3395.

166. Zhang N, Schroppel B, Lal G, Jakubzick C, Mao X, Chen D, Jessberger R, Ochando JC, Bromberg JS. Regulatory T cells sequentially migrate from the site of tissue inflammation to the draining LN to suppress allograft rejection. Immunity, 2009,30:458-469.

167. Xu, J, Yang, Y, Qiu, G, Lal, G, Wu, Z, Levy DE, Ochando, JC, Bromberg, JS, Ding Y. c-maf regulates IL-10 expression during Th17 polarization. J. Immunol., 2009, 182:6226-6236.

168. Markey, KA, Banovic, T, Kuns RD, Olver, SD, Don, ALJ, Raffelt, NC, Pettit, AR, Bromberg, J, Hill, GR, MacDonald, KPA. Conventional dendritic cells are the critical donor APC presenting alloantigen after BMT. Blood, 2009, 113: 5644-5649.

169. Sawinski D, Wyatt CM, Casagrande L, Myoung P, Bijan I, Akalin E, Schroppel B, DeBoccardo G, Sehgal V, Dinavahi R, Lerner S, Ames S, Bromberg J, Huprikar S, Keller M, Murphy B. Factors associated with failure to list HIV-positive kidney transplant candidates. Am. J. Transplant., 2009, 9:1467–1471.

170. Buonamici, S, Trimarchi, T, Ruocco, MG, Reavie, L, Cathelin, S, Klinakis, A, Mar, BG, Lukyanov, Y, Tseng, J-C, Sen, F, Gehrie, E, Li, M, Newcomb, E, Zavadil, J, Meruelo, D, Efstratiadis, A, Lipp, M, Ibrahim, S, Zagzag, D, Bromberg, JS, Dustin, ML, Aifantis, I. CCR7 signaling as an essential regulator of CNS infiltration in T cell leukemia. Nature, 2009, 459:1000-1004.

171. Chin, E, Hazzan, D, Edye, M, Wisnivesky, JP, Herron, DM, Ames, SA, Palese, M, Pomp, A, Gagner, M, Bromberg, JS. The first decade of a laparoscopic donor nephrectomy program: effect of surgeon and institution experience with 512 cases from 1996 to 2006. J. Am. Coll. Surg., 2009, 209:106-113.

172. Boros, P, Bromberg, JS. Human FOXP3+ regulatory T cells in transplantation. Am. J. Transplant., 2009, 9:1719-1724.

173. Busque S, Leventhal J, Brennan D, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg J, Vincenti F, Hariharan H, Slakey D, Peddi VR, Fisher R, Lawendy N, Wang C, Chan G. Calcineurin-inhibitor-free immunosuppression based on Cp-690,550: 12-month follow-up of a pilot study in de novo renal allograft recipients. Am. J. Transplant., 2009, 9:1936-1945.

174. Lal, G, Bromberg, JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood., 2009, 114:3727-3735.

58

175. Zhang N, Kruger B, Lal G, Luan Y, Zang W, Lin M, Grimm M, Waaga-Gasser AM, Bromberg JS, Murphy B, Schroppel B. Inhibition of TLR4 signaling prolongs Treg dependent murine islet allograft survival. Immunol. Letters, 2010, 127:119-125.

176. Blázquez, AB, Knight, AK, Getachew, H, Bromberg, JS, Lira, SA, Mayer, L, Berin, MC. A functional role for CCR6 on pro-allergic T cells in the gastrointestinal tract. Gastroenterology, 2009, 138:275-284.

177. Kelly S, Edye M, Vanderbeek L, Bromberg JS, Cohen E. MRI estimation of total renal volume demonstrates significant association with healthy donor weight. Eur. J. Radiol., 2009, 71:283-287.

178. Ginhoux, F, Liu, K, Helft, J, Bogunovic, M, Greter, M, Hashimoto, D, Price, J, Yin, Bromberg, J, Lira, SA, Stanley, RE, Nussenzweig, M, Merad, M. The origin and development of non-lymphoid tissue CD103+ DCs. J. Exp. Med., 2009, 206: 3115-3130.

179. Rafiq MA, de Boccardo G, Schröppel B, Bromberg JS, Sehgal V, Dinavahi R, Murphy B and Akalin E. Differential outcomes in 3 types of acute antibody-mediated rejection. Clin. Transplant., 2009, 23:951-957.

180. Kim, J-Y, Akalin, E, Dikman, S, Gagliardi, R, Schiano, T, Bromberg, J, Murphy, B, de Boccardo, G. The variable pathology of kidney disease after liver transplantation. Transplantation, 2010, 89:215-221.

181. Bromberg, JS, Heeger, PS, Li, XC. Evolving paradigms that determine the fate of an allograft. Am. J. Transplant., 2010, 10:1143-1148.

182. Schroppel, B, Kruger, B, Walsh, L, Harris, S, Breggia, A, Yeung, M, Garrison, K, Himmelfard, J, Lerner, S, Ames, S, Bromberg, JS, Zhang, PL, Bonventre, JV, Wang, Z, Farris, AB, Colvin, RB, Murphy, BT, Vella, JP. Tubular expression of kidney injury molecule-1 does not predict delayed function after transplantation. JASN, 2010, 21:536-542.

183. Rodriguez Garcia M, Ledgerwood L, Yang Y, Xu J, Lal G, Burrell B, Ma G, Grisotto M, Hashimoto D, Li Y, Boros P, van Rooijen N, Matesanz R, Tacke R, Ginhoux F, Ding Y, Chen S-H, Randolph G, Merad M, Bromberg JS, Ochando J. Monocytic suppressive cells mediate transplantation tolerance in mice. J. Clin. Invest., 2010, 120:2486-2496.

184. van der Touw W and Bromberg JS. Natural killer cells and the immune response in solid organ transplantation. Am. J. Transplant., 2010, 10:1354-1358.

185. Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, Ames S, Lerner S, Ebcioglu Z, Nair V, Dinavahi R, Sehgal S, Schroppel B, Murphy B. Immune reconstitution following rabbit antithymocyte globulin. Am. J. Transplant., 2010, 10:2132-2141.

59

186. Krüger, B, Yin, N, Zhang, N, Yadav, A, Coward, W, Lal, G, Zang, W, Heeger, P, Bromberg, JS, Murphy, B, Schröppel, B. Islet-expressed TLR2 and TLR4 sense injury and mediate graft failure after transplantation. Eur. J. Immunol., 2010, 40:2914-2924.

187. Boros P, Ochando JC, Chen S-H, Bromberg JS. Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Human Immunol., 2010, 71:1061-1066.

188. Lal, G, Yin, N, Xu, J, Lin, M, Schroppel, B, Ding, Y, Marie, I, Levy, DE, Bromberg, JS. Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of Foxp3 expression and Treg function. Am. J. Transplant., 2011, 11:203-214.

189. Xu, J, Yang, Y, Qiu, G, Lal, G, Yin, N, Wu, Z, Bromberg, JS, Ding, Y. Stat4 is critical for the balance between Th17 and Treg in colitis. J. Immunol., 2011, 186:

6597-6606.

190. Hippen, KL, Merkel, SC, Schirm, DK, Sieben, CM, Sumstad, D, Kadidlo, DM, McKenna, DH, Bromberg, JS, Levine, BL, Riley, JL, June, CH, Miller, JS, Wagner, JE, Blazar, BR. Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity. Sci. Transl. Med. 2011, 3:83ra41.

191. Yin, N, Zhang, N, Xu, J, Shi, Q, Ding, Y, Bromberg, JS. Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation, 2011, 92:25-30.

192. Drachenberg, C et al. Guidelines for the diagnosis of antibody mediate rejection in pancreas allograft – Updated Banff grading schema. Am. J. Transplant., 2011, 11: 1792-1802.

193. Chen, C, Chai, J, Singh, L, Kuo, C-Y, Jin, L, Feng, T, Marzano, S, Galeni, S, Zhang, N, Iacovino, M, Qin, L, Hara, M, Stein, R, Bromberg, JS, Kyba, M, Ku, HT. Characterization of an in vitro differentiation assay for pancreatic-like cell development from murine embryonic stem cells: detailed gene expression analysis. Assay Drug Dev Technol., 2011, 9:403–419.

194. Yin, N, Zhang, N, Lal, G, Xu, J, Yan, M, Ding, Y, Bromberg, JS. Lymphangiogenesis is Required for Pancreatic Islet Inflammation and Diabetes. PLoS ONE, 2011, 6 (11):e28023.

195. Dinavahi, R, George, A, Tretin, A, Akalin, E, DiPaola, N, Bromberg, JS, Lerner, SM, Mehotra, A, Nadasdy, T, Paz-Artal, E, Salomon, DR, Schroppel, B, Murphy, BT, Sachidanandam, R, Heeger, PS. Antibodies Reactive to Non-HLA Antigens in Transplant Glomerulopathy. J Am Soc Nephrol. 2011, 22:1168-78.

196. Fayek, SA, Keenan, JE, Haririan, A, Cooper, M, Barth, RN, Schweitzer, E, Bromberg, JS, Bartlett, ST, Philosohpe, B. Ureteral stents are associated with

60

reduced risk of ureteral complications after kidney transplantation: A Large Single Center Experience. Transplantation, 2012, 93:304-308.

197. Burrell, BE, Bromberg, JS. Fates of CD4+ T Cells in a Tolerant Environment Depend on Timing and Place of Antigen Exposure. Am. J. Transplant., 2012, 12:576-589.

198. Yin, N, Xu, J, Ginhoux, F, Randolph, GJ, Merad, M, Ding, Y, Bromberg, JS. Functional Specialization of Islet Dendritic Cell Subsets. J. Immunol. 2012, 188: 4921–4930.

199. Nakayama, Y, Bromberg, JS. Murine lymphotoxin-beta receptor signaling regulates stromal cell chemokine expression and neutrophil trafficking required for tolerance. Am. J. Transplant. 2012, 12: 2322–2334.

200. Van der Touw, W, Burrell, B, Lal, G, Bromberg, JS. NK cells are required for co-stimulatory blockade induced tolerance to vascularized allografts. Transplant. 2012, 94:575-584.

201. Xu, J, Wang, D, Liu, D, Fan, Z, Zhang, H, Liu, O, Ding, G, Gao, R, Zhang, C, Ding, Y, Bromberg, JS, Chen, W, Sun, L, Wang, S. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood 2012, 120:3142-3151.

202. Burrell, BE, Nakayama, Y, Xu, J, Brinkman, CC, Bromberg, JS. Treg induction, migration, and function in transplantation. J. Immunol. 2012, 189:4705-4711.

203. Nair, V, Sawinski, D, Akalin, E, Friedlander, R, Ebioglu, Z, Sehgal, V, Dinavahi, R, Khaim, R, Ames, S, Lerner, S, Murphy, B, Bromberg, JS, Heeger, PS, Schroppel, B. Effect of high dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin. Transplant. 2012, 26:E261-8.

204. Fayek, SA, Twaddell, W, Munivenkatappa, R, Rasetto, F, Barth, RN, Modi, A, Potosky, D, Bromberg, J, Philosophe, B. The value of C4d deposit in posttransplant liver biopsies. Transplant Immunol. 2012, 27:166-70.

205. Halloran PF, Pereira, A, Chang, J, Matas, A, Picton, M, De Freitas, D, Bromberg, J, Seron, D, Sellares, J, Einecke, G, Reeve, J. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: the INTERCOM study. Am. J. Transplant. 2013, 13: 2352–2363.

206. Halloran PF, Pereira, A, Chang, J, Matas, A, Picton, M, De Freitas, D, Bromberg, J, Seron, D, Sellares, J, Einecke, G, Reeve, J. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am. J. Transplant. 2013, 13: 2865–2874.

61

207. Scornik JC, Bromberg JS, Norman DJ, Bhanderi M, Gitlin M, Petersen J. An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival. BMC Nephrology 2013, 14:217.

208. Fricke WF, Maddox C, Song Y, Bromberg JS. Human Microbiota Characterization in the Course of Renal Transplantation. Am. J. Transplant. 2014, 14:416-427.

209. Warren KJ, Iwami D, Harris DG, Bromberg JS, Burrell BE. Vascular basement membrane proteins laminin alpha 4 and laminin alpha 5 differentially influence CD4+ T cell lymph node trafficking and allograft fate. J. Clin. Invest. 2014, 124:2204-2218.

210. Bromberg JS. What’s Hot, What’s New – Basic Science at the WTC. Am. J. Transplant. 2015, 15:320-326.

211. Iwami D, Brinkman CC, Bromberg JS. VEGF-C/VEGFR-3 Signaling regulates chemokine gradients and lymphocyte migration from tissues to lymphatics. Transplantation 2015, 99:668-677.

212. Bromberg JS, Fricke WF, Brinkman CC, Simon T, Mongodin EF. Microbiota and Organ Transplantation. Nat Rev Nephrol 2015, 11:342-353.

213. Burrell BE, Warren KJ, Nakayama Y, Iwami, D, Brinkman, CC, Bromberg JS. The lymph node stromal fiber (ER-TR7) functions to modulate CD4+ T cell lymph node trafficking and transplant tolerance. Transplantation 2015, 99:1119-1125.

214. Nakayama Y, Brinkmann, CC, Bromberg JS. Fibroblastic reticular cells in lymph node regulate immune responses through CD40-CD40L interactions. Transplantation 2015; 99:1561–1567.

215. Lal G, Nakayama Y, Sethi A, Singh AK, Burrell BE, Kulkarni N, Brinkman CC, Iwami D, Hehlgans T, Bromberg JS. IL-10 from marginal zone precursor B cell subset is required for transplantation tolerance through regulation of Tfh induction of Th17. Transplantation 2015; 99:1817-1828.

216. Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar IDR, Lopez MM, Matas A, Picton M, de Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve1 J. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc. Nephrol. 2015; 26: 1711-1720.

217. Harris AD, Fleming B, Bromberg JS, Rock P, Nkonge G, Emerick M, Harris-Williams M, Thom KA. Surgical Site Infection after Renal Transplantation. Infect Control Hosp Epidemiol 2015; 36: 417-423.

218. Bromberg JS. WTC Clinical Papers. Transplantation 2015; 99:275-277.

62

219. Ahmad S, Inouye B, Sulek J, Phelan MS, Kramer AC, Weir MR, Barth RN, LaMattina JC, Schweitzer EJ, Leeser DB, Niederhaus SV, Bartlett ST, Bromberg JS. Live Donor Renal Transplant with Simultaneous Bilateral Nephrectomy for APKD: 10-year experience. Transplantation 2016; 100:407-415.

220. Xiong Y, Ahmad S, Iwami D, Brinkman CC, Bromberg JS. T-bet regulates natural Treg afferent lymphatic migration and suppressive function. J. Immunol. 2016; 196:2526-2540.

221. Brinkman CC, Iwami D, Hritzko MK, Xiong, Y Ahmad, Bromberg JS. Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nature Communications 2106; 7:12021. DOI: 10.1038/ncomms12021

222. Tostanoski LH, Chui Y-C, Gammon JM, Simon T, Andorko J, Bromberg JS, Jewell CM. Reprogramming the local lymph node microenvironment during autoimmunity promotes systemic, yet antigen-specific tolerance. Cell Reports 2016, 16:2940–2952.

223. Greenan G, Ahmad SB, Anders MG, Leeser A, Bromberg JS, Niederhaus SV. Recreational Marijuana Use is Not Associated with Worse Outcomes After Renal Transplantation. Clinical Transplantation 2016, 30:1340-1346. doi: 10.1111/ctr.12828.

224. Lal G, Kulkarni N, Nakayama Y, Singh AK, Sethi A, Burrell BE, Brinkman CC, Iwami D, Zhang T, Hehlgans T, Bromberg JS. IL-10 from marginal zone precursor B cells controls the differentiation of Th17, Tfh and Tfr cells during costimulatory blockade induced tolerization. Immunology Letters 2016, 170:52-63.

Articles Accepted for Publication

Scalea JR, Bromberg J, Bartlett ST, Scalea TM. Mechanistic Similarities between Trauma, Atherosclerosis, and other Inflammatory Processes. J. Critical Care

Husson J, Sparkes T, Stafford K, Haririan A, Bromberg JS, Redfield R, Davis, C, Amoroso A. Association between Duration of HIV-1 Viral Suppression Prior to Renal Transplantation and Acute Cellular Rejection. Am. J. Transplant

RD Bloom, JS Bromberg, E Poggio, S Bunnapradist, A Langone, P Sood, A Matas, S Mehta, A Sharfuddin, B Fischbach, M Narayanan, S Jordan, D Cohen, D Hiller, P Prasad, R Woodward, M Grskovic, J Sninsky, JP Yee, DC Brennan. Cell-free DNA and Active Rejection in Kidney Allografts. J. Am. Soc. Nephrol.

Articles Submitted for Publication

Y Xiong, CC Brinkman, KS Famulski, EF Mongodin, CJ Lord, KL Hippen, BR Blazar, JS Bromberg. A robust in vitro model for trans-lymphatic endothelial migration.

63

JS Bromberg, RD Bloom, E Poggio, S Bunnapradist, A Langone, P Sood, A Matas, S Mehta, A Sharfuddin, B Fischbach, M Narayanan, S Jordan, D Cohen, D Hiller, P Prasad, R Woodward, M Grskovic, J Sninsky, JP Yee, DC Brennan. Biological Variation of Donor-derived Cell-free DNA: Clinical Implications

SR Datla, Y Guo, R Mishra, L Chen, S Sharma, G Bigham, G Jack, K Balachandran, L Sun, G Bittle, CC Brinkman, A Burke, K Deatrick, A Garzino-Demo, J Bromberg, S Karathanasis, S Kaushal. Allogeneic Cardiac Progenitor Cells Are Immune Tolerant with Immune Modulatory Potentials.

Chapters in Books and Invited Reviews

1. Lake, P, and Bromberg, JS. Viruses and alloantigens can act as helper determinants for antibody responses to another surface antigen, Thy-1. In: Cell Biology and Immunology of Leukocyte Function, MR Quastel, Ed., Academic Press, 1979; pp 427-435.

2. Bromberg, JS, Brennan, M, Clark, EA, Lake, P, Mitchison, NA, Nakashima, I, and Sainis, KB. Associative recognition in the response to alloantigens (and xenogenization of alloantigens). In: Immunological Xenogenization of Tumor Cells, GANN Monograph on Cancer Research n. 23, H Kobayashi, Ed., University Park Press, Baltimore, Maryland, 1979; pp 185-192.

3. Greene, MI, Bromberg, JS, Nepom, J, Finberg, R, Whitaker, B, Fox, I, Germain, RN, Perry, LL, Wetzig, R, Takaoki, M, Nisonoff, A, Benacerraf, B, and Sy, M-S. The role of idiotypy in guiding cellular responses. In: Immunoglobulin Idiotypes and Their Expression, C Janeway, EE Sercarz and H Wigzell, Eds., Academic Press, 1981; pp 725-729.

4. Drebin, JA, Perry, LL, Bromberg, JS, Nepom, JT, Benacerraf, B, and Greene, MI. The effects of antisera directed to I-region gene products on syngeneic tumor immunity. In: Immunohematology UE Nydegger, Ed., Academic Press, 1982; pp 99-108.

5. Bromberg, JS, Takaoki, M, Sy, M-S, Tominaga, A, Perry, L, and Greene, MI. Regulation of the immune response to cell surface antigens. In: The Potential Role of T Cells in Cancer Therapy, Progress in Cancer Research and Therapy, Vol. 22, A Fefer and AL Goldstein, Eds., Raven Press, 1982; pp 269-278.

6. Bromberg, JS, Tominaga, A, Takaoki, M, and Greene, MI. I-J subregion and suppressor signals. Surv Immunologic Res 1982; 1:67-75.

7. Tominaga, A, Bromberg, JS, Takaoki, M, Lefort, S, Noseworthy, J, Benacerraf, B, and Greene, MI. Activation signals for immune effector and suppressor T cells reactive with haptenic determinants. Immunological Tolerance to Self and Non-

64

Self, Ann NY Acad Sci, Ed. JR Battisto, HN Claman and DW Scott, 1982; 392:309-317.

8. Bromberg, JS, Delovitch, TL, and Greene, MI. Multiple signals for the induction of specific suppressor T cells. Immunological Tolerance to Self and Non-self, Ann NY Acad Sci, Ed. JR Battisto, HN Claman and DW Scott, 1982; 392:380-381.

9. Greene, MI, Schatten, S, and Bromberg, JS. Delayed hypersensitivity. In: Fundamental Immunology, WE Paul, Ed., Raven Press, 1982; pp 685-696.

10. Bromberg, JS. Triggering events associated with the induction of specific suppressor T cells. Ph.D. Thesis, Harvard University, Cambridge Massachusetts. 1981; 298 pp.

11. Lake, P, Mitchison, NA, Clark, EA, Khorshidi, M, Nakashima, I, Bromberg, JS, Brunswick, MR, Szensky, T, Sainis, KB, Woody, JN, and Lebwohl, D. The regulation of antibody response to antigens of the cell surface: Studies with Thy-1 and H-2 antigens. In: Cell Surface Antigen Thy-1: Immunology, Neurology, and Therapeutic Applications, AE Reif and M Schlesinger, Eds., Dekker, New York, 1989; pp 367-394.

12. Turcotte, JG, Campbell, DA Jr, Bromberg, JS, Punch, JD, Hillemeier, AC, and Merion, RM. Hepatic Transplantation. In: Surgery of the Alimentary Tract, GB Zuidema and JG Turcotte, Eds., 4th edition, Vol. 3, Chapter 38, WB Saunders, Philadelphia, Pennsylvania, 1995; pp 600-615.

13. Bromberg, JS, and Qin, L. Gene Transfer to the Transplanted Organ. In: Local Immunosuppression of Organ Transplants, Gruber, SA, Editor, RG Landes, Georgetown, Texas, 1995.

14. Bromberg, JS. IL-10 immunosuppression in transplantation. Current Opinion in Immunology. 1995; 7:639-643.

15. Bromberg, JS, Tolerance in the 90's. Ann. Surg. 1995; 222: SI-SIV.

16. Virella, G and Bromberg, JS. Transplantation Immunology. In: Introduction to Medical Immunology, G. Virella, Ed., 4th edition, Chapter 27, Marcel Dekker, Inc., New York, New York, 1998, pp. 517-534.

17. Bromberg, JS. Transplant Immunology. In: Surgery Scientific Principles and Practice, LJ Greenfield, M. Mulholland, KT Oldham, GB Zelenock, and KD Lillemoe, Eds., 2nd edition, Chapter 16, Lippincott-Raven, Philadelphia, Pennsylvania, 1997; pp. 527-556.

18. Turcott, JG, Magee, JC, Bromberg, JS, Campbell, DA, Dickinson CJ, Fontana, RJ, Henley, KS, Hillemeier, AC, Lok, ASF, Lown, KS, Olson, AD, Punch, JD, Su, GL, and Merion, RM. Update of the adult and pediatric liver transplant program at the

65

University of Michigan. In: Clinical Transplants 1996, JM Cecka and PI Terasaki, Eds., UCLA Tissue Typing Laboratory, Los Angeles, California, 1997, pp. 203-216.

19. Punch, JD, and Bromberg, JS. Cytokines and transplantation. In: Cytokines in Health and Disease, Remick and Friedland, Eds., Marcel Dekker, Inc., 1997, 557-562.

20. Bromberg, JS, DeBruyne, LA, Sung, RS, Qin, L. Gene transfer to facilitate transplantation In: Gene Therapy in Inflammatory Diseases In: Progress in Inflammation Research, C. Evans and P. Robbins Eds., Birkhäuser Verlag AG, Basel, Switzerland, 2000, pp.163-204.

21. Saragovi, HU, Rebai, N, Roux, E, Gagnon, M, Zhang, X, Robaire, B, Bromberg, J, and Greene, MI. Signal transduction and antiproliferative function of the mammalian receptor for type 3 reovirus. Curr. Topics Microbiol. Immunol.1997; 233:155-166.

22. Bromberg, JS, DeBruyne, LA, Sung, RS, Qin L. Gene therapy in transplantation. Chapter 39 in: Clinical Transplantation Immunology, R. Duquesnoy and Y. Li Eds., Science Press, Peoples Republic of China, 2000.

23. Bromberg, JS and Magee, JC. Transplant Immunology. In: Surgery Scientific Principles and Practice, LJ Greenfield, M. Mulholland, KT Oldham, GB Zelenock, and KD Lillemoe, Eds., 3rd edition, Chapter 16, Lippincott, Williams and Wilkins, Philadelphia, Pennsylvania. 1999.

24. Magee, JC, Sung, RS, Bromberg, JS. Gene therapy in organ transplantation: applicabilities and shortcomings. In: Current & Future Immunosuppression Therapies Following Transplantation. MH Sayegh, and G Remuzzi, Eds., Kluwer Academic Publishers, 2001.

25. Virella, G, Knight, R, and Bromberg, J. Transplantation Immunology. In: Introduction to Medical Immunology, G. Virella, Ed., 2nd edition, Marcel Dekker, Inc., New York, New York, 2001.

26. Akalin, E, Bromberg, J. Gene Therapy and Solid Organ Transplantation, Kidney International, 2002; 61, Symposium 1.

27. Bromberg, JS, Boros, P, Ding, Y, Fu, S, Ku, T, Qin, L, Sung, R. Gene Transfer Methods for Transplantation, Methods in Enzymology, 2002, 346:199-224.

28. Bromberg, JS, Murphy, B. Routes to allograft survival. J Clin Invest, 2001; 107:795-796.

29. Ding, Y, Fu, S, Zamarin, D, Bromberg, JS. Interleukin-10, The Cytokine Handbook Fourth Edition, A.W. Thomson, M.T.Lotze, eds., Academic Press, San Diego, CA, 2003, chapter 25, pp. 603-625.

66

30. Chen, D, Sung, R, Bromberg, JS. Gene therapy in transplantation, Transplant Immunology, 2002; 9:301-314.

31. Ding, Y, Fu, S, Zamarin, D, Bromberg, JS. Interleukin-10. Encyclopedia of Hormones & Related Cell Regulators, H.H. Henry, A.W. Norman, eds., Academic Press, San Diego, CA, 2003.

32. Chen, D, Murphy, B, Sung, R, Bromberg, JS. Adaptive and Innate Immune Responses to Gene Transfer Vectors: Role of Cytokines and Chemokines in Vector Function. Gene Therapy, 2003, 10:991-998.

33. Akalin, EA, Bromberg, JS. Solid organ transplantation. Textbook on Immunology, J.B. Zabriskie, ed., Rockefeller University Press, New York, NY, 2004.

34. Yopp, AC, Krieger, N, Ochando, J, Bromberg JS. Therapeutic manipulation of T cell chemotaxis in transplantation, Current Opinion in Immunology, 2004, 16:571-577.

35. Zhang N, Bertera S, Qu S, He J, Su D, Bottino R, Bromberg J, Dong HH. Therapeutic angiogenesis for islet revascularization, Immun., Endoc. and Metab. Agents in Med. Chem., 2006, 6.

36. Ochando JC, Ledgerwood LG, Yopp AC, Bromberg JS. Trafficking and migration in tolerance, Current Opinion in Transplantation, 2006, 11:379-384.

37. Akalin E, Bromberg JS. Kidney Transplantation in Highly-Sensitized Recipients, Acta Nephrologica, 2007, 21:1-8.

38. Bromberg JS, Boros P, Zhang N. Future Developments: Gene Therapy in Living Donor Organ Transplantation, ed. R.W.G. Gruessner and E Benedetti, McGraw-Hill, 2008, Chapter 40, pp.760-768.

39. Lerner S, Bromberg JS. Technical Aspects of Renal Transplantation and Surgical Complications in Therapy in Nephrology and Hypertension: A Companion to Brenner & Rector’s The Kidney, 3rd Edition, ed. C.S. Wilcox, Saunders, 2008, Chapter 86, in press.

40. Gehrie E, Van der Touw W, Bromberg JS, Ochando JC. Plasmacytoid Dendritic Cells in Tolerance, Methods in Molecular Biology, 2011, 677:127-47.

41. Rodriguez-García M, Boros P, Bromberg JS, Ochando JC. Immunotherapy with myeloid cells for tolerance induction, Current Opinions in Organ Transplantation, 2010, 15:416-21.

42. Bromberg JS. Literature Watch: Fundamental Findings in Tissue Injury andRepair: New Insights Into the Etiology of Renal Fibrosis. Am J Transplant., 2011, 11:3.

67

43. Bromberg JS. Literature Watch: The Inflammasome: The Heart of Transplant Morbidity? Am J Transplant., 2011, 11:189.

44. Bromberg JS. Literature Watch: What’s in a Name? Type 1and Type 2 Responses. Am J Transplant., 2011, 11:417.

45. Bromberg JS. Literature Watch: Markers of Organ Function: If You Search, What Will You Find? Am J Transplant., 2011, 11:643.

46. Bromberg JS. Literature Watch: Stimulation of Beta Cells: Trying to ReapWhat We Grow. Am J Transplant., 2011, 11:877.

47. Azimzadeh A, Lees JR, Ding Y, Bromberg JS. Immunobiology of Transplantation: Impact on Targets for Large and Small Molecules. Curr Pharm Ther, 2011, 90:229-242.

48. Lees JR, Azimzadeh AM, Bromberg JS. Myeloid derived suppressor cells in transplantation. Curr Op Immunol, 2011, 23:692–697.

49. Bromberg JS. Literature Watch: Microbial Pathophysiology and Opportunistic Infections: Surprises Ahead. Am J Transplant., 2011, 11:1111.

50. Bromberg JS. Literature Watch: IFN, NF-B, TLR, TNF, S1P: The s of Endogenous Ligands. Am J Transplant., 2011, 11:1347.

51. Bromberg JS. Literature Watch: The Genetics of Renal Failure. Am J Transplant., 2011, 11:1549.

52. Bromberg JS. Literature Watch: GWAS, Gee Whiz. New Treatment for HCV. Am J Transplant., 2011, 11:1763.

53. Burrell BE, Ding Y, Nakayama Y, Park K-S, Xu J, Yin N, Bromberg JS. Tolerance and lymphoid organ structure and function. Frontiers in Immunological Tolerance. 2011, 2: article 64, 1-16.

54. Bromberg JS. Literature Watch: Searching for Pathogens. Am J Transplant., 2011, 11:2001.

55. Bromberg JS. Literature Watch: Anatomy of Tolerance. Am J Transplant., 2011, 11:2269.

56. Xu J, Ding Y, Bromberg JS. T regulatory cell migration during an immune response. Trends in Immunology, 2012, 33:174-80.

57. Alegre ML, Bromberg JS. Literature Watch: The Anti-Infectious Role of the IL -17 Pathway. Am J Transplant., 2012, 12:3.

68

58. Fairchild RL, Bromberg JS. Literature Watch: Initiating Immune Responses in States of Sterile Inflammation. Am J Transplant., 2012, 12:271.

59. Krams SM, Bromberg JS. Literature Watch: Fetal T Cells and Immunological Tolerance. Am J Transplant., 2012, 12:511.

60. Alessandrini A, Bromberg JS. Literature Watch: AHR and Tryptophan Catabolism: Putting the Effector T-Cell Response to Sleep. Am J Transplant., 2012, 12:801.

61. Bromberg JS. Literature Watch: Transmissable Fatty Liver Disease. Am J Transplant., 2012, 12:1071.

62. Ford M, Bromberg JS. Literature Watch: Memory T Cells: New Insights Into the Molecular Basis of Sensitivity and Heterogeneity. Am J Transplant, 2012, 12: 1361.

63. Maltzmann JS, Bromberg JS. Literature Watch: Leukocyte: Tempus Fugit Vel Carpe Diem. Am J Transplant, 2012, 12:1665.

64. Alegre M-L, Bromberg JS. Literature Watch: Commensal Microbiota Determine Intestinal iTreg. Am J Transplant, 2012, 12:1967.

65. Li XC, Bromberg JS. Literature Watch: Mast Cells: Infl ammatory, Immunoregulatory or Something In Between? Am J Transplant, 2012, 12:2265.

66. Turnquist HR, Bromberg JS. Alarmin’ Findings: IVIGs Suppress Inflammation Through the “Alarmin” IL-33. Am J Transplant, 2012, 12:2567.

67. Alessandrini A, Bromberg JS. CCR9+ Plasmacytoid Dendritic Cells are “Central” to Tolerance. Am J Transplant, 2012, 12:2867.

68. Fairchild RL, Bromberg JS. Molecular Assassins from within: Intracellular DAMPs from Injured Cells Initiate Tissue Inflammation. Am J Transplant, 2012, 12:3167.

69. Riella L, Bromberg JS. System Nework: Tackling the Complexity of the Immune System. Am J Transplant, 2013, 13:3.

70. Krams SM, Bromberg JS. ENCODE: Life, the Universe and Everything. Am J Transplant, 2013, 13:245.

71. Bromberg JS. TNF-α trips up Treg cells in rheumatoid arthritis. Nat Med, 2013, 19:269 – 270.

72. Valujskikh A, Bromberg JS. The House That Jack Built: Expanding the Concept of Plasma Cell Niches. Am J Transplant, 2013, 13:533.

73. Barth RN, Bromberg JS. Transplantation: The promise of co-stimulatory blockade in transplantation. Nat Rev Nephrol, 2013, 9:189-190.

69

74. Upadhyay V, Fu Y-X, Bromberg JS. Moving from infection to colonization: the role for the microbiota in transplantation. Am J Transplant, 2013, 13:829.

75. Valujskikh A, Bromberg JS. A closer look at B cell memory. Am J Transplant, 2013, 13:1117.

76. Muller YD, Meier RPH, Bromberg JS, Buhler LH. Blastocyst complementation for chimeras for xenotransplantation. Am J Transplant, 2013, 13: 1377.

77. Remuzzi G, Bromberg JS. Mesenchymal stromal cells: What’s in the name? (and for what?). Am J Transplant, 2013, 13: 1625.

78. Brinkman, CC, Burrell, BE, Iwami, D, Nakayama, Y, Warren, KJ, Xiong, Y, Bromberg, JS. Anatomy of Tolerance. Curr. Op. Organ Transplant 2013, 18:393-401.

79. Azimzadeh, AM, Bromberg, JS. Negative vaccination to modulate transplant immunity. Nat Rev Nephrol, 2013, 9:557-9.

80. Chong AD, Bromberg JS. Inflaming alloreactivity through infection, tissue damage and inflammasomes. Am J Transplant, 2013, 13: 1943.

81. Wells AD, Bromberg JS. Lineage Determination and Epigenetics of Regulatory T Cells. Am J Transplant, 2013, 13: 2235.

82. Kreisel D, Bromberg JS. Lymphoid Neogenesis in Allografts: Bad, Good or Neither? Am J Transplant, 2013, 13: 2513.

83. Kupiec-Weglinski JW, Bromberg JS. New Insights Into Tolerogenic Functions of Skin Langerhans Cells. Am J Transplant, 2013, 13: 2783.

84. Neujahr D, Bromberg JS. Lung Macrophages Influence Regulatory T Cells in Asthma Models. Am J Transplant, 2013, 13:3055.

85. Lamattina JC, Bromberg JS. Transplantation of a Recellularized Rat Renal Scaffold. Am J Transplant, 2014, 14:3.

86. Campbell DJ, Bromberg JS. A skulk of Foxes Controls Treg Cell Development and Function. Am J Transplant, 2014, 14:247.

87. Julliard W, Bromberg JS, Mezrich J. Aryl Hydrocarbon Receptor: Is the Environment Playing a Role in Transplant Outcomes? Am J Transplant, 2014, 14:501.

88. Li XC, Bromberg JS. The Elusive Role of mTOR in Treg Functions. Am J Transplant, 2014, 14:743.

70

89. Weltz A, Scalea J, Popescu M, Xu J, Bromberg JS. Mechanisms of Immunosuppressive Drugs, in Kidney Transplantation, ed. MR Weir, EV Lerma. Springer, New York. 2014.

90. Maltzman JS, Bromberg JS. Cell-Permeable Peptides as Potential Diagnostics and Therapeutics. Am J Transplant, 2014, 14:987.

91. Miller ML, Bromberg JS. Bridging the Gap: Innate Lymphoid Cells and Tissue Repair. Am J Transplant, 2014, 14:1229.

92. Alessandrini A, Bromberg JS. Foxp3 Cells by Any Other Name? Am J Transplant, 2014, 14:1471.

93. Thomson AW, Bromberg JS. Adding Complexity to Immune Regulation by mTOR. Am J Transplant, 2014, 14:1713.

94. Ford ML, Bromberg JS. Fueling Memory: How Cellular Metabolism Drives T Cell Immunity. Am J Transplant, 2014, 14:1953.

95. Lees J, Azimzadeh A, Ding Y, Xu J, Bromberg JS. Mechanisms of Immune Modulation, Chapter 17 in Textbook of Organ Transplantation, edited by AD Kirk, SJ Knechtle, CP Larsen, JC Madsen, TC Pearson, and SA Webber, Wiley Health Sciences 2014.

96. Bromberg JS. Islet implanation in a pocket. Nature Biotech, 2015, 33:493-494.

97. Pierson RN, Bromberg JS. Alloantibodies and Allograft Arteriosclerosis: Accelerated Adversity Ahead? Circ Res, 2015, 117: 398-400.

98. Report of IPITA-TTS Opinion Leaders on the Future of Beta Cell Replacement. Bartlett ST, Markmann JF, Johnson P, Korsgren O, Hering BJ, Scharp D, Kay TWH, Bromberg J, Odorico JS, Weir GS, Bridges N, Kandaswamy R, Stock P, Friend P, Gotoh M, Cooper DKC, Park C-G, O’Connell P, Stabler C, Matsumoto S, Ludwig B, Choudhary P, Khovatchev B, Rickels MR, Sykes M, Wood K, Kraemer K, Hwa A, Stanley E, Ricordi C, Zimmerman M, Greenstein J, Montanya E, Otonkoski T. Transplantation, 2016, in press.

99. Brinkman CC, Bromberg JS. Biological sensors shed light on ligand geography. Nature Immunol, 2015, 16:1209-1211.

100. Lees JR, Azimzadeh AM, Ding Y, Webb TJ, Bromberg JS. Cells of the Immune System, Chapter 2 in Transplant Immunology, edited by XC Li and AM Jevnikar, Wiley Blackwell 2016.

101. Fricke WF, Bromberg JS. Checks and balances - microbiota shifts in immunosuppressed mice. Transplantation 2016, 101:26-27.

71

102. Ahmad S, Siskind E, Bromberg JS. Innovations in Kidney Transplant Research. In: Kidney Transplantation, Bioengineering and Regeneration. Giuseppe Orlando, Giuseppe Remuzzi, David F Williams, Eds. Associated Press, NY, USA. In press.

On-Line Videos

1. Bromberg, J.S. Inflammation and Innate Immunity in Organ Transplantation. The ASTS Academic Universe. 26 April 2008. The American Society of Transplant Surgeons. http://ASTSuniverse.org.

Abstracts, Letters, Book Reviews, Editorials

1. Bromberg, JS, Delovitch, T, and Greene, M. Multiple signals for the induction of specific suppressor cells, 1981, New England Immunology conference on Immunological Tolerance to Self and Non-self, Woodshole, MA.

2. Greene, MI, Perry, LL, Drebin, JA, Carter, R, Bromberg, JS, Nepom, J, Dorf, M, and Benacerraf, B. The influence of anti-I-A and anti-I-J antibodies on sygeneic tumor immunity, in vivo, 1981, Workshop on Immunopathological Aspects of Immunoglobulin Infusions, Basel, Switzerland.

3. Brunswick, M, Sainis, KB, Lake, P, and Bromberg, JS. The effect of DNP specific helper and suppressor cells on the anti-Thy-1 response, 1981, Spring Meeting of the British Society for Immunology, London, England.

4. Lake, P, and Bromberg, JS. Requirements for immunogenicity of cell-surface antigens: Immunological help from alloantigens and viral antigens in antibody responses to Thy-1, 1978, 12th International Leukocyte Culture Conference, Tel Aviv, Israel.

5. Chavin, KD, Bromberg, JS, Naji, A and Barker, CF. In vivo roles of cell surface receptors and cytokines in cell mediated immunity, 1980, Society of University Surgeons, Los Angeles, CA.

6. Bromberg, JS, Barker, CF, Grossman, RJ, Naji, A, Perloff, LJ and DaFoe, DC. Adrenal suppression in renal transplant recipients, 1990, Society of University Surgeons, Los Angeles, CA.

7. Bromberg, JS, Chavin, KD, Kunkel, SL, Naji, A and Barker, CF. Monoclonal antibodies as probes of immune function and immunomodulators, 1990, American Society of Transplant Surgeons, Chicago, IL.

8. Bromberg, JS, Alfrey, EJ, Barker, CF, Chavin, KD, DaFoe, DC, Holland, T, Naji, A, Perloff, LJ, Zellers, LA and Grossman, RA. Adrenal suppression in renal

72

transplant recipients - A reappraisal, 1990, American Society of Transplant Physicians, Chicago, IL.

9. Bromberg, JS, Chavin, KD, Lau, HT, Naji, A and Barker, CF. CD2 mediates cellular immune responses in vivo, 1990, XIII International Congress of the Transplantation Society, San Francisco, CA.

10. Chavin, KD, Bromberg, JS, Kunkel, SL, Naji, A and Barker, CF. Effects of a polyclonal anti-TNF antibody on cell mediated immunity in vivo, 1990, XIII International Congress of the Transplantation Society, San Francisco, CA.

11. Chavin, KD, Lau, H, Posselt, A, Roark, J, Naji, A, Barker, CF, and Bromberg, JS. Prolongation of xenogeneic and allogeneic pancreatic islet cell grafts with antibodies to murine and rat CD2, 1991, ACS, South Carolina Chapter, Spartanburg, SC.

12. Redmond, HP, Kelly, CJ, Chavin, K, Leon, P, Shou, J, Bromberg, JS, and Daly, JM. The protective effects of anti-interferon-gamma (MoIFN-g) in the acute septic response, 1991, American Surgical Association, Boca Raton, FL.

13. Chavin, K, Kunkel, S, Naji, A, Barker, C and Bromberg, JS. The in vivo effect of a polyclonal anti-TNF antibody on cell mediated immunity, 1991, Society of University Surgeons, Galveston, TX.

14. Chavin, KD, Naji, A, Barker, CF, Altevogt, P, and Bromberg, JS. The in vivo effect of a CD2 antibody on cell mediated immunity, 1991, Federation Meeting, Atlanta, GA, FASEB J., 5:A1428.

15. Chavin, KD, Yon, RW, Qin, LH, and Bromberg, JS. In vitro antigenic modulation of CD2 using rat anti-murine CD2 monoclonal antibody, 1991, 6th Annual Meeting, Clinical Applications of Cytometry, Charleston, SC.

16. Chavin, KD, and Bromberg, JS. Anti-CD2 monoclonal antibodies are superior to anti-CD3 monoclonal antibodies in prolonging allograft survival, 1992, Society of University Surgeons, Cincinnati, OH.

17. Kaplan, AJ, Chavin, KD, and Bromberg, JS. Production and characterization of soluble CD2 receptor constructs with the baculovirus expression vector, 1992, Society of University Surgeons, Cincinnati, OH.

18. Bromberg, JS, and Chavin, KD. Anti-CD2 monoclonal antibodies inhibit cytotoxic T lymphocytes in vivo and in vitro, 1992, Federation Meeting, Anaheim, CA. FASEB J., 6:A2006.

19. Kaplan, AJ, Chavin, KD, Yagita, H, and Bromberg, JS. Characterization of murine CD2 receptor constructs: CD2 homotypic adhesion, 1992, Federation Meeting, Anaheim, CA, FASEB J., 6:A1432.

73

20. Chavin, KD, and Bromberg, JS. Comparison of anti-CD2 and anti-CD3 monoclonal antibodies in prolonging allograft survival, 1992, Federation Meeting, Anaheim, CA, FASEB J., 6:A1406.

21. Chavin, KD, and Bromberg, JS. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival with decreased side effects, 1992, American Society of Transplant Surgeons, Chicago, IL.

22. Chavin, KD, and Bromberg, JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival and decrease the associated cytokine syndrome, 1992, American College of Surgeons Surgical Forum, New Orleans, LA.

23. Bromberg, JS, and Chavin, KD. Multiple mechanisms of anti-CD2 immunosuppression: Receptor blockade, generation of suppressors, and alteration of cytokine production, 1992, American College of Surgeons Surgical Forum, New Orleans, LA.

24. Chavin, KD, and Bromberg, JS. Anti-CD2 monoclonal antibodies synergize with anti-CD3 to prolong allograft survival and decrease cytokine production, 1992, XIVth International Congress of the Transplantation Society, Paris, France.

25. Chavin, KD, and Bromberg, JS. Anti-CD2 monoclonal antibody disrupts cytokine pathways while synergizing with anti-CD3 to prolong allograft survival, 1992, Association of Academic Surgery, Montreal, Canada.

26. Kaplan, AJ, Chavin, KD, and Bromberg, JS. CD2 homophilic interactions in an in vitro assay of intercellular adhesion, 1992, Association of Academic Surgery, Montreal, Canada.

27. Chavin, KD, Yon, RW, Qin, L, Lin, J, Kaplan, AJ, and Bromberg, JS. Immunosuppression by anti-CD2 is accompanied by down modulation of cell surface CD2 and CD3 and an increase in the expression of other cell surface adhesion molecules, 1992, 7th Annual Meeting, Clinical Applications of Cytometry, Charleston, SC.

28. Kaplan, AJ, Chavin, KD, Qin, LH, Lin, J, Lookadoo, S, Lindenmayer, GE, and Bromberg, JS. CD2 mediated homophilic adhesion, 1992, 7th Annual Meeting, Clinical Applications of Cytometry, Charleston, SC.

29. Chavin, KD, Qin, L, Lin, J, Kaplan, AJ, and Bromberg, JS. Anti-CD2 monoclonal antibody suppresses cytotoxic T lymphocyte generation in vivo and in vitro, 1992, Society for Leukocyte Biology, 29th Annual Meeting, Charleston, SC.

30. Chavin, KD, Qin, LH, Lin, J, Kaplan, AJ, Baliga, P, and Bromberg, JS. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering cytokine production, 1993, Society of University Surgeons, Seattle, WA.

74

31. Kaplan, AJ, Chavin, KD, Qin, LH, Lin, J, and Bromberg, JS. Flow cytometric evidence of a homophilic component in CD2 mediated binding, 1993, Society of University Surgeons, Seattle, WA.

32. Bromberg, JS, Chavin, KD, Qin, L, and Lin, J. Combination CD2 and CD3 monoclonal antibodies induce tolerance while altering IL-2, IL-4, TNF and TGF production, 1993, American Surgical Association, Baltimore, MD.

33. Gates, CE, Reed, CE, Bromberg, JS, Everett, ET, and Baron, PL. p53 mutations found with high incidence in patients with squamous cell carcinoma of the esophagus, 1993, American Association for Thoracic Surgery, Chicago, IL.

34. Baliga, P, Chavin, KD, Qin, L, Lin, J, Linsley, DS, and Bromberg, JS. CTLA-4Ig inhibits cell mediated immunity while prolonging allograft survival, J Immunol 1993; 150: 249A.

35. Kaplan, AJ, Chavin, KD, Qin, L, Lin, J, and Bromberg, JS. CD2 and CD48 interact in cis on the cell surface to regulate CD48 mediated intercellular adhesion, J Immunol 1993; 150: 268A.

36. Bromberg, JS, Qin, L, Lin, J, and Chavin, KD. Anti-CD2 monoclonal antibody suppresses the generation of cytotoxic T lymphocytes in vivo and in vitro, J Immunol 1993; 150:279A.

37. Chavin, KD, Qin, L, Lin, J, Kaplan, AJ, and Bromberg, JS. Combination CD2 and CD3 monoclonal antibodies induce transplant tolerance while altering the cytokines IL-2, IL-4, TNF and TGF, J Immunol 1993; 150: 323A.

38. Chavin, KD, Qin, L, Tahara, H, Robbins, PD, Lotze, MT, and Bromberg, JS. Gene transfer of TGF and viral IL-10 prolong cardiac allograft survival, 1993, American College of Surgeons Surgical Forum, San Francisco, CA.

39. Bromberg, JS, Chavin, KD, Qin, L, Lin, J, Woodward, J, and Baliga, P. Combined anti-CD2 and anti-CD3 monoclonal antibody treatment induces tolerance and alters activation and cytokine pathways, 1993, Third Basic Science Symposium, The Transplantation Society, Big Sky, MT.

40. Rajagopalan, PR, Hanevold, CD, Orak, JK, Cofer, JB, Bromberg, JS, Baliga, P, and Fitts, CT. Valve bladder does not affect the outcome of renal transplants in children with renal failure due to posterior urethral valves, 1993, First International Congress on Pediatric Transplantation, Minneapolis, MN.

41. Borowicz, MR, Hanevold, CD, Cofer, JB, Bromberg, JS, Orak, JK, and Rajagopalan, PR. Extrinsic compression in the iliac fossa can cause renal vein occlusion in pediatric kidney recipients but graft loss can be prevented, 1993, First International Congress on Pediatric Transplantation, Minneapolis, MN.

75

42. Chavin, KD, Qin, L, Tahara, H, Robbins, PD, Lotze, MT, and Bromberg, JS. IL-10 gene transfer prolongs cardiac allograft survival, 1993, Association of Academic Surgery, Hershey, PA.

43. Baliga, P, Chavin, KD, Qin, L, Lin, J, Woodward, J, Linsley, PS, and Bromberg, JS. CTLA41g prolongs graft survival and suppresses T cell mediated immunity, 1993, Association of Academic Surgery, Hershey, PA.

44. Cofer, JB, Baliga, PK, Galbraith, RM, Bailey, M, Bromberg, JS, Rajagopalan, PR, and Fitts, CT. The development of liver transplantation in South Carolina, 1993, Southern Medical Association, New Orleans, LA.

45. Cofer, JB, Uber, L, Baliga, P, Genco, P, Bromberg, JS, Rajagopalan, PR, Fitts, CT, Galbraith, R, and Rinaldi, MG. Fluconazole levels in bile following orthotopic liver transplantation (LTX): A case report, 1993, Southern Medical Association, New Orleans, LA.

46. Chavin, KD, Qin, L, Lin, L, Woodward, JE, and Bromberg, JS. Anti-CD2 monoclonal antibodies modulate anti-CD3 driven programmed cell death (apoptosis) in vivo and in vitro as detected by gel electrophoresis and flow cytometry, 1993, 8th Annual Meeting, Clinical Applications of Cytometry, Charleston, SC.

47. Bolus, KS, Bromberg, JS, and Ullian, ME. Risk factors for blood transfusion after renal transplantation, J Am Soc Nephrol, 1993, 4:926.

48. Chavin, KD, Qin, L, Woodward, JE, Lin, J, Bromberg, JS, and Baliga, P. CTLA4Ig prolongs allograft survival by inhibiting cell mediated immunity, 1994, Society of University Surgeons, Jackson, MS.

49. Bromberg, JS. Letter to the Editor on “Glucocorticoid therapy and pituitary-adrenal responses to corticotropin-releasing hormone”. N Eng J Med, 1992; 327:283.

50. Bromberg, JS. Letter to the Editor on “Pancreatic and islet transplantation for diabetes”. N Eng J Med, 1993; 328:1497.

51. Bromberg, JS. Letter to the Editor on “Sick building syndrome”. N Eng J Med, 1993; 329:504.

52. Bromberg, JS. Book review of “Immunopharmacology in autoimmune diseases and transplantation”. J Am Acad Derm, 1994; 31:139.

53. Bromberg, JS, Baliga, PR. Letter to the Editor on “Renal Transplantation in a noncompliant patient”. N Eng J Med, 1994; 330:371.

54. Bromberg, JS, Qin, KH, Ding, Y, Favarro, J, Lin, J, Chavin, K. Gene therapy for transplantation: Prolongation of allograft survival with TGF, 1994, Experimental Biology 94, Anaheim, CA.

76

55. Qin, LH, Chavin, KD, Tahara, H, Robbins, PD, Lotze, MT, Bromberg, JS. IL-10 gene transfer prolongs cardiac allograft survival, 1994, Experimental Biology 94, Anaheim, CA.

56. Baliga, P, Woodward, J, Qin, L, Chavin, KD, Lin, J, Linsley, PS, Bromberg, JS. CTLA4Ig suppresses both CD4 and CD8 T cell alloimmunity, 1994, American Society of Transplant Physicians, Chicago, IL.

57. Friedman, RJ, Schiff, CF, Bromberg, JS. Use of supplemental stress steroids in orthopedic surgery, 1994, Association of Bone and Joint Surgeons, 46th Annual Meeting, Carlsbad, CA.

58. Woodward, J, Baliga, P, Qin, L, Chavin, K, Lin, J, Ding, Y, Linsley, P, Bromberg, JS. Anti-CD2 MAb plus CTLA4Ig alter cytokine and cytokine receptor expression, 1994, Society for Leukocyte Biology, Tucson, AZ.

59. Chavin, KD, Qin, L, Ding, Y, Tahara, H, Robbins, PD, Lotze, MT, Bromberg, JS. Viral IL-10 gene transfer prolongs cardiac allograft survival by promoting TH2 mediated suppression, 1994, American College of Surgeons Surgical Forum, Chicago, IL.

60. Baliga, P, Woodward, J, Qin, L, Chavin, K, Linsley, P, Bromberg, JS. Induction of tolerance by simultaneous blockade of multiple coreceptors, 1994, American College of Surgeons Surgical Forum, Chicago, IL.

61. Baliga, P, Chavin, K, Woodward, J, Qin, L, Bromberg, J, Linsley, P. Tolerance induction by simultaneous blockade of the T cell coreceptors CD2 and CD28/CTLA4, 1995, International Symposium on Tolerance Induction, Breckenridge, CO.

62. Krieger, NR, Holm, B, Bromberg, JS, DaFoe, DC, Alfrey, EJ. Anti-CD2 monoclonal antibody induces T cell unresponsiveness in vascularized rat cardiac allografts, 1995, Society of University Surgeons, Denver, CO.

63. Punch, JD, Sheik, VL, Campbell, DA, Bromberg, JS, Turcotte, JG, and Merion, RM. Corticosteroid withdrawal after liver transplantation, 1995, Central Surgical Association, Cleveland,OH.

64. Bromberg, JS, Chavin, KD, Ding, Y, Woodward, JE, Favaro, JP, Lin, J, Qin, L. Gene transfer of transforming growth factor-1 inhibits intragraft cell mediated immunity, 1995, Experimental Biology, Atlanta, GA.

65. Lin, J, Chavin, KD, Qin, L, Ding, Y, Woodward, JE, Bromberg, JS. Elevated cAMP and PKA activity induced by anti-CD2 mAb down modulate CD25 and CD49d expression, 1995, Experimental Biology, Atlanta, GA.

77

66. Qin, L, Chavin, KD, Tahara, H, Ding, Y, Lin, J, Robbins, PD, Lotze, MT, Bromberg, JS. Viral IL-10 gene transfer prolongs cardiac allograft survival by inhibiting cell-mediated immunity, 1995, Experimental Biology, Atlanta, GA.

67. Woodward, J, Baliga, P, Chavin, KD, Bayor, A, Linsley, P, and Bromberg, JS. Blockade of costimulatory pathways induces alloantigen specific hyporesponsiveness while altering IL-2 and IL-4 production and CD25 expression, 1995, Experimental Biology, Atlanta, GA.

68. Lin, J, Qin, L, Ding, Y, Punch, and Bromberg, JS. CD2 ligation disrupts TCR expression and is associated with cAMP and PKA mediated suppression of T cell responses, 1995, American Society of Transplant Physicians, Chicago, IL.

69. Bromberg, JS, Chavin, KD, Ding, Y, Lin, J, Qin, L. Gene transfer of transforming growth factor 1 prolongs allograft survival, 1995, American Society of Transplant Surgeons, Chicago, IL.

70. Chavin, KD, Woodward, JE, Bayer, AL, Nabavi, N, Bromberg, JS, Baliga, P. In vivo blockade of T cell costimulation via combination anti-CD28 ligand (B7-1,-2) monoclonal antibodies prolongs allograft survival and alters cell mediated immunity, 1995, American Society of Transplant Surgeons, Chicago, IL.

71. Krieger, NR, Holm, B, Most, D, Huie, P, Sibley, RK, Bromberg, JS, Dafoe, DC, Alfrey, EJ. Anti-CD2 monoclonal antibody induced tolerance: Evidence for upregulation of both TH1 and TH2 type cytokine profiles, 1995, American Society of Transplant Surgeons, Chicago, IL.

72. Merion, RM, Bromberg, JS, Howell, T, Chenault, RH. Partial T cell activation, TH1/TH2 switching, and anergy induced by polyclonal antilymphocyte globulin, 1995, American Society of Transplant Surgeons, Chicago, IL.

73. Bromberg, JS, Lin, J, Qin, LH, Ding, Y, and Punch, JD. CD2 plus CD3 ligation induces tolerance and disrupts TCR expression, 1995, 9th International Congress of Immunology, San Francisco, CA.

74. Qin, LH, Chavin, KD, Tahara, H, Ding, X, Lin, J, Robbins, PD, Lotze, MT, and Bromberg, JS. Gene Transfer of viral IL-10 induces local immunosuppression and prolongs cardiac allograft survival, 1995, 9th International Congress of Immunology, San Francisco, CA.

75. Chavin, KD, Woodward, JE, Bayer, AL, Nabavi, N, Bromberg, JS, and Baliga, P. In vivo blockade of multiple receptor-ligand pairs of the T cell costimulatory pathway CD28/CTLA4 prolongs allograft survival indefinitely, 1995, American College of Surgeons Surgical Forum, New Orleans, LA.

76. Chavin, KD, Baliga, P, Woodward, JE, Bayer, AL, Nabavi, N, Bromberg, JS. Sequential blockade of the B7-1, B7-2 costimulatory pathways induces allograft tolerance, 1995, Association of Academic Surgery, Dearborn, MI.

78

77. Bromberg, JS, Ding, Y, Qin, LH, Woodward, JE, Punch, JD. A novel murine model for the assessment of human CD2 related reagents in vivo, 1995, Association of Academic Surgery, Dearborn, MI.

78. Punch, JD, Merion, RM, Campbell, DA, Sawyer, RG, Bromberg, JS, Turcotte, JG. Percutaneous cannulation for venovenous bypass is the preferred technique for liver transplantation, 1995, International Society for Liver Disease, London, England.

79. Punch, JD, Ding, Y, Qin, LH, Bromberg, JS. Receptor driven tolerance induction is mediated by TH-2 and IL-4, 1996, Society of University of Surgeons, Washington, D.C.

80. Bromberg, JS, Ding, Y, Robson, ND, Pahud, DR, Shaked, A, and Qin, LH. Viral IL-10 gene transfer inhibits the immune response to both alloantigen and adenoviral vector, 1996, American Association of Immunologists, New Orleans, LA.

81. Qin, LH, Sawyer, RG, Ding, Y, Robson, ND, Pahud, DR, and Bromberg, JS. Viral IL-10 gene transfer initiates a TH1/TH2 cytokine switch and impairs APC function within the allograft, 1996, American Association of Immunologists, New Orleans, LA.

82. Qin, LH, Ding, Y, Robson, ND, Pahud, DR, Shaked, A, and Bromberg, JS. Adenovirus-mediated gene transfer of viral interleuken 10 inhibits the immune response to both alloantigen and adenoviral antigen, 1996, American Society of Transplant Physicians, Dallas, TX.

83. Punch, JD, Fontana, RJ, Lok, ASF, Greenson, JK, Rossi, SJ, Bromberg, JS, Campbell, DA, Sawyer, RG, Turcotte, JG, and Merion, RM. Rejection and CMV are not risk factors for survival after liver transplantation for Hepatitis C, 1996, American Society of Transplant Physicians, Dallas, TX.

84. Sawyer, RG, Qin, LH, Ding, Y, Robson, ND, Pahud, DR, and Bromberg, JS. Viral interleukin 10 gene transfer alters TH1/TH2 cytokines and impairs antigen presentation within the graft, 1996, American Society of Transplant Surgeons, Dallas, TX.

85. Punch, JD, Qin, LH, and Bromberg, JS. Antigen and IL-4 are required to maintain tolerance, 1996, American Society of Transplant Surgeons, Dallas, TX.

86. Bromberg, JS. Gene Transfer and gene therapy in allografting, Blood Purification, 1996, 14(S1):92.

87. Tono, T, DeBruyne, LA, Punch, JD, and Bromberg, JS. TH2 T cell lines prolong cardiac allograft survival, 1996, Association for Academic Surgery, Chicago, IL.

88. Rossi, SJ, Armstrong, DR, Punch, JD, Waidley, MR, Schmouder, RL, Bromberg, JS, Leichtman, AB, and Merion, RM. Identification of the major independent risk

79

factors for allograft rejection. Graft loss and death after renal transplantation by multivariate stepwise proportional hazards analysis, 1996, American Society of Nephrology, New Orleans, LA.

89. Blazar, BR, Taylor, PA, Panoskaltsis-Mortari, A, Yagita, H, Bromberg, JS, and Vallera, DA. Blockade of CD2:CD48 interaction inhibits CD4+T cell mediated GVHD lethality but impairs allogeneic marrow engraftment, 1996, American Society of Hematology, Orlando, FL.

90. DeBruyne, LA, Kewang, L, Qin, L, Bishop, KD, and Bromberg, JS. Lipid-mediated gene transfer of viral IL-10 prolongs graft survival in a vascularized cardiac allograft model, 1997, Fourth International Conference on Tolerance Induction, Breckenridge, CO.

91. DeBruyne, LA, Kewang, L, Chan, SY, Qin, L, Bishop, DK, and Bromberg, JS. Cationic lipid-mediated gene transfer of viral IL-10 inhibits cardiac allograft rejection, 1997, Keystone Symposium on Molecular and Cellular Biology of Gene Therapy, Snowbird, UT.

92. Bromberg, JS, Ding, Y, Virsik, PA, Pahud, DR, Chang, E, Imperiale, MJ, and Qin, L. Promoter attenuation in gene therapy: IFN- and TNF- inhibit transgene expression, 1997, Keystone Symposium on Molecular and Cellular Biology of Gene Therapy, Snowbird, UT.

93. Qin, L, Ding, Y, Pahud, DR, Robson, ND, Shakefd, A, and Bromberg, JS. Viral interleukin 10 gene transfer inhibits auto-allograft and anti-adenovirus immunity, 1997, Keystone Symposium on Molecular and Cellular Biology of Gene Therapy, Snowbird, UT.

94. Punch, JD, Shieck, VL, Bromberg, JS, Campbell, DA, Magee, JC, Turcotte, JG, Merion, RM. Long term follow-up of liver transplant recipients maintained on cyclosporine without corticosteroids.1997, American Society of Transplant Physicians, Chicago, IL.

95. Qin, L, Ding, Y, Pahud, DR, Chang, E, Imperiale, MJ, Bromberg, JS. Promoter attenuation in gene therapy: IFN and TNF inhibit transgene expression, 1997, American Society of Transplant Physicians, Chicago, IL.

96. Qing, Y, Qin, L, Ding, Y, Bromberg, JS. CD2 is specifically involved in CD3-mediated T cell receptor trafficking: combined modulation of CD2 and CD3 impairs TCR recovery after stimulation, 1997, American Society of Transplant Physicians, Chicago, IL.

97. Bromberg, JS, Qin, L, Pahud, DR, Ding, Y, Baker, JR. Efficient transfer of genes into murine cardiac grafts by starburst polyamidoamine dendrimers, 1997, American Society of Transplant Surgeons, Chicago, IL.

80

98. Punch, JD, Tono, T, Yang, Q, Bromberg, JS. TH2 cytokines are necessary for receptor mediated tolerance induction, 1997, American Society of Transplant Surgeons, Chicago, IL.

99. Tono, T, DeBruyne, LA, Bromberg, JS. TH1 type response is dominant over TH2 type response in murine cardiac allograft survival, 1997, American Society of Transplant Surgeons, Chicago, IL.

100. Punch, JD, Yang, Q, Bluestone, JA, Bromberg, JS. CD2 and CD3 receptor mediated tolerance: constraints on T cell activation, 1997, American Society of Transplant Surgeons, Chicago, IL.

101. Askari, FK, Turcotte, JG, Bromberg, J, Dickenson, CJ, Ciotti, M, McDonnell, WM. Infra-hepatic auxiliary liver transplantation with preservation of the entire liver in the treatment of crigler najjar syndrome, 1997, Digestive Disease Week, Washington D.C.

102. Sawyer, RG, Punch, JD, Merion, RM, Bromberg, JS, Campbell, DA, Armstrong, DR, Turcotte, JG. Incidence and management of biliary complications after 291 liver transplants following the introduction of transcystic stenting. 1997, Fourth Congress International Liver Transplantation Society, Seattle, Washington

103. Bromberg, JS. Gene therapy vectors: Improvement in transfer and expression to prolong allograft survival, Blood Purification, 1997, 15 (S1):106.

104. Bromberg, JS. Gene transfer and gene therapy in allografting, Blood Purification, 1998, 16 (S1):96-98.

105. Bromberg, JS, Qin, L, DeBruyne, L, Sung, R. Use of gene therapy for tolerogenic signals, 1998, XVII World Congress of the Transplantation Society, Montreal, Canada.

106. Magee, JC, DeBruyne, LA, Bromberg, JS, Divergent effects of conventional immunosuppression agents on gene therapy in transplantation. 1998, Seventeenth Annual Scientific Meeting, American Society of Transplant Physicians, Chicago, IL.

107. Beatty, RB, Krams, SM, Bromberg, JS, Martinez, OM. Differential effects of viral IL-10 and human B cell lines. 1998, Molecular Aspects of Viral Immunity, Tamarron, CO.

108. Magee, JC, Bromberg, JS, Punch, JD, Leichtman, AB, Dimond, JB, Merion, RM. Long term resource utilization and economic outcomes analysis after bladder-drained pancreas-kidney transplantation (BD-SPK). 1998, Seventeenth Annual Scientific Meeting, American Society of Transplantation Physicians, Chicago, IL.

109. Boasquevisque CHR, Mora BNM, Boglione M, Bromberg, JS, Scheule RK. Liposome-mediated gene transfer in rat lung transplantation: a comparison between

81

the in vivo and ex vivo approach. 1998, American Association of Thoracic Surgery, Boston, MA

110. Sung, RL, Qin, L, Bromberg, JS. CMV promoter characteristics determine cytokine sensitivity and gene expression in adenovirus mediated gene transfer. 1998, Seventeenth Annual Scientific Meeting, American Society of Transplant Physicians, Chicago IL.

111. Magee JC, DeBruyne LA, Buelow R, Bromberg JS. Gene transfer of immunosuppressive peptides B2702 and RDP1257 prolongs allograft survival: Evidence suggesting a role for heme oxygenase-I. 1998, American Society of Transplant Surgeons, Chicago, IL, Transplantation (1998) 66:S18.

112. Punch JD, Tono T, Qin L, Bromberg JS. Requirement for IL-4 in tolerance: Restoration by adoptive cellular or gene transfer. 1998, American Society of Transplant Surgeons, Chicago, IL, Transplantation (1998) 66:S11.

113. DeBruyne LA, Magee JC, Buelow R, Bromberg JS. Gene transfer of immunosuppressive peptides B2702 and BC1 correlates with heme oxygenase-I induction and enhanced allograft survival. 1998, American Society of Gene Therapy, Seattle, WA.

114. Qin L, Pahud DR, Ding Y, Bielinska AU, Kukowska-Latallo JF, Baker JR, Bromberg JS. StarburstTM polyamidoamine dendrimers efficiently transfer genes into murine cardiac grafts. 1998, American Society of Gene Therapy, Seattle, WA.

115. Punch JD, Bunchman TE, Bromberg JS, Merion RM. Cyclosporine based immunosuppression in pediatric liver transplantation. 1998, Third International Congress on Pediatric Transplantation, Boston, MA.

116. Ding Y, Qin L, Bromberg JS. Identification of the interleukin-10 immunostimulatory domain. Blood Purif. 1999; (suppl 1) 17:46-48.

117. Bromberg, JS. A review of adeno-associated virus vectors: potential for gene therapy. Graft 1998; 1:135.

118. Bromberg, JS. Summary of ASTS/ASTP steroid withdrawal conference in St. Louis, September 16 - 17, 1998. Chimera (1998) X(2):18-19.

119. Magee JC, DeBruyne LA, Mascarenhas J, Bromberg, JS. Mycophenolate mofetil inhibits plasmid mediated gene transfer. Keystone Symposium on Cellular and Molecular Biology of Gene Therapy, 1998, Snowbird, UT.

120. Qin L, Ding D, and Bromberg, JS. Protein kinase C regulates transgene expression from moloney murine leukemia virus long terminal repeat. 1999; Signal Transduction and Therapeutic Strategies, Nature Biotechnology. Miami, FL.

82

121. Ding Y, Qin L, and Bromberg JS. A single amino acid determines the immunostimulatory activity of cellular IL-10. 1999; Signal Transduction and Therapeutic Strategies, Nature Biotechnology, Miami, FL.

122. DeBruyne LA, Magee JC, Buelow R, and Bromberg JS. Gene transfer of immunomodulatory peptides correlates with heme oxygenase-1 induction and enhanced allograft survival. Keystone Symposium on Molecular and Cellular Biology of Transplantation, 1999; Lake Tahoe, NV.

123. Sung RS, Qin L, and Bromberg, JS. TNF and INF influence early adenovirus mediated gene expression in vivo, 1999, 25th Annual Scientific Meeting, American Society of Transplant Surgeons, Chicago, IL.

124. Magee JC, Mascarenhas J, DeBruyne LA, and Bromberg JS. Mycophenolate inhibits plasmid medicated gene transfer, 1999, 25th Annual Scientific Meeting, American Society of Transplant Surgeons, Chicago, IL.

125. DeBruyne LA, Li K, Bishop K, and Bromberg JS. Gene transfer of virally encoded chemokine antagonists, vMIP-II and MC148, prolongs cardiac allograft survival, 1999, 25th Annual Scientific Meeting, American Society of Transplant Surgeons, Chicago, IL.

126. Qin L, Ding Y, Tahara H, and Bromberg JS. Viral IL-10 induced immunosuppression requires TH2 cytokines and impairs APC function within the allograft, Experimental Biology, Washington, D.C., FASEB J. (1999) 13:A1128.

127. Ding Y, Qin L, Kotenko SV, Pestka S, and Bromberg JS. A single amino acid determines the immunostimulatory activity of IL-10, Experimental Biology, Washington, D.C., FASEB J. (1999) 13:A656.

128. Punch JD and Bromberg JS. A CD4+ IL-4 secreting cell is required for tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies, Experimental Biology, Washington, D.C., FASEB J. (1999) 13:A982.

129. Bromberg JS and Ding Y. Structural determinants of IL-10 activity. Blood Purification (2000) 18 (suppl 1):48-50.

130. Magee JC, Mascarenhas J, DeBruyne LA, and Bromberg JS. Plasmid mediated gene transfer is inhibited by depletion of guanosine nucleotides. 1999, American Society of Gene Therapy, Washington, DC.

131. DeBruyne LA, Li, K, Bishop, DK, and Bromberg, JS. Gene transfer of virally encoded chemokine antagonists, vMIP-II and MC148, prolongs cardiac allograft survival. 1999, American Society of Gene Therapy, Washington, D.C.

132. Sung RS, Qin L, and Bromberg JS. Adenovirus mediated gene expression is altered by TNF and IFN in vivo. 1999, American Society of Gene Therapy, Washington, D.C.

83

133. Ding Y, Qin L, Kotenko SV, Petska S, and Bromberg JS. Immunostimulatory and immunosuppressive domains of IL-10. 1999, 2nd International IL-10 Workshop, Milano, Italy.

134. Qin L, Ding Y, Tahara H, and Bromberg JS. Viral IL-10 induced immunosuppression requires TH2 cytokines and impairs APC function within the allograft. 1999, 2nd International IL-10 Workshop, Milano, Italy.

135. Itano H, Ritter JH, McCarthy TJ, Yew NS, Bromberg JS, Mohanakumar T, Patterson GA. Endobronchial transfection of naked viral interleukin-10 gene in rat lung allotransplantation. 2000, 36th Annual Meeting of the Society of Thoracic Surgeons, Fort Lauderdale, FL.

136. Bai Y, Ding Y, Spencer S, Lasky LA, Bromberg JS. Molecular association between CD2BP1 and the T cell surface antigen CD2 and its regulation. 2000, American Association of Immunologists, Seattle, WA.

137. Ding Y, Qin L, Schnur D, Kotenko SV, Pestka S, Bromberg JS. Differential IL-10R1 expression plays a critical role for IL-10-mediated immune regulation. 2000, American Association of Immunologists, Seattle, WA.

138. Zhang H, Chen F, Qin L, Bromberg JS. TNF enhances nuclear complex binding to NFB and cap initiation site homologous sequences of the HCMVie1 promoter and inhibits transgene expression. 2000, American Society for Gene Therapy, Denver, CO.

139. Bromberg JS, Qin L, Ding Y. Gene transfer of IL-10 for prolonged allograft survival. 2000, Baxter Extramural Grant Program, Chicago, IL.

140. Wang Y, Qin L, Bielinska AU, Kukowska-Latallo, JF, Baker Jr. JR, Bromberg JS. DNA/Dendrimer complexes mediate gene transfer into murine cardiac transplants ex vivo. Molecular Therapy (2000) 1: S210.

141. Bromberg JS, Wang Y, Qin L, Bielinska AU, Kukowska-Latallo JF, Baker Jr. JR. Combination of electroporation and DNA/Dendrimer complexes enhances gene transfer into cardiac transplants. Molecular Therapy (2000) 1: S202-S203.

142. Zhang H, Chen F, Qin L, Bromberg JS. TNF enhances nuclear complex binding to NFB and Cap initiation site homologous sequences of the HCMVie1 promoter and inhibits transgene expression. Molecular Therapy (2000) 1: S197.

143. Patterson EJ, Gagner M, Bromberg JS, Florman S, Knight R, Burrows L, Edye M. Comparison of laparoscopic versus laparoscopic hand-assisted donor nephrectomy. 2001, SAGES, St. Louis, MO.

84

144. Ding Z, Qin L, Bromberg JS. The suppressor of cytokine signaling (SOCS)1 and SOCS3 proteins inhibit IL-10 mediated immune responses. American Association of Immunologists, Experimental Biology, 2001, Orlando, FL.

145. Bai Y, Wang Y, Bromberg JS. CD2-CD48 interactions are more important than 2B4-CD48 for allograft survival. American Association of Immunologists, Experimental Biology, 2001, Orlando, FL.

146. Bai Y, Qin L, Bromberg JS. Lymph node residency is required to induce alloantigen specific tolerance. American Association of Immunologists, Experimental Biology, 2001, Orlando, FL.

147. Bai Y, Qin L, Bromberg JS. Anti-L-selectin prevents tolerance induction by inhibiting T lymphocyte homing to the lymph node. Am. J. Transplant. 2001:1 (Suppl.1):274.

148. Bai Y, Wang Y, Qin L, Bromberg JS. Hierarchy of CD2-CD48 and 2B4-CD48 receptor-ligand interaction in prolongation of allograft survival. Am. J. Transplant. 2001:1 (Suppl.1):448.

149. Ku H, Keller G, Bromberg JS. In vitro generation of pancreatic endocrine type cells from mouse embryonic stem cells. Am. J. Transplant. 2001:1 (Suppl.1):338.

150. Honig SM, Bai Y, Bromberg JS. Lymph node localization is necessary for tolerance induction in mice. Am. J. Transplant. 2001:1 (Suppl.1):332.

151. Ku HT, Kubo A, Keller G, Bromberg JS. In vitro generation of pancreatic endocrine cells from embryonic stem cells. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):1271

152. Ku HT, Keller G, Bromberg JS. Isolation and characterization of putative murine adult pancreatic stem/progenitor cells. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):517

153. Honig SM, Mao X, Randolph G, Gunn M, Bromberg JS. FTY720 stimulates the multidrug transporters Mdr 1A/1B and MRP to cause chemokine dependent T cell lymph node homing. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):905

154. Fu S, Mao X, Ding Y, Bromberg JS. A subset of CD4+CD25+ regulatory T cells expresses high levels of IL-10R1. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):102

155. Fu S, Mao X, Chen D, Ding Y, Bromberg JS. FIV virus mediated viral IL-10 gene transfer prolongs allograft survival. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):1224

85

156. Fishbein TM, Liu J, Boros P, Bromberg JS. FTY720 prolongs the survival of orthotopically transplanted rat small bowel grafts in combination with donor specific spleen cells. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):734

157. Paramesh A, Doan Y, Emre S, Wayne M, Fishbein T, Bromberg JS. Comparison of onset of renal failure in hepatitis C positive and negative liver transplant patients requiring subsequent kidney transplant. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):622

158. Genden EM, Iskander A, Bromberg JS, Mayer L. Murine orthotopic tracheal transplants undergo mucosal repopulation. American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):781

159. Akalin E, Dikman S, Murphy D, Bromberg JS, Hancock WW. Differential expression of chemokines, chemokine receptors and ICOS in chronic allograft nephropathy (CAN) with or without transplant nephropathy (TGP). American Transplant Congress, Washington, DC., Am. J. Transplant. (2002) 2 (Suppl.3):950

160. Ding Y, Qin L, Su R, Bromberg JS. IL-10 inhibits IFN and autoregulates IL-10 signaling through SOCSs. Experimental Biology 2002, New Orleans, LA., FASEB J. (2002) 16:A313.

161. Honig SM, Mao X, Randolph G, Gunn M, Bromberg JS. FTY720 causes MRP, CCR7, and VLA-4 dependent lymph node homing. Experimental Biology 2002, New Orleans, LA., FASEB J (2002) 16:A1032.

162. Chen D, Ding Y, Schröppel B, Chen D, Bromberg JS. Adenoviral vectors stimulate potent chemokine expression in transplanted hearts. American Society of Gene Therapy 2002, Boston, MA, Mol. Therapy (2002) 5:S7.

163. Fu S, Mao X, Chen D, Ding Z, Bromberg JS. FIV virus mediated vIL-10 gene transfer prolongs cardiac allograft survival. American Society of Gene Therapy 2002, Boston, MA, Mol. Therapy (2002) 5:S234.

164. Chen D, Ding Y, Fu S, Mao X, Bromberg JS. vIL-10 gene transfer inhibits expression of multiple proinflammatory genes in transplanted hearts. American Society of Gene Therapy 2002, Boston, MA, Mol. Therapy (2002) 5:S297.

165. Zhang N, Schröppel B, Murphy B, Bromberg JS. Adenovirus transduction promotes the expression of multiple chemokines in -TC3 cells and murine pancreatic islets. American Society of Gene Therapy 2002, Boston, MA, Mol. Therapy (2002) 5:S346.

166. Zhang N, Schröppel B, Murphy B, Bromberg JS, Sung R. Adenovirus transduction impairs engraftment of murine pancreatic islet transplants. American Society of Gene Therapy 2002, Boston, MA, Mol. Therapy (2002) 5:S350.

86

167. Akalin E, Dikman S, Murphy B, Bromberg JS, Hancock W. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy (CAN) with transplant glomerulopathy (TGP). JASN (2002) 13:23A.

168. Akalin E, Ames S, Sehgal V, Fotino M, Sung R, Daly L, Murphy B, Bromberg JS. Intravenous immunoglobulin (IVIG) and thymoglobulin induction treatment facilitate kidney transplantation in complement dependent cytotoxicity (CDC) B cell and flow cytometry (T and/or B cell) cross-match positive patients. JASN (2002) 13:48A.

169. Sung RS, Zhang N, Schroppel B, Murphy B, Bromberg JS. Adenovirus transduction promotes the expression of CCL2 (MCP-1) in Beta-TC3 cells and murine pancreatic islets, and impairs engraftment of murine pancreatic islet transplants. Transplantation (2002) 74:A455.

170. Safadi R, Ohta M, Alvarez CE, Cooreman MP, Eng FJ, Mehal W, Bromberg JS and Friedman SL. Diminished fibrosis and altered lymphocyte subsets in transgenic mice with hepatocyte overexpression of interleukin-10 . Hepatology (2002) 36(4): 330A.

171. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Ding Y, Bromberg JS. The subset of CD4+CD25+ T regulatory cells expressing high levels of L-selectin has the greatest suppressive and proliferative potential. Am. J. Transplant. (2003) 3 (suppl. 5):155.

172. Yopp AC, Honig SM, Fu S, Bromberg JS. FTY720 enhances T cell homing to peripheral lymph nodes through sequential activation of multidrug transporters. Am. J. Transplant. (2003) 3 (suppl. 5):183.

173. Yopp AC, Fu S, Honig SM, Krieger N, Bromberg JS. FTY720 enhances T cell migration to the CCR2 ligand MCP-1 (CCL2). Am. J. Transplant. (2003) 3 (suppl. 5):183.

174. Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, Bromberg JS. Intravenous immunoglobulin (IVIG) and thymoglobulin induction treatment in complement dependent cytotoxicity (CDC) B cell and flow cytometry (T and/or B cell) cross-match positive patients. One year follow-up. Am. J. Transplant. (2003) 3 (suppl. 5):174.

175. Paramesh A, Roayaie S, Doan Y, Bromberg JS, Akalin E. Post liver transplantation acute renal failure: factors predicting the development of end stage renal disease. Am. J. Transplant. (2003) 3 (suppl. 5):247.

176. Chen D, Ding Y, Zhang N, Fu S, Schroppel B, Zhang H, Bromberg JS. Viral IL-10 gene transfer inhibits the expression of multiple chemokine and chemokine receptor genes induced by inflammatory or adaptive immune stimuli. Am. J. Transplant. (2003) 3 (suppl. 5):396.

177. Chen D, Ding Y, Schroppel B, Zhang N, Fu S, Chen D, Zhang H, Bromberg JS. Ischemia-reperfusion, alloantigen, and adenovirus gene transfer result in differential

87

expression of chemokine and chemokine receptor genes in cardiac grafts. Am. J. Transplant. (2003) 3 (suppl. 5):271.

178. Ding Y, Su R, Bromberg JS. The mechanism of IL-10 and IL-6 mediated Th differentiation. Am. J. Transplant. (2003) 3 (suppl. 5):272.

179. Zhang N, Schroppel B, Chen D, Murphy BM, Bromberg JS, Sung RS. Adenovirus vector transduction promotes the expression of multiple chemokines in murine pancreatic islets and impairs islet engraftment. Am. J. Transplant. (2003) 3 (suppl. 5):411.

180. Zhang N, Schroppel B, Chen D, Murphy BM, Bromberg JS, Sung RS. Inhibition of islet engraftment by adenovirus vector: role of CCR2 and CCR5. Am. J. Transplant. (2003) 3 (suppl. 5):287.

181. Schroppel B, Zhang N, Chen D, Hudkins KL, Kuziel WA, Sung R, Bromberg JS, Murphy B. The role of the MCP-1/CCR2 pathway in acute islet allograft rejection. Am. J. Transplant. (2003) 3 (suppl. 5):207.

182. Liu J, Li Y, Boros P, Bromberg JS, Fishbein TM. A functional orthotopic small bowel transplant model in mice. Am. J. Transplant. (2003) 3 (suppl. 5):395.

183. Krieger NR, Artis T, Roayaie S, Gondolesi GE, Florman S, Wayne M, Fishbein TM, Schiano T, Kim-Schluger L, Bromberg JS, Schwartz ME, Miller CM, Emre S. Safe use of hepatic allografts from older donors: evaluation of 179 cadaveric donors > 70 years. Am. J. Transplant. (2003) 3 (suppl. 5):450.

184. Ku HT, Kubo A, Mao M, O’Connor R, Keller G, Bromberg J. Generation of endoderm vs. ectoderm derived insulin expressing cells from murine embryonic stem cells in culture. Am. J. Transplant. (2003) 3 (suppl. 5):172.

185. Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Murphy B, Bromberg JS. Cytomegalovirus disease in Thymoglobulin treated transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am. J. Transplant. (2003) 3 (suppl. 5):505

186. Yopp AC, Fu S, Honig SM, Bromberg JS. FTY720 enhances T cell migration to the CCR2 ligand, MCP-1. FASEB J. (2003) 17:C70.

187. Ding Y, Bromberg JS. The mechanism of IL-10 and IL-6 mediated Th differentiation. FASEB J. (2003) 17:C131.

188. Chen D, Ding Y, Zhang N, Fu S, Schroppel B, Bromberg JS. Viral IL-10 gene transfer regulates innate and adaptive immunity through chemokine and chemokine receptor gene expression in transplanted hearts. FASEB J. (2003) 17:C112.

189. Chen D, Ding Y, Schroppel B, Zhang N, Fu S, Chen D, Zhang H, Bromberg JS. Differential chemokine and chemokine receptor gene induction by ischemia/

88

reperfusion, alloantigen, and gene transfer in cardiac grafts. FASEB J. (2003) 17:C133.

190. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Chen D, Mao M, Ding Y, Bromberg JS. The CD4+CD25+CD65L+ T regulatory cell subset has optimal suppressive and proliferative potential. FASEB J. (2003) 17:C311.

191. Yopp AC, Fu S, Honig SM, Bromberg JS. FTY720 enhances T cell migration to the CCR2 ligand, MCP-1. Surgical Forum (2003).

192. Akalin E, Fotino M, Friedlander R, Murphy B, Ames S, Sehgal V, Daly L, Bromberg JS. Intravenous immunoglobulin (IVIG) and Thymoglobulin induction treatment downregulates preformed donor-specific anti-HLA antibodies (DSA), but does not prevent the development of de novo DSA. ASN (2003).

193. Akalin E, Bromberg JS, Sehgal V, Ames S, Daly L, Murphy B. Decreased incidence of cytomegalovirus infection in Thymoglobulin treated transplant patients with 6 months valganciclovir propylaxis. ASN (2003).

194. Akalin E, Bromberg JS, Sehgal V, Ames S, Murphy B. Decreased incidence of cytomegalovirus infection in Thymoglobulin treated kidney transplant patients with 6-months valganciclovir prophylaxis. Am. J. Transplant. (2004) 4:148-149.

195. Ochando JC, Llodra J, Randolph GJ, Rudensky AY, Bromberg JS, Krieger NR. Direct and indirect allorecognition: visualization of dendritic cell interactions in graft rejection. Am. J. Transplant.(2004) 4 (Suppl. 8):411.

196. Zhang N, Fu S, Chen D, Zhang H, Ding Y, Bromberg JS. CD4+CD25+ T cells inhibit innate immune responses of murine islets. Am. J. Transplant.(2004) 4 (Suppl. 8):429.

197. Yopp AC, Fu S, Ochando JC, Krieger NR, Bromberg JS. Inhibition of transendothelial T lymphocyte migration by P-FTY720 and sphingosine 1-phosphate (S1P). Am. J. Transplant.(2004) 4 (Suppl. 8):248.

198. Akalin E, Bromberg JS, Sehgal V, Ames S, Daly L, Murphy B. 6 months valganciclovir prophylaxis significantly decreases cytomegalovirus infection incidence in Thymoglobulin treated transplant patients. Am. J. Transplant.(2004) 4 (Suppl. 8):495.

199. Akalin E, Fotino M, Friedlander R, Murphy B, Ames S, Sehgal V, Daly L, Bromberg JS. Intravenous immune globulin (IVIG) and Thymoglobulin induction treatment down regulate preformed donor-specific anti-HLA antibodies (DSA), but do not prevent the development of de novo DSA. Am. J. Transplant.(2004) 4 (Suppl. 8):550.

200. Ochando JC, Llodra J, Randolph GJ, Rudensky AY, Bromberg JS, Krieger NR. Dendritic cell interactions in rejection and tolerance. AAI 2004.

89

201. Yopp AC, Fu S, Ochando JC, Krieger NR, Bromberg JS. Sphingosine 1-phosphate receptor (S1PR) activation: evidence for anatomically distinct chemokine compartments. AAI 2004.

202. Ku HT, Zhang N, Kubo A, O’Connor R, Mao M, Keller G, Bromberg J. Committing murine embryonic stem cells to early endocrine pancreas in vitro. ADA 2004.

203. Zhang N, Fu S, Chen D, Zhang H, Ding Y, Bromberg JS. CD4+CD25+ regulatory T cells protect islets from innate immune responses. ADA 2004.

204. Zhang N, Clement N, Zhang H, Chen D, Fu S, Linden M, Bromberg JS. Transduction of pancreatic islets with pseudotyped adeno-associated virus: effect of viral capsid. Molec.Therapy, 2004 (Supplement 1) 9:S379.

205. Zhang N, Fu S, Chen D, Ding Y, Bromberg JS. CD4+CD25+ regulatory T cells protect islets from innate immune response. Diabetes, 2004 (suppl. 2) 53:A26-A27(113-OR).

206. Ku HT, Zhang N, Kubo A, O'Connor R, Mao M, Keller G, Bromberg JS. Committing murine embryonic stem cells to early endocrine pancreas in vitro. Diabetes, 2004 (suppl. 2) 53:A381(1591-P).

207. Zhang N, Richter A, Harbaran S, Altomonte J, Zhang H,Song K, Meseck M, Bromberg JS, Dong H. Intra-graft production of VEGF is associated with enhanced islet neovascularization and improved outcome of marginal islet transplantation in diabetic mice. Diabetes, 2004 (suppl. 2) 53:A456(1908-P).

208. Akalin E, Sehgal V, Ames S, Dikman S, Fotino M, Bromberg JS, Murphy B. Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy. Transplantation, 2005, 79:257-258

209. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS. Safety of using hepatitis B core antibody (HbcAb) or surface antigen (HbsAg) positive donors in kidney or pancreas transplantation. (ASN) 2004.

210. Akalin E, Ames S, Sehgal V, Murphy B, Fotino M, Friedlander R, Bromberg JS. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk living kidney transplant recipients. ASN (2004).

211. Schroppel B, Chen P, Bromberg JS, Murphy B. The role of donor-derived CCL2/MCP-1 in murine islet transplantation. ASN (2004).

212. Akalin E, Ames A, Sehgal V, Murphy B, Fotino M, Friedlander R, Bromberg JS. Intravenous immunoglobulin and Thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation, 2005, 79:742.

90

213. Akalin E, Ames S, Sehgal V, Murphy B, Fotino M, Friedlander R, and Bromberg JS. Deleterious effect of preformed anti-HLA Class I donor-specific antibodies despite intravenous immunoglobulin induction treatment in living kidney transplant recipients. Am. J. Transplant. (2005) 5 (suppl. 11):324.

214. Akalin E, Murphy B, Ames S, Sehgal V, Vanderbeek L and Bromberg JS. Rapid steroid withdrawal in hepatitis C virus positive kidney transplant recipients. Am. J. Transplant. (2005) 5 (suppl. 11):302.

215. Akalin E, Ames S, Sehgal V, Murphy B and Bromberg JS. Safety of using Hepatitis B Core antibody or surface antigen positive donors in kidney or pancreas transplantation. Am. J. Transplant. (2005) 5 (suppl. 11):558-9.

216. Zhang N, Chen D, Fu S, Ding Y, and Bromberg JS. Natural and TGF- Driven T regulatory cells (Treg) inhibit innate chemokine production by pancreatic islets and prevent early islet graft loss. Am. J. Transplant. (2005) 5 (suppl. 11):388.

217. Zhang N, Chen D, Fu S, Ding Y, and Bromberg JS. CD4+CD25+T cells inhibit effector T cell migration. Am. J. Transplant. (2005) 5 (suppl. 11):256.

218. Yopp AC, Ochando JC, Mao M, Ledgerwood L, Ding Y, and Bromberg JS. Sphingosine 1-phospate receptors regulate chemokine driven transendothelial migration of lymph node but not splenic T cells. Am. J. Transplant. (2005) 5 (suppl. 11):543.

219. Chen D, Zhang N, Fu S, Ding Y, and Bromberg JS. CD4+CD25+ T regulatory cells inhibit islet chemokine expression through a cell contact dependent mechanism. Am. J. Transplant. (2005) 5 (suppl. 11):256.

220. Hermesh T, Homma C, Ochando JC, Yopp AC, and Bromberg JS. CCL17+ alloantigen presenting cells migrate to the high endothelial venules during tolerization. Am. J. Transplant. (2005) 5 (suppl. 11):432.

221. Ochando JC, Frimer M, Hermesh T, and Bromberg JS. Tolerogenic dendritic cells process alloantigen in a P and E-selection dependent manner. Am. J. Transplant. (2005) 5 (suppl. 11):248.

222. Ochando JC, Yopp AC, Yang Y, Li Y, Boros P, Llodra J, Ding Y, Krieger NR and Bromberg JS. Peripheral development of alloantigen-specific Foxp3 regulatory T cells occurs in the lymph nodes of tolerized recipients. Am. J. Transplant. (2005) 5 (suppl. 11):416.

223. Ochando JC, Yopp AC, Krieger NR, and Bromberg JS. Regulatory T cell lymph node migration is required to induce alloantigen-specific tolerance. Am. J. Transplant. (2005) 5 (suppl. 11):537.

91

224. Ochando JC, Li Y, Boros P, Llodra J, Ding Y, and Bromberg JS. Alloantigen presenting plasmacytoid dendritic cells promote regulatory T cell development in the lymph node. Am. J. Transplant. (2005) 5 (suppl. 11):564-5.

225. Yang Y, Ochando JC, Yopp A, Ding Y, and Bromberg JS. A new pathway for early IL-4 expression: C-MAF induction by IL-6. Am. J. Transplant. (2005) 5 (suppl. 11):436.

226. Yang Y, Ochando JC, Yopp A, Ding Y, and Bromberg JS. Cyclosporin A and FK506 Block IL-6 Mediated C-MAF Expression. Am. J. Transplant. (2005) 5 (suppl. 11):222.

227. Yang Y, Ochando JC, Yopp A, Ding Y and Bromberg JS. Stat 3 Trans-activates the C-MAF promoter in vivo. Am. J. Transplant. (2005) 5 (suppl. 11):226.

228. Yang Y, Ochando JC, Ding Y, and Bromberg JS. CD8 Cell TC2 Development is limited by TCR initiated IL-4. Am. J. Transplant. (2005) 5 (suppl. 11):379.

229. Ku TH, and Bromberg JS. Sox17 drives insulin I expression in differentiated murine embryonic Stem (ES) cells. Am. J. Transplant. (2005) 5 (suppl. 11):522.

230. Blondeau B, Sauter B, Akalin E, Hoppenhauer L, Rodriguez-Laiz, Bromberg JS, Gondolesi G. Pre-transplant immunomodulation of highly sensitized small bowel transplant candidates with IVIG. Am. J. Transplant. (2005) 5 (suppl. 11):229.

231. Yopp A, Ochando J, DingY, Bromberg JS. Sphingosine 1-phosphate receptors regulate chemokine driven migration of lymph node but not splenic T cells. J. Am. Coll. Surgeons (2005) 201(S3):S91-S92.

232. Ku HT, Kim Y-J, Chai J, White P, Kaestner K, Bromberg JS. Insulin-expressing colonies developed from murine embryonic stem cell-derived pancreatic -cell progenitors. FASEB conference on Pancreatic Islets: From development to transplantation, Taos, NM, February 25, 2006.

233. Akalin, EA, Ganeshan, SV, deBoccardo, G, Sehgal, V, Schroppel, B, Ames, S, Bromberg, JS, Murphy, B. Hyperuricemia is an independent risk factor for the development of cardiovascular disease in kidney transplant recipients. World Transplant Congress, Boston, MA, July 22-27, 2006.

234. Ochando, JC, Yang, Y, Ledgerwood, LG, Garin, A, Ding, Y, Lira, SA, Brombeg, JS. High endothelial venules upregulate adhesion molecules to promote lymph node homing during tolerance to vascularized allografts. World Transplant Congress, Boston, MA, July 22-27, 2006.

235. Zhang, N, Ochando, JC, Chen, D, Bromberg, JS. Migration to islet grafts but not lymph nodes is important for Treg effector function. World Transplant Congress, Boston, MA, July 22-27, 2006.

92

236. Zhang, N, Martin, AP, Lira, SA, Bromberg, JS. Protection of islet grafts from allo-and autoimmune destruction by blockade of the chemokine system. World Transplant Congress, Boston, MA, July 22-27, 2006.

237. Ochando, JC, Tacke, F, Randolph, GJ, Bromberg, JS. Monocyte-derived dendritic cells do not process alloantigen in donor vascularized allografts. World Transplant Congress, Boston, MA, July 22-27, 2006.

238. Ochando, JC, Homma, C, Tacke, F, Boros, P, Ding, Y, Nussenzweig, MC, Randolph, GJ, Bromberg, JS. Human and mouse plasmacytoid dendritic cells display phagocytic properties. World Transplant Congress, Boston, MA, July 22-27, 2006.

239. Ku, HT, Chai, J, Zhang, N, Qin, L, Bromberg, JS. Sox17 enhances differentiation of pancreatic-like structures from murine embryonic stem cells. World Transplant Congress, Boston, MA, July 22-27, 2006.

240. Ku, HT, Chai, J, Bromberg, JS. Generation of insulin and glucagon expressing cells from human embryonic stem cells in vitro. World Transplant Congress, Boston, MA, July 22-27, 2006.

241. Yang, Y, Ding, Y, Bromberg, JS. Identification of a novel T-BET enhancer conserved in human and murine CD8 T cells. World Transplant Congress, Boston, MA, July 22-27, 2006.

242. Yang, Y, Ochando, JC, Ding, Y, Bromberg, JS. C-MAF inhibits eomes expression and CD8 effector responses. World Transplant Congress, Boston, MA, July 22-27, 2006.

243. Akalin, E, Murphy, B, deBoccardo, G, Sehgal, V, Schroppel, B, Friedlander, R., Fotino, M, Ames, S, Bromberg, JS. Intravenous immunoglobulin and thymoglobulin induction treatment in kidney transplant recipients with donor-specific anti-HLA antibodies. World Transplant Congress, Boston, MA, July 22-27, 2006.

244. Ochando, JC, Yang, Y, Boros, P, Ding, Y, Jessberger, RJ, Bromberg, JS. SWAP-70 expression is required during tolerance to vascularized allografts. World Transplant Congress, Boston, MA, July 22-27, 2006.

245. Zhang, N, Ochando, JC, Chen, D, Bromberg, JS. TGF-β induces e-selectin ligand in Foxp3+ T regulatory cells. World Transplant Congress, Boston, MA, July 22-27, 2006.

246. Ledgerwood, LG, Ochando, JC, Yopp, AC, Bromberg, JS. Sphingosine 1-phosphate receptor activitiy is required for T cell migration from peripheral tissue into afferent lymph and lymph nodes. World Transplant Congress, Boston, MA, July 22-27, 2006.

93

247. Ochando, JC, Yang, Y, Garin, A, Ledgerwood, LG, Ding, Y, Jessberger, RJ, Trinchieri, G, Lira, SA, Randolph, GJ, Bromberg, JS. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. World Transplant Congress, Boston, MA, July 22-27, 2006.

248. Akalin, E, Murphy, B, Sehgal, V, Schroppel, B, deBoccardo, G, Bromberg, JS. Routine C4d staining of transplant kidney biopsies: low prevelance in chronic allograft nephropathy and transplant glomerulopathy patients. World Transplant Congress, Boston, MA, July 22-27, 2006.

249. Akalin, E, Murphy, B, Ames, S, Sehgal, V, deBoccardo, G, Schroppel, B, Bromberg, JS. Rapid steroid withdrawal in african-american kidney transplant recipients. World Transplant Congress, Boston, MA, July 22-27, 2006.

250. Akalin E, Ames, S, Friedlander, R, Sehgal, V, Murphy, B, Schroppel, B, deBoccardo, G, Fotino, M, Bromberg, JS. Intravenous immunoglobulin and thymoglobulin induction treatment in donor-specific anti-HLA antibody negative but cross-match positive kidney transplant recipients. World Transplant Congress, Boston, MA, July 22-27, 2006.

251. Ku, HT, Kim, Y, Chai, J, White, P, Kaestner, K, Bromberg, JS. Generation of insulin-expressing colonies from murine embryonic stem cell-derived β-cell progenitors. World Transplant Congress, Boston, MA, July 22-27, 2006.

252. Uva, P, deBoccardo, G, Bromberg, JS, Ames, S, Sehgal, V, Schroppel, B, Murphy, B, Akalin, E. Rapid steroid withdrawal in hepatitis C virus positive kidney transplant recipients. World Transplant Congress, Boston, MA, July 22-27, 2006.

253. Yang, Y, Ochando, JC, Ding, Y, Bromberg, JS. IL-12/Stat4 mediated T-BET expression is required for CD8 effector response againse adenovirus. World Transplant Congress, Boston, MA, July 22-27, 2006.

254. Akalin, E, Murphy, B, Sehgal, V, Schroppel, B, deBoccardo, G, Bromberg, JS, Ames, S, Dikman, S. Low prevelance of C4D positivity in chronic allograft nephropathy and transplant glomerulopathy biopsies. American Society of Nephrology, San Diego, CA, November 14-19, 2006.

255. Akalin, E, Ames, S, Murphy, B, Sehgal, V, deBoccardo, G, Schroppel, B, Friedlander, R, Fotino, M, Bromberg, JS. Intravenous immunoglobulin and thymoglobulin induction treatment in flow-cytometry cross-match positive kidney transplant recipients: 5 years experience. American Sociey of Nephrology, San Diego, CA, November 14-19, 2006.

256. Bromberg, JS, LeRoith, D. Diabetes Cures – Is the Glass Half Full? New Engl. J. Med. 2006, 355:1372-1374.

94

257. Lal, G., Zhang, N., Ledgerwood, L.G., Esses, S.J., Bromberg, J.S. The Sphingosine 1-phosphate receptor (S1PR) agonist FTY720 inhibits lymphatic transendothelial migration. Am. J. Transplant (2007) 7 (suppl. 2):154.

258. Zhang, N., Ochando, J.C., Chen, D., Bromberg, J.S. Selectin ligand dependent migration determines Treg suppressive function in islet transplantation. Am. J. Transplant (2007) 7 (suppl. 2):154.

259. Ledgerwood, L.G., Lal, G., Esses, S.J., Ochando, J.C., Bromberg, J.S. Development of a novel assay for T cell lymphatic migration: role for sphingosine 1-phosphate receptor, S1P1. Am. J. Transplant (2007) 7 (suppl. 2):328.

260. Ma, G., Yang, Y., Ding, Y., Bromberg, J.S. TGFβ and anti-IL-2 favor Th17 development. Am. J. Transplant (2007) 7 (suppl. 2):330.

261. Yang, Y., Ma, G., Ding, Y., Bromberg, J.S. Eomes antagonizes TGFβ mediated inhibition of CD8 effector responses. Am. J. Transplant (2007) 7 (suppl. 2):330.

262. Yang, Y., Ding, Y., Bromberg, J.S. T-bet plays a dominant role in suppressing early IL-4 expression in CD8 T cells. Am. J. Transplant (2007) 7 (suppl. 2):330.

263. Yang, Y., Ma, G., Ochando, J.C., Ding, Y., Bromberg, J.S. A new mouse model for studying Treg and Th17. Am. J. Transplant (2007) 7 (suppl. 2):330.

264. Dinavahi, R., Bromberg, J.S., Friedlander, R., Fotino, M., Ames, S., Sehgal, V., deBoccardo, G., Lerner, S., Schroppel, B., Murphy, B., Akalin, E. Flow-cytometry cross-match positive kidney transplant recipients with strong anti-HLA class I antibodies require plasmapheresis with intravenous immunoglobulin. Am. J. Transplant (2007) 7 (suppl. 2):343.

265. del Pozo, A., Kim, J., Dikman, S., Hoppenhauer, L., Rodriguez-Laiz, G., Gondolesi, G., Schiano, T., Akalin, E., Murphy, B., Emre, S., Bromberg, J.S., deBoccardo, G. Analysis of renal dysfunction and pathology in a population of small bowel transplant recipients. Am. J. Transplant (2007) 7 (suppl. 2):407.

266. Ma, G., Yang, Y., Ding, Y., Bromberg, J.S. Stat1 is required for IFNγ to inhibit Th17 differentiation. Am. J. Transplant (2007) 7 (suppl. 2):219.

267. Lal, G., Ding, Y., Bromberg, J.S. Epigenetic regulation of Foxp3 expression and generation of regulatory T cells from naïve CD4+CD25- T cells. Am. J. Transplant (2007) 7 (suppl. 2):219.

268. Yang, Y., Ma, G., Ding, Y., Bromberg, J.S. IL-6 combined with TGFβ induces Tc17 generation in CD8 T cells. Am. J. Transplant (2007) 7 (suppl. 2):220.

269. Ochando, J.C., Nikolayevskiy, H., Gonzalez, N., Ledgerwood, L.G., Yang, Y., Boros, P., Ding, Y., Bromberg, J.S. Donor-derived cell migration into the lymph

95

nodes is required for DST plus anti-CD40L mediated tolerance to vascularized allografts. Am. J. Transplant (2007) 7 (suppl. 2):409.

270. Yang, Y., Ochando, J.C., Ding, Y., Bromberg, J.S. ROG is negatively regulated by c-Maf in T cells. Am. J. Transplant (2007) 7 (suppl. 2):481.

271. Yang, Y., Ma, G., Ding, Y., Bromberg, J.S. T-bet inhibits emoes through a repressor region. Am. J. Transplant (2007) 7 (suppl. 2):481.

272. Zhang, N., Ochando, J.C., Bromberg, J.S. Treg influence the dendritic cell early response in islet allografts. Am. J. Transplant (2007) 7 (suppl. 2):256.

273. Dinavahi, R., Dikman, S., Murphy, B., Sehgal, V., Schroppel B., deBoccardo, G., Bromberg, J.S., Akalin, E. Not all transplant glomerulopathy is due to chronic antibody-mediated rejection. Am. J. Transplant (2007) 7 (suppl. 2):259.

274. Dinavahi, R, Bromberg, JS, Ames, S, Friedlander, R, Sehgal, V, DeBoccardo, G, Lerner, S, Schroppel, B, Fotino, M, Murphy, B, Akalin, E. The addition of pre-or peri-transplant plasmapheresis to intravenous immunoglobulin reduces the risk of early antibody-medicated rejection in patients with strong class I anti-HLA antibodies. American Society of Nephrology, San Francisco, CA, October 31, 2007.

275. Ames, SA, Comellas, CD, Akalin, E, Vanderbeek, LB, Grossman, E, Bromberg, JS. Maximizing importation and use of locally unwanted kidneys. 2007 Organ Donation Congress, Philadelphia, PA, November 11-14, 2007.

276. Ames, SA, Dikman, S, Grossman, EB, Akalin, E, Lerner, S, Bromberg, JS. How accurate are frozen section biopsies of deceased donor kidneys? 2007 Organ Donation Congress, Philadelphia, PA, November 11-14, 2007.

277. Bromberg, JS, Ledgerwood, L, Zhang, N, Lal, G, Ochando, J. S1P1 stimulation inhibits afferent lymphatic migration. Keystone Symposium on Lymphocyte Trafficking, Keystone, CO, January 13-18, 2008.

278. Lal, G, Zhang, N, Ding, Y, Bromberg, J. Epigenetic regulation of Foxp3 expression and efficient generation of regulatory CD4+ T cells from peripheral naïve CD4+CD25- T cells. Keystone Symposium on Tolerance in Transplantation and Autoimmunity, Keystone, CO, January 29 – February 3, 2008.

279. Rafiq, MA, de Boccardo, G, Schroppel, B, Bromberg, JS, Sehgal, V, Dinavahi, R, Murphy, B, Akalin, E. Poor prognosis in type II and II acute antibody-mediated rejection. American Society of Nephrology, Philadelphia, PA, November 7, 2008.

280. Akalin, E, Dinavahi, R, de Boccardo, G, Schroppel, B, Sehgal, V, Murphy, B, Bromberg, JS. Rational desensitization protocols: treatement according to median fluorescence intensity values of luminex flow beads. American Society of Nephrology, Philadelphia, PA, November 8, 2008.

96

281. Sawinski, D, Wyatt, C., Casagrande, L, Myoung, P, Bijan, I, Akalin, E, Schroppel, B., Keller, M, Huprikar, S, deBoccardo, G, Sehgal, V, Dinavahi, R, Lerner, S, Ames, S, Bromberg, JS, Murphy, B. Barriers to transplantation of HIV-positive kidney transplant candidates. Am. J. Transplant (2008) 8 (suppl. 2):198.

282. Lal, G, Zhang, N, van der Touw, W, Ding, Y, Bromberg, JS. A novel epigenetic approach to generate mouse and human CD4+CD25+Foxp3+ regulatory T cells. Am. J. Transplant (2008) 8 (suppl. 2):203.

283. Lal, G, Ding, Y, Bromberg, JS. DNA methylation has a major role in regulating Foxp3+ transcription. Am. J. Transplant (2008) 8 (suppl. 2):223.

284. Zhang, N, Schroppel, B, Lal, G, Bromberg, JS. Chemokine receptors important for Treg lymphatic migration and suppressive function. Am. J. Transplant (2008) 8 (suppl. 2):223.

285. Zhang, N, Ochando, JC, Bromberg, JS. Treg trafficking from the islet allograft to the draining lymph node is required to inhibit antigen-specific immunity. Am. J. Transplant (2008) 8 (suppl. 2):248.

286. Yang, Y, Xu, J, Niu, Y, Bromberg, JS, Ding, Y. Blocking both Th1 and Th2 pathways favors TGFβ driven Treg generation. Am. J. Transplant (2008) 8 (suppl. 2):249.

287. Zhang, N, Schroppel, B, Lal, G, Ochando, JC, Bromberg, JS. Regulatory T cells sequentially migrate from the site of tissue inflammation to the draining LN to suppress allograft rejection. Am. J. Transplant (2008) 8 (suppl. 2):264.

288. Yang, Y, Niu, Y, Xu, J, Ding, Y, Bromberg, JS. Th17 are limited in their ability to reject allografts. Am. J. Transplant (2008) 8 (suppl. 2):313.

289. del Pozo, A, Mazzella, L, del Rio Martin, J, Rodriguez-Laiz, G, Sturdevant, M, Iyer, K, Schiano, T, Akalin, E, Murphy, B, Bromberg, JS, Ames, S, Lerner, S, deBoccardo, G. Outcome of combined liver and kidney transplant in Hepatitis C recipients: a single center long-term follow-up experience. Am. J. Transplant (2008) 8 (suppl. 2):329.

290. Schroppel, B, deBoccardo, G, Sehgal, V, Dinavahi, R, Murphy, B, Dikman, S, Bromberg, JS, Akalin, E. Clinical significance of C4d positivity of early transplant kidney biopsies from patients with donor-specific antibodies receiving desensitization protocols. Am. J. Transplant (2008) 8 (suppl. 2):356.

291. Nef, PC, Kim, J, Gagliardi, R, Schiano, T, del Rio Martin, J, Bromberg, JS, Murphy, B, Akalin, E, deBoccardo, G. Impact of pre-transplant creatinine levels on long-term patient outcomes after orthotophic liver transplantation. Am. J. Transplant (2008) 8 (suppl. 2):376.

97

292. Rafiq, M, Dinavahi, R, Bromberg, JS, Sehgal, V, deBoccardo, G, Schroppel, B, Dikman, S, Ames, S, Lerner, S, Murphy, B, Akalin, E. The predictors and the prognosis of antibody-mediated rejection. Am. J. Transplant (2008) 8 (suppl. 2):511.

293. Yang, Y, Niu, Y, Han, DK, Bromberg, JS, Ding, Y. Regulation of Th17 differentiation by IFNγ and STAT1. Am. J. Transplant (2008) 8 (suppl. 2):617.

294. Gallichio, M, Bromberg, J, Distant, D, Powell, T, Cohen, D, Conti, D. New York State guidelines for live-kidney donation. Transplantation (2008) 86 (suppl. 2S):3.

295. Bromberg, JS, Gill, J. Heavy LYFTing: KASting pearls before swine. Am. J. Transplant. (2009) 9:1489-1490.

296. Yang, Y, Xu, J, Ochando, JC, Bromberg, J, Ding, Y. TH17 cells antagonize Treg cells to reject allografts. Am. J. Transplant. (2009) 9 (suppl. 2): 626.

297. Kruger, B, Zhang, N, Coward, W, Lin, M, Lal, G, Bromberg, JS, Murphy, BT, Schroppel, B. TLR2 and TLR4 signaling mediate injury in pancreatic islets after transplantation. Am. J. Transplant. (2009) 9 (suppl. 2): 668.

298. Lal, G, Zhang, N, van der Touw, W, Ding, Y, Bromberg, JS. Epigenetic regulation of Foxp3 expression in tolerance and inflammation. Am. J. Transplant. (2009) 9: (suppl. 2) 242.

299. Yin, N, Zhang, N, Bromberg, JS. Lymphangiogenesis is required for immunity to pancreatic islets. Am. J. Transplant. (2009) 9 (suppl. 2): 719.

300. Yang, Yu, Xu, J, Ochando, JC, Bromberg, J, Ding, Y. Limiting TH1 and TH2 favors Treg and TH17 to prolong allograft survival. Am. J. Transplant. (2009) 9 (suppl. 2): 265.

301. Lal, G, Yin, N, Schroppel, B, Bromberg, JS. IL-6 and TLR2 differentially inhibit Foxp3 expression in regulatory T cells by epigenetic regulation. Am. J. Transplant. (2009) 9 (suppl. 2): 265.

302. Yang, Y, Xu, J, Ochando, JC, Bromberg, JS, Ding, Y. STAT6 or T-bet is required for acute allograft rejection. Am. J. Transplant. (2009) 9 (suppl. 2): 294.

303. Yang, Y, Xu, J, Ochando, JC, Bromberg, JS, Ding Y. TH17 cells are not suppressed by IL-10 and induce acute allograft rejection. Am. J. Transplant. (2009) 9 (suppl. 2): 295.

304. Xu, J, Yang, Y, Lal, G, Bromberg, JS, Ding, Y. TGFβ attenuates Th17 responses by c-Maf induction: a new regulatory pathway for IL-10. Am. J. Transplant. (2009) 9 (suppl. 2): 332.

98

305. Xu, J, Yang, Y, Lal, G, Bromberg, JS, Ding, Y. Gene array analysis identifies chemokine receptors specfic for Treg and Th17. Am. J. Transplant. (2009) 9 (suppl. 2): 401.

306. Yin, N, Zhang, N, Bromberg, JS. Indentification of pancreatic islet dendritic cell subsets: lineage and migration. Am. J. Transplant. (2009) 9 (suppl. 2): 466.

307. Nakayama, Y, Bromberg, JS. LTβR Signaling Is Required for Costimulatory Blockade Induced Tolerance. Am. J. Transplant. (2010) 10 (suppl. 4):39.

308. Yang, Y, Xu, J, Ochando, J, Qiu, G, Wu, Z, Bromberg, JS, Ding, Y. Th1 Signals Are Required for Transplant Graft Survival. Am. J. Transplant. (2010) 10 (suppl. 4):41.

309. Yin, N, Zhang, N, Bromberg, JS. Identification of the Islet Dendritic Cell Subsets Required for Diabetes. Am. J. Transplant. (2010) 10 (suppl. 4):95.

310. Xiao, X, Liu, W, Ding, Y, Bromberg, J, Demirci, G, Li, XC. OX40 Engagement Controls the Induction of Foxp3+ Tregs and Th17 Cells Via Different Molecular Pathways. Am. J. Transplant. (2010) 10 (suppl. 4):106.

311. Lal, G, Tietjens, J, van der Touw, W, Yang, Y, Ding, Y, Ochando, JC, Bromberg, JS. B Cell Depletion Prevents Costimulatory Blockade Induced Tolerance. Am. J. Transplant. (2010) 10 (suppl. 4):182.

312. Lal, G, Yin, N, Lin, M, Xu, J, Tietjens, J, Schroppel, B, Ding, Y, Bromberg, JS. TLR2 Stimulation Inhibits Foxp3 Expression by an Interferon Regulatory Factor 1 (IRF1) Dependent T Cell Intrinsic Mechanism. Am. J. Transplant. (2010) 10 (suppl. 4):183.

313. van der Touw, W, Lal, G, Ochando, J, Ding, Y, Bromberg, JS. Natural Killer Cells Are Required for Costimulatory Blockade Induced Tolerance to Murine Cardiac Allografts. Am. J. Transplant. (2010) 10 (suppl. 4):183.

314. Yin, N, Zhang, N, Lal, G, Ding, Y, Bromberg, JS. Lymphangiogenesis Is Required for Immunity to Pancreatic Islets. Am. J. Transplant. (2010) 10 (suppl. 4):184.

315. Yang, Y, Xu, J, Ochando, J, Qiu, G, Wu, Z, Bromberg, JS, Ding, Y. Th17 Antagonize Treg To Impair Tolerance Induction. Am. J. Transplant. (2010) 10 (suppl. 4):205.

316. Xu, J, Yang, Y, Ochando, JC, Bromberg, JS, Ding, Y. Stat1 Mediated c-Maf Expression Is Critical for IL-27 To Promote Differentiation of Tr1 Cells. Am. J. Transplant. (2010) 10 (suppl. 4):364.

317. Burrell, BE, Bromberg, JS. Tracking Graft-Reactive Cell Fates Following Transplantation in a Tolerogenic Environment: Timing Is Everything. Am. J. Transplant. (2010) 10 (suppl. 4):463.

99

318. Shapiro, R, Halloran, PF, Delmonico, FL, Bromberg, JS. The “Two, One, Zero” Decision: What to do with Suboptimal Deceased Donor Kidneys. Am. J. Transplant. (2010) 10:1959-1960.

319. Bromberg, JS, Lal, G, Burrell, B, Yin, N, Nakayama, Y, Xu, J, Ding, Y. Induction, Migration, and Function of Treg, Keystone Symposium on Immunoregulatory Networks, Breckenridge, CO, April 1-6, 2011.

320. Xu, J, Yang, Y, Qiu, G, Wu, Z, Bromberg, JS, Ding, Y. T Cells Express Early IL-17 and are Involved in Transplant Rejection. Am. J. Transplant. (2011) 11 (suppl. s2):30. DOI: 10.1111/j.1600-6143.2011.03533.x

321. Philosophe, B, Bromberg, JS, Barth, RN, Fayek, SA, Schweitzer, EJ, Cooper, M, Bartlett, ST, Munivenkatappa, RB. Improving the Utilization of >70 Year Old Donor Kidneys in the United States. Am. J. Transplant. (2011) 11 (suppl. s2):59. DOI: 10.1111/j.1600-6143.2011.03533.x

322. Philosophe, B, Manitpisitkul, W, Wilson, NS, Barth, RN, Cooper, M, Bromberg, JS, Schweitzer, EJ, Fayek, SA, Bartlett, ST, Munivenkatappa, RB. Sirolimus Conversion Improves Transplant Outcomes of Marginal Kidneys with Intermediate Maryland Aggregate Pathology Index (MAPI) Scores. Am. J. Transplant. (2011) 11 (suppl. s2):67. DOI: 10.1111/j.1600-6143.2011.03533.x

323. Fayek, S, Keenan, J, Haririan, A, Cooper, M, Barth, R, Schweitzer, E, Bromberg, J, Bartlett, S, Phiosophe, B. The Value of Ureteral Stents in Kidney Transplantation. A Large Single Center 5 Years Experience. Am. J. Transplant. (2011) 11 (suppl. s2):73. DOI: 10.1111/j.1600-6143.2011.03533.x

324. Lal, G, Nakayama, Y, Burrell, BE, Ding, Y, Bromberg, JS. Non-Humoral Function of B Cells Is Required for Tolerance. Am. J. Transplant. (2011) 11 (suppl. s2):105. DOI: 10.1111/j.1600-6143.2011.03533.x

325. Nakayama, Y, Bromberg, JS. LTβR Signaling Is Required for Tolerogenic LN Structure. Am. J. Transplant. (2011) 11 (suppl. s2):186. DOI: 10.1111/j.1600-6143.2011.03533.x

326. Bromberg, J, Cibrik, D, Steinberg, S, West-Thielke, P, Yang, H, Erdman, J, First, R, Holman, J. A Phase 2 Study To Assess the Safety and Effi cacy of Alefacept (ALEF) in De Novo Kidney Transpalnt Recipients. Am. J. Transplant. (2011) 11 (suppl. s2):190. DOI: 10.1111/j.1600-6143.2011.03533.x

327. Yin, N, Xu, J, Ding, Y, Bromberg, J. Islet Dendritic Cell Subsets: Phenotypes and Antigen Presentation. Am. J. Transplant. (2011) 11 (suppl. s2):217. DOI: 10.1111/j.1600-6143.2011.03534.x

100

328. Lal, G, Yin, N, Xu, J, Ding, Y, Bromberg, JS. Inflammatory Signals Induce Epigenetic Modifi ations that Control Natural Regulatory CD4 T Cells (nTreg). Am. J. Transplant. (2011) 11 (suppl. s2):342. DOI: 10.1111/j.1600-6143.2011.03534.x

329. Burrell, BE, Bromberg, JS. Differential Fates of Alloantigen Specific T Cells in a Tolerant Environment: Timing and Antigen Dependency. Am. J. Transplant. (2011) 11 (suppl. s2):518. DOI: 10.1111/j.1600-6143.2011.03534.x

330. Yin, N, Lal, G, Xu, J, Ding, Y, Bromberg, J. Pancreatic Macrophages Contribute to Islet Lymphangiogenesis and Enhanced Myeloid Cell Recruitment. Am. J. Transplant. (2011) 11 (suppl. s2):520. DOI: 10.1111/j.1600-6143.2011.03534.x

331. Xu, J, Yang, Y, Qiu, G, Wu, Z, Bromberg, JS, Ding, Y. Limited Role for IL-35 in Graft Acceptance or Tolerance Induction. Am. J. Transplant. (2011) 11 (suppl. s2):522. DOI: 10.1111/j.1600-6143.2011.03534.x

332. Yin, N, Zhang, N, Bromberg, J. Lymphangiogenesis Is Required for Islet Inflammation and Allograft Rejection. Am. J. Transplant. (2011) 11 (suppl. s2):524. DOI: 10.1111/j.1600-6143.2011.03534.x

333. Burrell, BE, Bromberg, JS. Lymph Node Architecture Changes Following Tolerance Induction: Everything in Its Right Place. Am. J. Transplant. (2011) 11 (suppl. s2):524. DOI: 10.1111/j.1600-6143.2011.03534.x

334. Bromberg, JS, Lal, G, Burrell, B, Yin, N, Nakayama, Y, Xu, J, Ding, Y. Treg as therapeutic tools for transplantation tolerance and control of autoimmunity. 13th World Congress of the International Pancreas and Islet Transplant Association, Prague, Czech Republic, June 1-4, 2011.

335. Scalea, J, Barth, R, Fayek, S, Bromberg, J, Philosophe, B, Bartlett, ST, Cooper, M. Metabolic syndrome and solitary pancreas transplantation: role for statin therapy. 13th World Congress of the International Pancreas and Islet Transplant Association, Prague, Czech Republic, June 1-4, 2011.

336. Cooper, M, Scalea, J, Barth, R, Fayek, S, Bromberg, J, Philosophe, B, Bartlett, S. Portal vs. systemic drainage of solitary pancreas transplantation: new views on old concepts. 13th World Congress of the International Pancreas and Islet Transplant Association, Prague, Czech Republic, June 1-4, 2011.

337. Bromberg, JS. Surgical challenges: Solutions in the lab. ASTS 12th Annual State of the Art Winter Symposium, Miami, FL, January 14, 2012. Am. J. Transplant. (2012) 12 (supplement s2):58.

338. Yin, N, Ding, Y, Bromberg, J. Functional Specialization of Islet Dendritic Cell Subsets. Am. J. Transplant. (2012) 12 (suppl. S3):94. DOI: 10.1111/j.1600-6143.2012.04112.x

101

339. Yin, N, Ding, Y, Bromberg, J. Lymphatic Endothelial Cells Are Required for Islet Inflammation and Allograft Rejection. Am. J. Transplant. (2012) 12 (suppl. S3):148. DOI: 10.1111/j.1600-6143.2012.04112.x

340. G. Lal,Y. Nakayama, B. E. Burrell, A. Sethi, Y. Ding, J. S. Bromberg. B Cell Derived IL-10 Is Required for Co-Stimulatory Blockade Induced Tolerance. Am. J. Transplant. (2012) 12 (suppl. S3):27. DOI: 10.1111/j.1600-6143.2012.04112.x

341. J. Xu, X. He, N. Yin, M. Wen, J.S. Bromberg, Y. Ding. IL-17 but Not IFNγ Producing γδ T Cells Respond Early and Are Involved in Transplant Rejection. Am. J. Transplant. (2012) 12 (suppl. S3):30. DOI: 10.1111/j.1600-6143.2012.04112.x

342. Y. Nakayama, J. S. Bromberg. LTβR Signaling in Lymph Node Stromal Cell Is Required for Tolerance. Am. J. Transplant. (2012) 12 (suppl. S3):87. DOI: 10.1111/j.1600-6143.2012.04112.x

343. G. Lal, Y. Nakayama, B. E. Burrell, A. K. Singh, Y. Ding, J. S. Bromberg. Follicular Helper T Cell (Tfh) and B Cell Cross-Talk in Germinal Centers Is Required for Co-Stimulatory Blockade Induced Tolerance. Am. J. Transplant. (2012) 12 (suppl. S3):87. DOI: 10.1111/j.1600-6143.2012.04112.x

344. Y. Nakayama, J. S. Bromberg. Neutrophils Cause Allograft Rejection Induced by LTβR Blockade. Am. J. Transplant. (2012) 12 (suppl. S3):148. DOI: 10.1111/j.1600-6143.2012.04112.x

345. J. Scalea, V. Whitlow, B. Philosophe, S. Fayek, J. Bromberg, S. Bartlett, M. Cooper. Knowing a Good Thing When You See It – The Utility of HCV+ Deceased Donor Kidney Transplantation. Am. J. Transplant. (2012) 12 (suppl. S3):177. DOI: 10.1111/j.1600-6143.2012.04112.x

346. B. E. Burrell, J. S. Bromberg. Lymph Node Stromal Cells Change Chemokine Expression and T Cell Position in Tolerance. Am. J. Transplant. (2012) 12 (suppl. S3):354. DOI: 10.1111/j.1600-6143.2012.04112.x

347. B. E. Burrell, J. S. Bromberg. Lymph Node Structure Changes in Response to Costimulatory Blockade Plus Donor Alloantigen Induced Tolerization. Am. J. Transplant. (2012) 12 (suppl. S3):354. DOI: 10.1111/j.1600-6143.2012.04112.x

348. J. Xu, X. He, N. Yin, M. Wen, J. Bromberg, Y. Ding. Critical Importance of IL-22 Suppression in Allograft Survival. Am. J. Transplant. (2012) 12 (suppl. S3):454. DOI: 10.1111/j.1600-6143.2012.04112.x

349. J. Scalea, W. Carlton, R. Barth, J. LaMattina, J. Bromberg, S. Bartlett, M. Cooper. Outcomes of En-Bloc Pediatric Deceased Donor Kidney Transplantation: A Little Goes a Long Way. Am. J. Transplant. (2012) 12 (suppl. S3):498. DOI: 10.1111/j.1600-6143.2012.04112.x

102

350. B. E. Burrell, J. S. Bromberg. Costimulatory Blockade with Donor Alloantigen Creates a Pool of Tolerogenic Graft Reactive CD4+ T Cells Maintained Post-Transplantation. Am. J. Transplant. (2012) 12 (suppl. S3):529. DOI: 10.1111/j.1600-6143.2012.04112.x

351. B. E. Burrell, J. S. Bromberg. Costimulatory Blockade with Donor Alloantigen Creates a Suppressive Environment That Maintains Graft Reactive Cells in a Quiescent State. Am. J. Transplant. (2012) 12 (suppl. S3):529. DOI: 10.1111/j.1600-6143.2012.04112.x

352. B. E. Burrell, J. S. Bromberg. Costimulatory Blockade with Donor Alloantigen Creates a Pool of Tolerogenic Graft Reactive CD4+ T Cells Prior to Transplantation. Am. J. Transplant. (2012) 12 (suppl. S3):530. DOI: 10.1111/j.1600-6143.2012.04112.x

353. J. S. Bromberg, Book review: Innate Alloimmunity Part 2: Innate Immunity and Allograft Rejection. Am. J. Transplant. (2012) 12:1950.

354. Bromberg, J.S., Ikle, D.N. Is the Time Ripe for Genomic Diagnosis and Prediction of Rejection? Am. J. Transplant. (2012) 12:2573-2574.

355. J.Petersen, J.C. Scornik, J.S. Bromberg, D. Norman, M. Bhanderi, M. Gitlin. A Systematic Review on the Impact of Pre-transplant Transfusions and Allosensitization on Allograft Survival. ASN Kidney Week 2012, FR-PO942.

356. Y. Nakayama, B. Burrell, J. Bromberg. Immune regulation by fibroblastic reticular cells in tolerance involves CD40-CD40L costimulatory interactions. Am. J. Transplant. (2013) 13 (suppl. 5):33.

357. Y. Nakayama, J. Bromberg. Lymphotoxin receptor signaling regulates tolerogenic functions of fibroblastic reticular cells in the lymph node. Am. J. Transplant. (2013) 13 (suppl. 5):33.

358. A. Pereira, J. Reeve, J. Chang, A. Matas, D. de Freitas, J. Bromberg, J. Sellares, G. Einecke, P. Halloran. Validating the microarray test for antibody-mediated rejection in a prospective trial: The INTERCOM study. Am. J. Transplant. (2013) 13 (suppl. 5):39.

359. A. Pereira, J. Reeve, J. Chang, A. Matas, D. de Freitas, J. Bromberg, J. Sellares, G. Einecke, P. Halloran. Validating the microarray test for T cell-mediated rejection in biopsies in a prospective trial: The INTERCOM study. Am. J. Transplant. (2013) 13 (suppl. 5):43.

360. B. Burrell, J. Bromberg. Specific lymphocyte trafficking via high endothelial venules is required for tolerance. Am. J. Transplant. (2013) 13 (suppl. 5):54.

361. B. Burrell, J. Bromberg.Tolerance requires unique remodeling of lymph node structure and stromal fibers. Am. J. Transplant. (2013) 13 (suppl. 5):55.

103

362. D. Iwami, J Bromberg. Treg require Th1 and Th2 transcription factors to prolong islet allograft survival. Am. J. Transplant. (2013) 13 (suppl. 5):79.

363. J. LaMattina, L. Goldschen, R. Munivenkatappa, C. Gurk-Turner, J Powell, D. Klassen, J. Bromberg, R. Barth. Decreased rejection and equivalent survival with selective alemtuzumab induction for renal transplantation. Am. J. Transplant. (2013) 13 (suppl. 5):84.

364. J. Reeve, J. Sellares, D. de Freitas, G. Einecke, J. Bromberg, A. Matas, P. Halloran. Predicting graft failure in kidney transplant patients: A combined clinical/molecular approach to analyzing biopsies. Am. J. Transplant. (2013) 13 (suppl. 5):109.

365. B. Burrell, J. Bromberg. Anti-ER-TR7 mAb prevents tolerogenic lymph node morphogenesis and overrides transplant tolerance. Am. J. Transplant. (2013) 13 (suppl. 5):163.

366. G. Lal, Y. Nakayama, A. Sethi, A. Singh, B. Burrell, N. Kulkarni, C. Brinkman, D. Iwami, J. Bromberg. IL-21R+ marginal zone precursor (MZP) B cells in the germinal center induce IL-10 dependent allogeneic tolerance. Am. J. Transplant. (2013) 13 (suppl. 5):204.

367. C. Brinkman, J. Bromberg. Lymphotoxin regulates Treg entry into the lymph node. Am. J. Transplant. (2013) 13 (suppl. 5):250.

368. C. Brinkman, J. Bromberg. Treg express a unique pattern of trafficking molecules and differentially rely on LFA-1 for migration compared to effector T cells. Am. J. Transplant. (2013) 13 (suppl. 5):252.

369. J. Bromberg, W. Fricke. Human microbiota characterization in the course of renal transplantation. Am. J. Transplant. (2013) 13 (suppl. 5):322.

370. A. Haririan, J. Papadimitriou, D. Klassen, R. Ugarte, J. Bromberg, D. Kukuruga, C. Drachenberg. Features of antibody-mediated rejection (AMR) in early and late protocol and indication renal allograft biopsies. Am. J. Transplant. (2013) 13 (suppl. 5):323.

371. B. Noell, N. Wilson, A. Haririan, M. Jason, C. Davis, M. Weir, S. Bartlett, J. Bromberg, W. Manitpisitkul. Oral treatment of multi-drug resistant urinary tract infection in transplant recipient: Resurgence of fosfomycin. Am. J. Transplant. (2013) 13 (suppl. 5):342.

372. A. Baxi, B. Burrell, J. Bromberg. Tolerance induction changes lymph node structure and function. Am. J. Transplant. (2013) 13 (suppl. 5):363.

373. N. Wilson, W. Manitpisitkul, M. Jason, B. Noell, M. Weir, S. Bartlett, J. Bromberg, A. Haririan. Impact of induction agent on repeat kidney transplant outcomes in

104

patients on maintenance immunosuppression. Am. J. Transplant. (2013) 13 (suppl. 5):428.

374. M. Jason, W. Manitpisitkul, N. Wilson, J. Bromberg, S. Bartlett, A. Haririan. The impact of six months ciprofloxacin prophylaxis on BK viremia and BK nephropathy. Am. J. Transplant. (2013) 13 (suppl. 5):434.

375. D. Iwami, C.C. Brinkman, Y. Xiong, S. Ahmad, J.S.Bromberg. Treg require transcription factor T-bet for proper migration to prolong islet allograft survival. IPITA, Monterey, CA, September 26, 2013.

376. S. Ahmad, S. Bartlett, R. Barth, J. LaMattina, E. Schweitzer, M. Weir, D. Leeser, S. Niederhause, M. Phelan, J. Bromberg. Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for APKD: 10-Year Experience. Transplantation 2014, 98 (suppl. 1):131.

377. D. Iwami, J. Bromberg. VEGF-C/VEGFR-3 Signaling Regulates Chemokine Gradients and Lymphocyte Migration From Tissues to Lymphatics. Transplantation 2014, 98 (suppl. 1):312.

378. Y. Xiong, D. Iwami, C. Brinkman, S. Ahmad, J. Bromberg. Treg Require T-bet to Migrate Into Afferent Lymphatic Vessels. Transplantation 2014, 98 (suppl. 1):315.

379. P. Rosenberry, S. Niederhaus, J. Bromberg, E. Schwietzer, S. Bartlett, D. Leeser. Leveraging Health Systems to Facilitate Transplant Care in Rural Communities. Transplantation 2014, 98 (suppl. 1):832.

380. B. Burrell, K. Warren, J. Bromberg. Novel Lymph Node Trafficking Patterns of CD4 T Cells During Tolerization. Transplantation 2014, 98 (suppl. 1):391.

381. Y. Xiong, D. Iwami, C. Brinkman, S. Ahmad, J. Bromberg. Treg Require Transcription Factor T-bet to Traffic to Draining Lymph Nodes and Prolong Islet Allograft Survival. Transplantation 2014, 98 (suppl. 1):38-39.

382. C. Brinkman, J. Bromberg.Treg Regulate Lymphatic Endothelial Cell Morphology Via Lymphotoxin and Noncanonical NF-B Signaling. Transplantation 2014, 98 (suppl. 1):39.

383. C. Brinkman, D. Iwami, Y. Xiong, S. Ahmad, J. Bromberg. Lymphotoxin Is Required for Treg Migration and Function for Islet Allograft Survival. Transplantation 2014, 98 (suppl. 1):39.

384. B. Burrell, K. Warren, D. Iwami, D. Harris, J. Bromberg. Laminin Stromal Fibers Regulate T Cell Trafficking Through Lymph Nodes During Tolerization. Transplantation 2014, 98 (suppl. 1):27.

385. J.S. Bromberg. WTC Clinical Papers. Transplantation 2015, 99:275-277.

105

386. K. Famulski, S. Niederhaus, J. Reeve, J. Bromberg, P. Halloran. In Pre-Implantation Biopsies Expression of Micro RNAs Is Not a Good Surrogate For Established mRNA Markers Of Kidney Injury. Abstract # 694. American Transplant Congress, 2015.

387. K. Famulski, S. Niederhaus, J. Reeve, J. Bromberg, P. Halloran. Gene expression profiles indicate that many discarded kidneys are potentially transplantable. Abstract # 318. American Transplant Congress, 2015.

388. C. Bostic, T.M. Stern, S. Niederhaus, J. Bromberg, D.B. Leeser. A Single Center Study of the Implementation Costs of the New Kidney Allocation System. Abstract #1533. American Transplant Congress, 2015.

389. S.B. Ahmad, E.J. Siskind, C. Drachenburg, J.S. Bromberg, S. Niederhaus. A Prospective Comparison of the Completeness of Donor Kidney Biopsies. Abstract #1447. American Transplant Congress, 2015.

390. S.B. Ahmad, Y. Xiong, C.C. Brinkman, J.S. Bromberg. IFN Is Required for nTreg Afferent Lymphatic Migration. Abstract #514. American Transplant Congress, 2015.

391. Y. Xiong, S. Ahmad, D. Iwami, C.C. Brinkman, J.S. Bromberg. T-bet Directs nTreg Homing Into Draining Lymph Nodes by Regulation of Specific Migration and Adhesion Receptors. Abstract #470. American Transplant Congress, 2015.

392. C.C. Brinkman, Y. Xiong, J.S. Bromberg. Lymphatic Endothelium Uniquely Enhances T Cell Migration to S1P. Abstract #465. American Transplant Congress, 2015.

393. C.C. Brinkman, L. Hittle, E.F. Mongodin, W.F. Fricke, J.S. Bromberg. The Gut Microbiota Regulates Murine Cardiac Transplant Outcome. Abstract #1690. American Transplant Congress, 2015.

394. C.C. Brinkman, Y. Xiong, S. Ahmad, J.S. Bromberg. Lymphotoxin Controls Treg Interactions With Lymphatic Endothelial Cells and Interstitial Migration In Vivo. Abstract #1705. American Transplant Congress, 2015.

395. T. Saavedra, O. Opara, R. McLoughlin, B. Philosophe, C. Drachenberg, M. Weir, S. Bartlett, D. Leeser, J. Bromberg, R. Barth. Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy. Abstract #1862. American Transplant Congress, 2015.

396. G. Greenan, M. Anders, A. Leeser, J. Bromberg, S. Niederhaus. Recreational Marijuana Use Is Not Associated With Worse Kidney Allograft Outcomes. Abstract #299. American Transplant Congress, 2015.

397. L.E. Hittle, C.C. Brinkman, W.F. Fricke, J. Bromberg, E.F. Mongodin. The Gut Microbiota Regulates Murine Cardiac Transplant Outcome. 3rd International

106

Society of Microbiota (ISM) World Congress on Targeting Microbiota, Paris - Pasteur Institute, October 21-23, 2015.

398. Xiong Y, Brinkman C, Hippen K, Blazar B, Bromberg J. A Unique In Vitro Migration Model for Leukocyte Trans-Lymphatic Endothelial Migration. Am J Transplant. 2016;16 (suppl 3).

399. Xiong Y, Ahmad S, Iwami D, Brinkman C, Bromberg J. T-Bet Regulates nTreg Stability and Suppression in an Islet Allograft Model. Am J Transplant. 2016;16 (suppl 3).

400. Brinkman C, Hippen K, Blazar B, Bromberg J. Human and Mouse Treg Use Lymphotoxin for Migration Across Lymphatic Endothelium. Am J Transplant. 2016;16 (suppl 3).

401. Famulski K, Reeve J, Aubert O, Loupy A, Niderhaus S, Bromberg J, Halloran P. Many Discarded Kidneys Are Similar to Kidneys Accepted for Transplantation as Judged by Their Histologic Lesions and Molecular AKI Scores. Am J Transplant. 2016;16 (suppl 3).

402. Brinkman C, Hittle L, Fricke W, Mongodin E, Bromberg J. Fecal Microbiota Transplant Results in Durable Changes to Host Microbiota That Correlate with Allograft Outcome. Am J Transplant. 2016;16 (suppl 3).

403. Simon T, Bromberg J. Lymph Node Stromal Laminins Differentially Regulate T Cell Immunity and Tolerance. Am J Transplant. 2016;16 (suppl 3).

404. Xiong Y, Brinkman C, Hippen K, Blazar B, Bromberg J. Sphingosine 1-Phosphate (S1P) Receptors Differentially Regulate Murine and Human CD4 T Cell Migration Across Lymphatic Endothelium. Am J Transplant. 2016;16 (suppl 3).

405. Halloran P, Reeve J, INTERCOMEX Study Group Real Time Assessment of Kidney Transplant Indication Biopsies by Microarrays: First Results of the INTERCOMEX Study. Am J Transplant. 2016;16 (suppl 3).

406. Madariaga H, Ugarte R, Drachenberg C, Costa N, Thomas B, Bromberg J, Weir M, Haririan A. Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation. Am J Transplant. 2016;16 (suppl 3).

407. E. F. Mongodin, L. E. Hittle, C. C. Brinkman, W. F. Fricke, J. Bromberg. The Gut Microbiota Regulates Murine Cardiac Transplant Outcome. American Society of Microbiology/Interscience Conference of Antimicrobial Agents and Chemotherapy, June 16-20, 2016, Boston, MA.

408. Famulski K, Reeve J, Niederhaus S, Bromberg J, Halloran P. Histo-Molecular Assessment of Pre-implantation Biopsies Demonstrates That Many Discarded Kidneys Are Similar to Successfully Transplanted Kidneys in Other Centers. SA-PO373, American Society of Nephrology Kidney Week, 2016, Chicago, IL.

107

409. Brinkman CC, Hippen K, Blazar B, Bromberg J. Lymphotoxin on Human and Mouse Treg Promotes Migration Across Lymphatic Endothelium. 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

410. Brinkman CC, Hittle L, Fricke WF, Mongodin E, Bromberg J. Host Microbiota of Cardiac Allograft Recipients is Durably Altered by Fecal Microbiota Transplant and These Changes Correlate with Allograft Outcome. 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

411. Simon T, Bromberg J. Lymph Node Stromal Laminins Affect CD4+ T Functions and Polarization. 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

412. Xiong Y, Ahmad S, Iwami D, Brinkman CC, Bromberg J. T-bet Regulates nTreg Homing into Draining Lymph Nodes to Suppress Alloimmune Responses. 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

413. Xiong Y, Brinkman CC, Hippen K, Blazar B, Bromberg J. Murine and Human CD4 T cell Migration Across Lymphatic Endothelium is Differentially Regulated by Sphingosine 1-phosphate (S1P) receptors. 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

414. Xiong Y, Brinkman CC, Hippen K, Blazar B, Bromberg J. Monitoring Leukocyte Trans-lymphatic Endothelial Migration with an in vitro Model. 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

415. Halloran PF, Reeve J, Madill-Thomsen K and the INTERCOMEX study group. Microarray assessment of kidney transplant indication biopsies in real time. First results of the INTERCOMEX Study. 26th International Congress of the Transplantation Society, August 17-23, 2016, Hong Kong.

416. E. F. Mongodin, L. E. Hittle, C. C. Brinkman, W. F. Fricke, J. Bromberg. The Gut Microbiota Regulates Murine Cardiac Transplant Outcome. International Human Microbiome Consortium, 6th Congress, November 9-11, 2016, Houston, TX.

417. Brennan DC, Bloom RD, Bromberg J, Poggio ED. Cell-free DNA to Discriminate Active Rejection in Kidney Allografts. American Society of Nephrology Kidney Week, 2016, Chicago, IL.

108